Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
- Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 04/16/2024
|
2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential
- AI could solve one of the biggest problems in drug development: the lengthy time it takes to bring a product to market. The AI in healthcare market is set to expand at a compound annual growth rate of nearly 50%.
- 04/16/2024
|
1 New Green Flag for Moderna and Merck Stock
- Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.
- 04/12/2024
|
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
- Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.
- 04/11/2024
|
3 Pharma Stocks to Sell in April Before They Crash & Burn
- There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
- 04/11/2024
|
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
- Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in value over the past six months, outpacing broader market gains.
- 04/11/2024
|
Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
- Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint.
- 04/11/2024
|
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
- Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
- 04/10/2024
|
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
- Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 04/10/2024
|
Among the biggest winners today are some major long-term losers, says Jim Cramer
- 'Mad Money' host Jim Cramer looks at today's market winners and losers.
- 04/09/2024
|
Moderna Reports Positive Results from Cancer Vaccine-Keytruda Combination Trial
- Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated with its experimental individualized MRNA cancer vaccine combined with Merck's (MRK) blockbuster drug Keytruda.
- 04/09/2024
|
S&P 500 Gains and Losses Today: Moderna Soars as Cancer Vaccine Shows Promise
- Major U.S. equities made little headway in the session preceding the release of Consumer Price Index (CPI) report for March.
- 04/09/2024
|
Moderna's stock jumps 6% as its cancer vaccine could treat more than just melanoma
- Moderna Inc.'s stock jumped 6% Tuesday to lead S&P 500 gainers, after the company shared cancer-vaccine data that suggests it may work in indications outside its target of melanoma.
- 04/09/2024
|
What made Moderna stock pop 10% on Tuesday?
- Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.
- 04/09/2024
|
Moderna jumps as personalized cancer vaccine shows benefit in early study
- Moderna shares rose 8% in morning trade on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer.
- 04/09/2024
|
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
- These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
- 04/09/2024
|
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
- The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.
- 04/05/2024
|
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
- With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one's buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.
- 04/05/2024
|
Moderna shares fall after judge sides with Arbutus in patent fight
- Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.
- 04/03/2024
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- 04/02/2024
|
Why Moderna (MRNA) Dipped More Than Broader Market Today
- Moderna (MRNA) reachead $105.60 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.
- 04/01/2024
|
Moderna Stock: Buy, Sell, or Hold?
- Moderna has proven that its approach can work, making an investment less risky. In addition to its COVID-19 vaccine, the company is developing other products.
- 04/01/2024
|
Better Recovery Story Buy: Pfizer vs Moderna
- Pfizer and Moderna, both coronavirus vaccine stars, now face declining demand -- and, as a result, declining revenue. But these top companies are expanding their growth potential with new candidates targeting various treatment areas.
- 04/01/2024
|
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
- Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.
- 03/28/2024
|
Three top U.S. biotech stocks to buy in April
- “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
- 03/28/2024
|
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
- Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.
- 03/28/2024
|
Better Cathie Wood Stock: Moderna vs. Intellia
- Cathie Wood added to her positions in these biotech stocks this week. The famous investor seeks out undervalued innovators to add to her funds and hold onto for the long term.
- 03/28/2024
|
Moderna CEO talks China investment, vaccine updates to boost growth post-pandemic
- Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% year-over-year in 2023. Yahoo Finance Health Reporter Anjalee Khemlani recaps her interview with Moderna CEO Stéphane Bancel, who discussed the company's $1 billion investment into mRNA manufacturing sites in China.
- 03/27/2024
|
Moderna Stock Pops After Acquiring Millions in Funding
- Moderna Inc (NASDAQ:MRNA) is 1.8% higher to trade at $109.29 at last check, after the company received $750 million in funding from Blackstone Life Sciences (BX) to develop mRNA flu vaccines.
- 03/27/2024
|
Moderna Gets $750 Million in Flu Shot Funding, Stock Advances
- Moderna Inc. (MRNA) shares advanced Wednesday as the biotech firm used its “Vaccines Day” event to make key announcements about new funding and the results of several vaccine trials.
- 03/27/2024
|
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
- Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
- 03/27/2024
|
Moderna shares continue to fall even as its 3 vaccines enter final stage trials
- Moderna Inc. saw its stock continue its downward trajectory on Wednesday morning, slipping by 1.2 percent to $106.21, following a decline of over 3 percent on Tuesday. The biotech company's shares have endured a 28% drop over the past year.
- 03/27/2024
|
Moderna CEO on vaccines pipeline: Investing aggressively to bring important medicine to patients
- Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's annual vaccines day, the announcement of multiple vaccine programs advancing to late-stage clinical trials, Moderna's vaccines pipeline outlook, and more.
- 03/27/2024
|
Moderna Gets $750 Million for Flu Program. Funding to Help Move Beyond Covid Vaccines.
- The vaccine maker announces that Blackstone Life Sciences has agreed to fund up to $750 million for its flu program.
- 03/27/2024
|
Moderna gets $750 mln funding from Blackstone Life Sciences to develop flu shots
- Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.
- 03/27/2024
|
Moderna Says 'Next-Generation' COVID-19 Shot Had Positive Phase 3 Test Results
- Moderna Inc. (MRNA) on Tuesday reported "positive interim results" from a late-stage study of what it calls the "next-generation COVID-19 vaccine."
- 03/26/2024
|
Moderna says new Covid vaccine showed stronger immune response than current shot in study
- Moderna's new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.
- 03/26/2024
|
Moderna Stock Pops as New Covid-19 Vaccine Shows Positive Results
- Moderna's ‘next generation,' Covid-19 vaccine has shown a higher immune response to the virus than the current version of the shot.
- 03/26/2024
|
Artificial Intelligence (AI) in Healthcare: 2 Top Stock Picks
- The AI-in-healthcare market is expanding in the double digits and could reach more than $148 billion by the end of the decade. Nvidia CEO Jensen Huang says AI may have the most impact in the healthcare industry.
- 03/23/2024
|
Moderna (MRNA) Increases Yet Falls Behind Market: What Investors Need to Know
- Moderna (MRNA) concluded the recent trading session at $104.26, signifying a +0.39% move from its prior day's close.
- 03/18/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
- Wood added to one of her flagship fund's biggest holdings. The superstar investor also picked up shares of two other innovators that have posted double-digit share declines in recent years.
- 03/18/2024
|
3 Precision Medicine Stocks That Could Benefit From the Industry's Rise
- Now might be a great time for investors to consider investing in precision medicine stocks. For those who don't know, precision medicine is an approach to disease treatment and prevention that tailors medical decisions to the individual patient.
- 03/15/2024
|
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery
- Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.
- 03/15/2024
|
What's Next For Moderna Stock After Nearly A 20% Rise In A Week?
- Moderna stock rallied 9% yesterday, after it launched phase 2/phase 3 clinical trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. As per an earlier study, a combination of the vaccine and Merck's blockbuster Keytruda immunotherapy resulted in a significant improvement in recurrence-free survival time in patients with late-stage melanoma.
- 03/13/2024
|
Moderna Stock: Bull vs. Bear
- Many investors still see Moderna as a coronavirus stock and have questioned growth prospects. The main bull case for Moderna is that it's poised to return to growth soon.
- 03/13/2024
|
Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript)
- Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript)
- 03/12/2024
|
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
- Moderna (MRNA) concluded the recent trading session at $110.43, signifying a -1.38% move from its prior day's close.
- 03/12/2024
|
Why Moderna (MRNA) Stock Price Was Up 9% on Monday
- Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.
- 03/12/2024
|
Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
- Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 03/12/2024
|
S&P 500 Gains and Losses Today: Moderna Stock Boosted by Cancer Vaccine Study
- Major U.S. equities indexes were mixed to open the trading week as stocks fluttered ahead of Tuesday's Consumer Price Inflation (CPI) report. After the previous CPI print revealed steeper-than-expected price increases in January, investors will be on the lookout for reassurances that inflation remains on a steadily declining path.
- 03/11/2024
|
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
- Moderna stock surged Monday, nearing its first breakout in over a year, after launching a third study of its cancer vaccine.
- 03/11/2024
|
Turnaround Plays: 3 Stocks to Buy for a Major Recovery in 2024
- As an investor, you never really know how your investments will play out. Some companies that have been in long-term decline can suddenly become turnaround stocks and rise again, surprising everyone.
- 03/08/2024
|
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
- The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes.
- 03/07/2024
|
It's Time! 3 Failing Biotech Stocks to Sell Right Now
- Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, treatment authorization, or any number of events that could be or break a company.
- 03/05/2024
|
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
- ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.
- 03/04/2024
|
Where Will Moderna Stock Be in 5 Years?
- Moderna's sales plunged in 2023 as demand for its COVID vaccine has been diminishing. The company has multiple products in its pipeline that could be key parts of its business in five years.
- 03/03/2024
|
5 Top Stocks to Buy in March
- Lululemon is showing no signs of slowing down. Moderna and Roku are poised for a comeback.
- 03/03/2024
|
3 Reasons to Buy Moderna Stock
- Moderna is gaining on a rival in the coronavirus vaccine market. The biotech is nearing an important approval.
- 03/02/2024
|
3 Magnificent Growth Stocks to Buy in March
- Eli Lilly could have the world's future best-selling drug in its lineup. Moderna is poised to expand beyond COVID with several new products potentially on the way.
- 03/02/2024
|
Earnings Seasons Score Card: 4 Stock Superstars and 3 That Fell Short
- Earnings season for the fourth quarter of calendar 2023 is coming to a close. Clear winners and losers are emerging from the reports.
- 02/28/2024
|
Moderna to Present at Upcoming Investor Conferences in March 2024
- CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference, on Wednesday March 6th at 1:30 pm ET. Barclays 26th Annual Global Healthcare Conference, on Tuesday March 12th at 2:35 pm ET.
- 02/28/2024
|
Moderna Stock Has 33% Upside, According to 1 Wall Street Analyst
- Moderna is trying to move on from its coronavirus vaccine heyday. Its respiratory syncytial virus (RSV) vaccine could launch this year.
- 02/28/2024
|
Cramer's Stop Trading: Moderna
- CNBC's Jim Cramer explains why he is keeping an eye on shares of Moderna.
- 02/26/2024
|
This pharma stock surged 13% in a day
- Moderna (NASDAQ: MRNA) stock significantly surged on February 22 after the company surpassed Wall Street's quarterly expectations.
- 02/23/2024
|
Moderna (MRNA) CFO on Earnings & Covid Vaccine Sales
- Moderna (MRNA) expects regulatory approval for its investigational RSV vaccine for older adults starting in 1H24. Moderna CFO Jamey Mock discusses 4Q earnings, as well as Covid vaccine sales.
- 02/22/2024
|
Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View
- Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
- 02/22/2024
|
Why Moderna Stock Is Jumping Today
- Moderna beat Wall Street's revenue and earnings estimates in Q4. The company was helped by deferred revenue from Gavi, the Vaccine Alliance, and an income tax benefit.
- 02/22/2024
|
Moderna (MRNA) Q4 Earnings and Revenues Beat Estimates
- Moderna (MRNA) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of a loss of $0.78 per share. This compares to earnings of $3.61 per share a year ago.
- 02/22/2024
|
Moderna Stock Jumps on Surprise Profit, Sales Ahead of Expectations
- Moderna reported a profit of 55 cents a share on revenue of $2.8 billion in the December quarter, beating analysts' expectations.
- 02/22/2024
|
Moderna posts surprise quarterly profit even as Covid vaccines sales plummet
- Moderna reiterated its full-year 2024 sales guidance of roughly $4 billion.
- 02/22/2024
|
Moderna reports surprise profit, sets out road map for RSV vaccine
- Moderna on Thursday reported a surprise fourth-quarter profit helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot.
- 02/22/2024
|
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
- Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
- 02/21/2024
|
Why Earnings Season Could Be Great for Moderna (MRNA)
- Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/21/2024
|
Looming Layoffs? 3 Companies That May Be the Next to Drop the Axe.
- Al Jazeera has called 2023 “the year of the layoffs.” As the news organization pointed out recently, it started badly in 2023, when Salesforce (NYSE: CRM ) cut 10% of its global staff.
- 02/19/2024
|
Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?
- Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
- 02/19/2024
|
Nvidia, Walmart, Moderna, and More Stocks to Watch
- The market is closed for Presidents Day on Monday. Then, Nvidia earnings, FOMC minutes, February Purchasing Managers' Indexes, and more.
- 02/18/2024
|
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
- Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
- 02/15/2024
|
Here's Why Moderna (MRNA) Gained But Lagged the Market Today
- The latest trading day saw Moderna (MRNA) settling at $85.95, representing a +0.68% change from its previous close.
- 02/14/2024
|
ChatGPT Stock Predictions: 3 Companies the AI Bot Thinks Have 10X Potential
- In a time when AI is a friend and a guide through complex financial markets, AI-driven insights provide delight and optimism. Let us begin a deep dive into how ChatGPT, a sophisticated AI model, can go through massive market data and uncover a few stars with fast-growing potential.
- 02/14/2024
|
Short sellers boosted by ‘Hedge Fund Nirvana' that sees most heavily-shorted companies suffer
- Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a new UBS report says.
- 02/12/2024
|
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
- The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.
- 02/11/2024
|
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
- Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.
- 02/09/2024
|
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln
- Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its initial target range.
- 02/08/2024
|
Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade
- In the most recent trading session, Moderna (MRNA) closed at $99.30, indicating a -0.73% shift from the previous trading day.
- 02/07/2024
|
Moderna-backed Metagenomi targets up to $638 mln valuation for US IPO
- Metagenomi Technologies, a genetic medicines company backed by Moderna , said on Monday it was targeting a valuation of up to $638 million for its initial public offering in New York.
- 02/05/2024
|
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
- CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.
- 02/01/2024
|
1 Growth Stock Down 79% That's a Screaming Buy Right Now, According to Several Wall Street Analysts
- Moderna's shares have plunged with declining demand for its COVID-19 vaccine. Several analysts have renewed optimism about the biotech stock as it expands beyond COVID.
- 01/26/2024
|
Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?
- With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.
- 01/25/2024
|
3 S&P 500 Stocks With 127% to 170% Upside in 2024, According to Select Wall Street Analysts
- The broad-based S&P 500 has been Wall Street's top "health" barometer for decades. High-water price targets from a trio of Wall Street analysts imply triple-digit gains to come for three S&P 500 components.
- 01/25/2024
|
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
- In the latest trading session, Moderna (MRNA) closed at $101.11, marking a -0.79% move from the previous day.
- 01/24/2024
|
1 Stock Down 43% to Buy and Hold for 10 Years
- Moderna's revenue and earnings dropped off a cliff last year. However, the biotech is close to launching a new product.
- 01/21/2024
|
Better Bull Market Buy: Pfizer vs. Moderna
- Pfizer is completing its biggest string of product launches ever, which should spur a new era of growth. Moderna expects to soon have a new RSV vaccine on the market, with other products to follow.
- 01/20/2024
|
3 Things That Could Help 2023 Loser-Stock Moderna Roar Higher in 2024
- Moderna went from being a stock market winner, soaring more than 400%, to a losing stock in recent times. Investors have worried about coronavirus vaccine declines and the biotech company's future revenue picture.
- 01/18/2024
|
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
- Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.
- 01/17/2024
|
7 Mighty Healthcare Stocks Changing the Game of Medicine
- With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.
- 01/17/2024
|
3 Struggling Businesses Investors Shouldn't Gamble on This Year
- Plug Power's financials are in horrible shape, and a lack of cash is a big concern for investors. Moderna's reliance on COVID and flu revenue could limit any growth it's able to generate ahead.
- 01/17/2024
|
7 Healthcare Stocks Taking Medicine to the Next Level
- While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.
- 01/14/2024
|
3 Megatrend Stocks that Will Revolutionize Your Portfolio
- Owning powerhouse stocks can add significant value to your portfolio. Megatrends are those that are shaping or will shape society in significant ways.
- 01/11/2024
|
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
- The latest trading day saw Moderna (MRNA) settling at $109.46, representing a -0.65% change from its previous close.
- 01/10/2024
|
Your Path to Wealth: 3 Stocks Predicted to Double Your Investment by 2025
- Today, identifying investments with promising growth potential is a quest every investor undertakes. Within the loud noises of the stock market, three standout companies are making waves.
- 01/09/2024
|
Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%
- Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.
- 01/09/2024
|
7 S&P 500 Stocks to Buy to Keep the Bull Market Running
- The S&P 500 is within striking distance of entering official bull market territory. To qualify, the index would need to rise more than 20% from its previous low and hit a new all-time high.
- 01/09/2024
|
Moderna, Inc. (MRNA) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript
- Moderna, Inc. (MRNA) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript
- 01/08/2024
|
Moderna, Bayer-backed genetic therapies company files for IPO
- Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN, OTC:BAYZF), filed for a US IPO on Friday. Founded in 2018 by scientists at UC Berkeley, Metagenomi's revenue to date has come from a trio of collaborations, including one with backer Moderna.
- 01/08/2024
|
Moderna Stock Is Rising. Sales Fell a Bit Less Than Expected in 2023.
- Covid-19 vaccine maker Moderna said 2023 product sales hit $6.7 billion, above the company's guidance, but down more than 60% from 2022.
- 01/08/2024
|
Moderna's stock rises on 2023 product sales of $6.7B
- Moderna Inc.'s stock MRNA, +2.26% was up by 1.2% after the drug maker said it sold $6.7 billion of products in 2023. Analyst expected the company to sell $6.35 billion in products in 2023.
- 01/08/2024
|
Moderna's 2023 prelim COVID vaccine sales meet target
- Moderna on Monday reported preliminary 2023 sales of $6.7 billion for its COVID vaccine, surpassing the lower end of its full-year forecast, while reiterating its goal of returning to sales growth in 2025.
- 01/08/2024
|
Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company's $6 billion forecast
- Moderna's sales show the steep drop in demand for Covid products as cases and public concern about the virus dwindled front their pandemic peaks.
- 01/08/2024
|
Moderna's Flu/COVID Vaccine Prospects Are Undervalued By The Market
- Moderna's mRNA-1083 vaccine, targeting COVID-19 and flu, in Phase 3, reflects innovation in combination vaccinations. Despite recent financial losses, Moderna maintains strong liquidity with $12.8 billion in cash and investments; however, faces operational cost challenges. Market sentiment is mixed with underperformance in stock and high institutional ownership, amidst competition from Pfizer's similar vaccine.
- 01/07/2024
|
Are defensive sectors ready to outshine growth in 2024?
- The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NASDAQ: MRNA, Merck & Co., Inc. NYSE: MRK and Viatris Inc. NASDAQ: VTRS.
- 01/06/2024
|
Jim Cramer looks at the worst Nasdaq performers of 2023
- 'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.
- 01/04/2024
|
Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
- Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.
- 01/04/2024
|
Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?
- Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.
- 01/04/2024
|
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
- Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
- 01/03/2024
|
Moderna (MRNA) Moves 13.1% Higher: Will This Strength Last?
- Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 01/03/2024
|
Moderna stock upgraded to outperform by Oppenheimer & Co
- Oppenheimer & Co Analyst, Hartaj Singh, recently upgraded Moderna (MRNA) shares to "Outperform," with a price target of $142 per share. News of the upgrade has caused shares of the stock to trade over 13% higher on Tuesday.
- 01/02/2024
|
Three-Stock Lunch: Apple, Tesla and Moderna
- Quint Tatro, Joule Financial president, joins 'Power Lunch' to discuss three stocks, including Apple, Tesla and Moderna.
- 01/02/2024
|
Moderna Stock Surges on Optimism of Bringing More Products to Market
- Moderna Inc. (MRNA) shares soared 15% Tuesday as the vaccine maker got two pieces of positive news.
- 01/02/2024
|
2 Major Reasons Why Moderna (MRNA) Stock Is Up Today
- The biotech sector has been hit hard in recent years. Among the most disappointing stocks for growth investors in this space has certainly been Moderna (NASDAQ: MRNA ), an RNA-based vaccine maker that surged during the pandemic but has tailed off recently due to diminishing demand for its core product.
- 01/02/2024
|
Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
- The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.
- 01/02/2024
|
Moderna stock climbs on growth plans, broker upgrade
- Moderna Inc shares shot up 14% to $113.72 in midday trading on Tuesday after the vaccine maker's CEO confirmed the company's goal of achieving sales growth in 2025. Brokerage firm Oppenheimer also upgraded Moderna stock to 'Outperform', noting the company could have five products on the market by 2026.
- 01/02/2024
|
Midday Movers: Moderna Rises After an Upgrade, While Apple Falls Following Downgrade
- U.S. equities began the first day of trading in 2024 mixed at midday, amid concerns over tech exports to China and naval military action in the Middle East. The Dow rose slightly, while the S&P 500 and Nasdaq slid.
- 01/02/2024
|
Moderna surges after CEO says sales growth expected in 2025
- Moderna shares rose more than 11% on Tuesday after the vaccine maker's CEO Stéphane Bancel said in a shareholder letter that the company expects its sales to grow in 2025.
- 01/02/2024
|
Moderna's stock soars 10% to lead S&P 500 gainers as Oppenheimer upgrades to buy
- Moderna Inc.'s stock soared 10% Tuesday to lead S&P 500 index gainers, after Oppenheimer upgraded the stock to the equivalent of buy and said it expects the biotech to have five products approved by 2026.
- 01/02/2024
|
Moderna Stock Starts 2024 With an Upgrade After a Terrible Year. Here's Why.
- The vaccine maker's shares tumbled 45% over the past 12 months, but Oppenheimer analysts can see a turning point.
- 01/02/2024
|
Revealed: The most disappointing stocks of 2023
- The general stock market is concluding 2023 on a positive note, propelled by specific equities that have spearheaded an end-of-year rally. Significantly, these gains have enabled several stocks to recover from losses incurred in 2022.
- 12/31/2023
|
Why the Market Dipped But Moderna (MRNA) Gained Today
- In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.
- 12/29/2023
|
Here are the 20 worst-performing stocks among the S&P 500 in 2023
- The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.
- 12/29/2023
|
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
- Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.
- 12/29/2023
|
S&P 500's Biggest Losers in 2023: Dollar General, Moderna, and More
- The five worst performers in the market benchmark so far this year could be set for brighter futures.
- 12/28/2023
|
The Winners and Losers: 2023 Stock Market Performance Review
- A 2023 stock market recap is a tale of highs and lows. We entered the year after a Fed tightening cycle proved restrictive but seemingly unsuccessful as inflation continued while rates rose.
- 12/27/2023
|
Moderna and Pfizer Stock Tumbled in 2023. Wall Street Sees a Rebound.
- Covid-19-vaccine makers Moderna and Pfizer saw shares drop in 2023, but analysts expect double-digit-percentage gains next year.
- 12/27/2023
|
Wall Street's top 5 stocks with the biggest upside in 2024
- With the possibility of an interest rate cut by the FED and fairly optimistic targets for the S&P 500 index by the largest analytical groups, investors might be looking for the best opportunities in the stock market for the upcoming 2024.
- 12/26/2023
|
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8th at 6:45 p.m.
- 12/20/2023
|
Don't Waste Another Minute: Dump These 3 F-Rated Stocks Now
- Investors need to understand and be able to steer clear of companies that have a poor future outlook. Whether from reduced financial guidance, overall financial instability, management issues, or relevancy surrounding their product and or services.
- 12/19/2023
|
Is Moderna Stock A Buy After Retaking Its 50-Day Line On Strong Cancer Vaccine Sales?
- Is Moderna stock a buy after announcing promising results for its Merck-tied cancer vaccine? Is MRNA stock a buy right now?
- 12/19/2023
|
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
- BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.
- 12/18/2023
|
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
- Investors have shied away from buying Moderna shares as demand for its coronavirus vaccine declines. But the biotech has set high goals, aiming to release many new products during the next few years.
- 12/18/2023
|
3 S&P 500 Stocks That Are About to Get Absolutely Crushed
- The bulls look to be firmly in control of the stock market now. The U.S. Federal Reserve has pivoted away from its monetary tightening regime and signaled three interest rate cuts in 2024.
- 12/16/2023
|
Moderna: MRNA-4157 Cancer Vaccine Data Points To A Future Beyond Spikevax
- Moderna and Merck reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former's cancer vaccine, MRNA-4157. This mRNA-based skin cancer regimen represents one of Moderna's pipeline programs diversifying the company's portfolio and potentially shaping its future beyond the pandemic. The positive outcomes from the MRNA-4157 trial contribute to a bullish outlook for Moderna, demonstrating its capacity to innovate and excel in the field of oncology.
- 12/16/2023
|
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
- Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
- 12/15/2023
|
Moderna RSV vaccine more than 80% effective, study shows
- Moderna Inc.'s MRNA, +9.25% investigational vaccine for respiratory syncytial virus is 84% effective against the lower respiratory tract illness linked with the virus, according to phase 3 study data published in the New England Journal of Medicine. The vaccine, which uses the mRNA technology also used in COVID shots, was studied in adults 60 years of age and older and resulted in no evident safety concerns, the study found.
- 12/15/2023
|
Moderna CEO talks skin cancer vaccine: It's a big deal for melanoma patients
- Moderna (MRNA) shares are surging Thursday after the company announced positive mid-stage trial data showing its experimental cancer vaccine, used in combination with Merck's (MRK) immunotherapy Keytruda, cut the risk of death or relapse by nearly half in patients with advanced melanoma skin cancer after three years. Moderna CEO Stéphane Bancel joined Yahoo Finance's health reporter Anjalee Khemlani to discuss the results.
- 12/15/2023
|
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
- Moderna (NASDAQ: MRNA ) has been on a rough trajectory in recent days. Indeed, continuous declines in MRNA stock earlier this week have hurt investor sentiment in the large-cap biotechnology company.
- 12/14/2023
|
Moderna shares soar on cancer drug results
- CNBC's Angelica Peebles joins 'Power Lunch' to report on Moderna's experimental cancer vaccine.
- 12/14/2023
|
Moderna-Merck Vaccine for Skin Cancer Shows Positive Results; Moderna Stock Jumps
- A personalized vaccine developed by Moderna (MRNA) and Merck (MRK) showed significant positive results in treating skin cancer in high risk patients.
- 12/14/2023
|
Midday Movers: Moderna Soars on Vaccine Trial, Adobe Slumps on Guidance Miss
- U.S. equities were up at midday, with the Dow adding to its record high set yesterday, as rising retail sales added to enthusiasm surrounding the Federal Reserve's comments signaling rate cuts next year. The S&P 500 and Nasdaq were up as well.
- 12/14/2023
|
Moderna's cancer vaccine shows promise, but regulatory hurdles loom
- Moderna Therapeutics Inc (NASDAQ:MRNA) revealed positive data from its second cut of the cancer vaccine for adjuvant melanoma in combination with Keytruda. The report indicates a 49% recurrence-free survival (RFS) benefit, an improvement from the previous 44%.
- 12/14/2023
|
Moderna Stock Soars After Cancer Vaccine's Strong Test Results
- Moderna's new mRNA vaccine reduces the chance of relapse or death of skin cancer by half when paired with Merck's immunotherapy drug Keytruda, new data shows, marking a step forward in the developing field of mRNA technology and sending Moderna's stock soaring Thursday morning.
- 12/14/2023
|
Moderna Stock on Track for Best Day Since 2022
- Moderna Inc (NASDAQ:MRNA) stock was last seen up 15.4% to trade at $90.72, one of the best stocks on the Nasdaq today, after data from a mid-stage trial showed the company's experimental cancer vaccine with Merck (MRK), combined with immunotherapy Keytruda, helped melanoma patients reduce the risk of death or relapse after three years.
- 12/14/2023
|
Moderna stock popped 15% on Thursday: explore why
- Moderna Inc (NASDAQ: MRNA) is up nearly 15% this morning after reporting mid-stage trial data for its experimental vaccine for skin cancer.
- 12/14/2023
|
Moderna CEO Stephane Bancel on melanoma treatment development: A big day for patients
- Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss new developments in the treatment for melanoma, after studies showed Moderna and Merck's experimental cancer vaccine, when used in combination with Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, the company's growth outlook, and more.
- 12/14/2023
|
2 Big Stocks Making Big Moves Thursday
- Stocks continued to move higher following the Federal Reserve's latest decision. Adobe shares fell as strong financial results weren't enough to overcome worries about future growth.
- 12/14/2023
|
Why Is Moderna (MRNA) Stock Up 11% Today?
- Moderna (NASDAQ: MRNA ) stock is rising thanks to positive results from the skin cancer vaccine developed alongside Merck (NYSE: MRK ). The big news here comes after a Phase 2b trial of mRNA-4157 as an investigational individualized neoantigen therapy while combined with KEYTRUDA.
- 12/14/2023
|
Moderna's stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck's Keytruda
- Moderna Inc.'s stock MRNA, +0.72% soared 7% early Thursday, after the biotech and partner Merck MRK, +2.65% announced positive data from a mid-stage trial of Moderna's mRNA-4157 in combination with Merck's blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said after about three years, the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%, compared with Keytrua alone.
- 12/14/2023
|
Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says
- Those results build on midstage trial data Moderna and Merck released earlier this year, which examined the efficacy of the combination over a shorter period.
- 12/14/2023
|
Moderna Reports More Promising Data on Its Cancer Treatment
- Moderna's personalized cancer vaccine is being used with a Merck immunotherapy drug to fight melanoma cancer.
- 12/14/2023
|
3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year
- Stocks won't automatically become more expensive when we shift into a new year. But those that have struggled this year and have strong long-term outlooks could rebound at any point.
- 12/13/2023
|
Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy
- The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.
- 12/12/2023
|
Moderna reorganizes to sharpen focus on vaccine sales, chief commercial officer to leave company
- Moderna Inc. MRNA, +2.09% on Tuesday announced a reorganization designed to sharpen the company's focus on driving sales of COVID vaccine Spikevax and on the expected 2024 launch of a vaccine for respiratory syncytial virus. Stephane Bancel, Moderna's CEO, will take on responsibility for sales and marketing next year, the company said, working directly with the commercial team.
- 12/12/2023
|
Moderna, Merck begin late-stage study for mRNA cancer therapy
- Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.
- 12/11/2023
|
Moderna, Inc. (MRNA) 2023 ESG Day Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) 2023 ESG Day Conference Call December 7, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Relations Stéphane Bancel - Chief Executive Officer Kyle Holen - Head of Development, Oncology & Therapeutics Jameka Hill - Senior Director, Clinical Trial Health Equity Hamilton Bennett - Senior Director of Vaccine Access & Partnerships Deborah Donovan - Senior Vice President and Head Environment, Health & Safety Tracey Franklin - Chief Human Resources Officer Katherine O'Malley - Executive Director of Communications Shannon Klinger - Chief Legal Officer Conference Call Participants Operator Good morning or good afternoon, everyone and welcome to Moderna's second ESG Day. Today, you will hear from team members across Moderna about progress we've made since last year, an important sustainability initiatives.
- 12/07/2023
|
Moderna cancer vaccine data expected to deliver only modest upside
- Moderna Therapeutics Inc (NASDAQ:MRNA)'s upcoming update on its cancer vaccine trial in patients with adjuvant melanoma will only prompt a modest positive stock reaction, according to analysts at Jefferies. The drugmaker is expected to provide an update on the cancer vaccine (INT) trial at 51 events by the year-end, following its previous first interim update at 40 events.
- 12/06/2023
|
3 Dirt Cheap Stocks You'll Regret Not Buying Before the New Year
- Carnival and Apple both have climbed this year -- but they still have plenty of room to run thanks to customer demand. Investors have shied away from Moderna as vaccine demand falls, but a new wave of growth may lie ahead thanks to potential new products.
- 12/04/2023
|
Moderna, Inc. (MRNA) Presents at 35th Annual Piper Sandler Healthcare Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) 35th Annual Piper Sandler Healthcare Conference November 30, 2023 12:30 PM ET Company Participants Jamey Mock - CFO Conference Call Participants Ted Tenthoff - Piper Sandler Ted Tenthoff My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler.
- 11/30/2023
|
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
- The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.
- 11/30/2023
|
Moderna begins work on China mRNA manufacturing site
- U.S. vaccine maker Moderna began construction of its first facility in China this month to manufacture mRNA medicines, the company said on Tuesday.
- 11/27/2023
|
BioNTech Vs. Moderna: Navigating The mRNA Landscape
- Moderna and BioNTech are pioneering companies in mRNA technology, known for their fast development of highly effective COVID-19 vaccines. Both companies have the potential to transform the treatment landscape for various diseases, including cancer and infectious diseases. Both companies hold late-stage assets that pave the road for near-term growth.
- 11/22/2023
|
3 Biotech Stocks That Could Be Millionaire Makers
- There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies and hold onto those shares for the long term.
- 11/22/2023
|
BioNTech says European Patent Office has declared Moderna patent invalid
- COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer.
- 11/21/2023
|
Don't Let the Q3 Earnings Miss Keep You From These 3 Stocks!
- Most of the earnings reports are in for the third quarter. But a contrarian play based on the results to date could actually be investment opportunities.
- 11/20/2023
|
Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade)
- Moderna experienced a significant decline in Q3 2023 revenue, primarily due to a slump in COVID-19 vaccine sales. The company incurred substantial costs, including inventory write-downs and manufacturing wind-downs. The stock price is nearing a significant support level and exhibiting indications of reversing from this point.
- 11/20/2023
|
Investing In Moderna: A Calculated Risk Worth Taking For Patient Investors
- Moderna reported $1.8 billion in revenue, beating estimates, but recorded a massive GAAP earnings-per-share loss. Wall Street analysts lowered price targets for Moderna stock following the lackluster quarter. Moderna's Spikevax vaccine sales are expected to decline in 2024, but the company plans to introduce new vaccines to drive future revenue growth.
- 11/20/2023
|
Moderna, Inc. (MRNA) Second Digital Investor Event Transcript
- Moderna, Inc. (NASDAQ:MRNA ) Second Digital Investor Event November 8, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of IR Stephane Bancel - CEO Brad Miller - Chief Information Officer Dave Johnson - Chief Data and Artificial Intelligence Officer Wenhao Liu - Director of Software Engineering Brice Challamel - Empowerment VP Conference Call Participants Hartaj Singh - Oppenheimer & Co. Jasmine Fels - UBS Jessica Fye - JP Morgan Lavina Talukdar Good morning, everyone, and welcome to Moderna's Second Digital Investor Event. Since our first digital event in early 2020, we have made great progress in our digital strategy and the role of AI in accelerating innovation, scale and value creation at Moderna.
- 11/11/2023
|
Why Moderna Stock Was Cratering This Week
- Several analysts cut their price targets on the once-hotly popular biotech. Moderna is known for its Spikevax coronavirus vaccine.
- 11/10/2023
|
Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.
- Moderna's stock hasn't done well lately now that coronavirus vaccine sales are falling. But the biotech has an ambitious plan to launch over a dozen medicines relatively soon.
- 11/09/2023
|
Moderna to Present at Upcoming Conferences in November 2023
- CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 2023 UBS Global Biopharma Conference on November 9th at 8:00 a.m. ET. 2023 Jefferies London Healthcare Conference on November 16th at 8:30 a.m.
- 11/08/2023
|
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
- One knock against Wall Street analysts is they're too bullish, especially when it comes to Nasdaq 100 stocks. No matter the market conditions, they seem able to find the silver lining.
- 11/08/2023
|
High Risk Alert: 7 Vulnerable Stocks to Dump Now
- Investors face a complicated picture heading into the holiday season. War, inflation, high interest rates, and a potential recession are among the risk factors on the horizon.
- 11/07/2023
|
Cathie Wood Just Bought This Struggling Stock After Its Billion-Dollar Quarterly Loss. Should You?
- Cathie Wood is known for buying a stock when everyone else is selling it -- as long as the company's long-term prospects look good. Wood favors holding on for the long term, so she isn't bothered by short-term price moves.
- 11/07/2023
|
Down 84% From Its Peak. Is It Finally Time to Buy Moderna?
- Moderna recently reported third-quarter results. The stock is down about 84% from its peak in 2021.
- 11/05/2023
|
Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?
- Moderna reported a billion-dollar loss in the third quarter and began downsizing its manufacturing infrastructure to match lower levels of vaccine demand. The company says coronavirus vaccine sales may fall further next year.
- 11/04/2023
|
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/03/2023
|
Moderna CEO discusses earnings and how the company aims to break even by 2026
- While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its shares find themselves under pressure over weakening COVID-19 vaccine demand.
- 11/02/2023
|
Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production
- Moderna (MRNA) shares tumbled over 6% Thursday after reporting a steep loss as the drug maker lost sales and cut back on making its COVID-19 vaccine, Spikevax, with demand waning.
- 11/02/2023
|
Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript
- Moderna, Inc. (NASDAQ:MRNA ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Relations Stéphane Bancel - Chief Executive Officer Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Gena Wang - Barclays Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Luca Issi - RBC Capital Hartaj Singh - Oppenheimer Evan Wang - Guggenheim Securities Operator Good morning. My name is Kevin.
- 11/02/2023
|
Moderna stock plummets on 3Q loss and weak sales guidance
- Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker's weak full-year sales forecast and a significant loss for the third quarter overshadowed better-than-expected revenue. For 3Q, Moderna's revenue fell from $3.4 billion in the same period in 2022 to $1.8 billion mainly due to decreased COVID-19 vaccine sales.
- 11/02/2023
|
Moderna CEO on Weak Sales Forecast, Future Acquisitions
- Moderna CEO Stephane Bancel says he wants to 'reset the business cost structure' after the vaccine maker forecast a drop in sales for 2024. Speaking on "Bloomberg Markets," Bancel says higher interest rates are adding pressure on the biotech industry.
- 11/02/2023
|
Moderna CEO Stephane Bancel on Q3 results
- Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, and more.
- 11/02/2023
|
Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots
- CNBC's Becky Quick reports on the company's quarterly earnings results.
- 11/02/2023
|
Moderna revenue tops expectations, expects to return to sales growth in 2025
- Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that it would return to sales growth in 2025 and break even the following year.
- 11/02/2023
|
Moderna posts wider-than-expected loss, reins in full-year outlook
- Moderna Inc. on Thursday reported a much wider-than-expected third quarter loss and reined in its full-year sales outlook as it resizes its pandemic-era manufacturing capacity and aims to break even in 2026.
- 11/02/2023
|
Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots
- Moderna's total revenue for the third quarter still topped Wall Street's expectations despite plummeting demand for its Covid-19 shot.
- 11/02/2023
|
Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
- Moderna should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry analysts.
- 11/01/2023
|
Why Moderna stock has spooked investors as demand for the COVID-19 vaccine slows
- Moderna (MRNA) stock has fallen off in the post-pandemic period as demand for its COVID-19 vaccine — the company's primary commercial product — decreased significantly. Pfizer (PFE) recently lowered guidance on declining vaccine revenue, which Moderna shares took a hit correlatively.
- 10/27/2023
|
Among the S&P 500, these 20 companies have made the best use of investors' money
- There is no easy way to select individual stocks. Measures of financial quality can highlight companies that are worth a closer look, but a decision to commit money must also take into consideration both recent developments and a look ahead.
- 10/25/2023
|
Moderna's stock snaps record losing streak as Cathie Wood's ETF boosts stake by more than $4 million
- Moderna Inc. investors enjoyed a rare rally Tuesday as shares of the biotechnology company headed for their first gain in two weeks.
- 10/24/2023
|
Moderna and Caris Life Sciences partner to develop mRNA oncology therapeutics
- Moderna Therapeutics Inc (NASDAQ:MRNA) has teamed up with Texas-headquartered private precision medicine and molecular science firm Caris Life Sciences for a multi-year partnership to advance mRNA-based oncology therapeutics. The companies said Tuesday that through this strategic agreement, Moderna will leverage Caris' library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including by optimizing clinical trial design, discovering novel biomarkers, and characterizing resistance mechanisms.
- 10/24/2023
|
Moderna Stock Hasn't Been This Cheap Since 2020: Is Now the Time to Buy?
- Moderna's earnings come out next month, and concerns are growing that they might not be all that strong. Revenue will decline sharply this year and it wouldn't be surprising if the company trims its forecast.
- 10/24/2023
|
Moderna's stock suffering record losing streak as ‘investor caution remains high' over COVID vaccine sales
- Shares of Moderna Inc. were in danger of breaking their record for consecutive declines as investors express increasing caution over slowing sales of COVID vaccines.
- 10/23/2023
|
3 Healthcare Stocks to Invest in for a Big Shot of Gains
- With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 500 index.
- 10/23/2023
|
Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks This Year?
- Amid dimming immediate prospects, the solar sector's long-term resilience could light the way for patient investors. Moderna's post-pandemic journey unveils the stark reality of biotech's boom-and-bust cycle.
- 10/22/2023
|
Why Moderna Stock Is Sinking This Week
- Pfizer cut its outlook for its COVID-19 product sales, which made investors worry about Moderna's prospects. However, Moderna issued a statement reaffirming its full-year 2023 sales guidance.
- 10/19/2023
|
3 Stocks That Are Dead in the Water
- The stock market appears to be entering choppy waters as the year winds down. Between high inflation, unpredictable interest rates and an increasingly frightful geopolitical landscape, risk factors abound.
- 10/19/2023
|
Pfizer and Moderna Don't See Eye to Eye on This 1 Particular Point
- Pfizer and Moderna recently launched updated coronavirus vaccines. The companies are monitoring current vaccine demand for clues about future sales potential.
- 10/19/2023
|
Japan agreed to buy additional COVID-19 vaccine doses from Pfizer and Moderna
- Japan agreed to buy an additional 9 million COVID-19 vaccine doses from Pfizer and another 1 million doses from Moderna , the health ministry said on Thursday.
- 10/19/2023
|
Moderna's stock pummeled to pace the S&P 500's decliners, as it heads for yet another 5-day losing streak
- Shares of Moderna Inc. MRNA, -6.07% took a 5.9% beating toward a three-year low in afternoon trading Tuesday, enough to lead the S&P 500's SPX, -0.21% losers, and to put them on track to suffer yet another five-day losing streak. The biotechnology and COVID vaccine company's stock has shed 17.2% during its current losing streak, the worst five-day performance since it plunged 19.2% during the five-day stretch that ended Feb. 24, 2023.
- 10/17/2023
|
Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View
- Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.
- 10/17/2023
|
Markets Pop on Bargain Hunting, Stronger Economy
- The small-cap Russell 2000, still under water over the past month, led the way higher today.
- 10/16/2023
|
Paxlovid contract renegotiation pushed Covid business over the edge, says BMO's Evan Seigerman
- Evan Seigerman, BMO Capital Markets analyst, joins 'Closing Bell: Overtime' to discuss Pfizer and BioNTech cutting guidance amid Covid sales falling, the weight loss boom, and more.
- 10/16/2023
|
Moderna Shares Slump Amid Concerns About COVID-19 Vaccine Demand
- Moderna (MRNA) was the worst-performing stock in the S&P 500 on Monday as shares lost over 6% after the biotech firm said it “remains comfortable” with its full-year guidance, but warned that it couldn't predict exact demand for its COVID-19 vaccines yet. The comments came after rival Pfizer (PFE) slashed its full-year outlook “Solely due to COVID products.
- 10/16/2023
|
Moderna's stock slides to three-year low as co-founder sells more shares
- Shares of Moderna Inc. extended their slide Monday toward a fourth straight loss, a streak whose start coincided with a sale of shares by company co-founder and chair Noubar Afeyan.
- 10/16/2023
|
Moderna Becomes Oversold
- In trading on Monday, shares of Moderna entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $90.18 per share.
- 10/16/2023
|
Moderna confirms COVID sales guidance as shares sink on Pfizer news
- With its shares under pressure due to revised COVID guidance from Pfizer Inc. PFE, +3.38%, Moderna Inc. MRNA, -3.19% on Monday said it “remains comfortable” with its existing guidance on full-year 2023 COVID-19 sales.
- 10/16/2023
|
Moderna reaffirms annual COVID vaccine sales forecast
- Moderna on Monday reaffirmed its forecast of $6 billion to $8 billion in COVID vaccine sales for the year, after rival Pfizer slashed forecast for its vaccine last week.
- 10/16/2023
|
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand
- Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.
- 10/16/2023
|
Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move
- Shares of Lululemon Athletica Inc. LULU, +1.00% rallied more than 5% after index provider S&P Dow Jones Indices said the stock will join the S&P 500 index SPX on Wednesday.
- 10/16/2023
|
Don't Hold On: 7 Stocks to Sell Before 2024
- Even as the end of 2023 is still months away, now may be the time to figure out which stocks to sell ahead of 2024. All bets are off whether stocks can end the year on a high note.
- 10/15/2023
|
1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid
- The AI in healthcare market may be worth more than $190 billion by the end of this decade, making it a great place to look for investing opportunities. It's important to consider the whole picture when choosing a stock instead of betting only on the company's AI program.
- 10/13/2023
|
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
- CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.
- 10/12/2023
|
3 Stocks That Are Down Big, But Are Due to Fall Much Further
- October is renowned for its potential to unsettle investors with significant market drops, a trend that continues from the previous month. Indeed, while certain stocks have shown an ability to weather volatility, some falling stocks are down and could still see greater declines.
- 10/12/2023
|
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
- In the closing of the recent trading day, Moderna (MRNA) stood at $102.76, denoting a -1.6% change from the preceding trading day.
- 10/11/2023
|
3 Shaky Stocks to Sell in October Before It's Too Late
- Uncertainty abounds in the market right now. Whether driven by fears tied to surging inflation, rising interest rates, or geopolitical turmoil, investors have plenty to consider moving forward.
- 10/09/2023
|
Novavax's updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall
- Novavax's Covid shot is arriving nearly three weeks after new jabs from Pfizer and Moderna reached Americans — but analysts aren't worried about that delay.
- 10/07/2023
|
Nobel for mRNA: Which other biotech stocks might be overlooked?
- Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic. The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).
- 10/06/2023
|
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
- With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows, and future earnings potential.
- 10/06/2023
|
Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market?
- Moderna just reported positive data from its combined flu/coronavirus vaccine candidate and aims to launch a phase 3 trial. The potential product could appeal to people who already go for flu vaccines -- that's about half of Americans.
- 10/06/2023
|
Investing In Moderna: A Speculative Buy For Long-Term Gains
- Moderna is a biotech company with high potential upside, despite the decline in demand for its COVID-19 vaccine. The company's mRNA platform approach has advantages over traditional vaccine manufacturing methods. Moderna has a large drug pipeline and plans to launch 15 new mRNA-based medicines over the next five years.
- 10/05/2023
|
Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study
- Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.
- 10/05/2023
|
Moderna reportedly files submission for RSV vaccine with Health Canada
- Moderna Therapeutics Inc (NASDAQ:MRNA) has filed a new drug submission for its vaccine aimed at preventing respiratory syncytial virus (RSV) in adults aged 60 and older with Health Canada, according to a report by MarketWatch. According to the report, the regulatory submission is based on positive data from a prespecified interim analysis of its ConquerRSV study, which included 37,000 adults aged 60 and older across 22 countries.
- 10/05/2023
|
Can Moderna Achieve Its Most Ambitious Goal Yet?
- Investors have worried about Moderna's post-pandemic earnings since the company relies on its coronavirus vaccine for revenue. Moderna has been progressing toward its goal of becoming a multiproduct company.
- 10/05/2023
|
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
- In the latest trading session, Moderna (MRNA) closed at $104.26, marking a +1.14% move from the previous day.
- 10/04/2023
|
Moderna CEO on combo Covid, flu vaccine moving to next trial phase
- A lot of Americans are planning on getting both a flu shot and Covid booster this fall. But Moderna (MRNA) has been working on a combination flu and Covid vaccine, so patients only need to get one shot instead of two.
- 10/04/2023
|
Moderna reports positive results for combination flu and COVID vaccine
- Moderna Inc. announced positive interim results from a Phase 1/2 trial of its combination vaccine against COVID-19 and flu on Wednesday, and said it would start a Phase 3 trial for adults aged 50 and above. The trial sought to evaluate the safety and immunogenicity of mRNA-1083 compared to a standard dose influenza vaccine, Fluarix, in adults 50-64 years of age, and against an enhanced influenza vaccine, Fluzone HD, in adults 65-79 years of age.
- 10/04/2023
|
Moderna combo COVID-19/flu vaccine succeeds in early-stage trial
- Moderna on Wednesday said its combination vaccine to protect against both COVID-19 and influenza generated a strong immune response compared to individual shots for the viruses in an early-stage study.
- 10/04/2023
|
Moderna combination Covid, flu vaccine moves to final stage trial after positive data
- Moderna and other vaccine makers like Pfizer believe combination shots will simplify what people can do to protect themselves against Covid, RSV and the flu.
- 10/04/2023
|
Novavax Surges After FDA Signs Off On Its Updated Covid Shot, Joining Pfizer, Moderna
- The Food and Drug Administration signed off on Novavax's updated Covid booster late Tuesday, and NVAX stock surged just before the close.
- 10/03/2023
|
FDA approves updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.
- Health officials see Novavax's protein-based vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna.
- 10/03/2023
|
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
- These three companies have a proven ability to develop innovative products in the healthcare field. All three have performed poorly on the market over the past year, but their prospects remain intact.
- 10/01/2023
|
Moderna's Shares Could Take Off if These 2 Things Happen
- Moderna has announced progress on late-stage programs and forecasts billion-dollar earnings down the road, but the stock continues to stagnate. Investors might be waiting for concrete signs of success before diving in.
- 09/30/2023
|
Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine
- Revenue from Moderna's COVID vaccine will continue for the foreseeable future. Moderna has a deep pipeline with several products in phase 3 trials.
- 09/30/2023
|
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
- Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
- 09/28/2023
|
Don't Miss the Boom: 3 Healthcare Stocks Set to Explode Higher
- According to the American Medical Association, U.S. healthcare spending totaled $4.3 trillion in 2021, equal to nearly $13,000 per person. Overall medical expenses account for nearly 20% of U.S. gross domestic product (GDP).
- 09/26/2023
|
Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.
- Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.
- 09/26/2023
|
EU in talks with Moderna over new COVID vaccine deal - FT
- The European Union is in talks with Moderna over a new procurement deal for the company's COVID-19 vaccines amid concerns over a rise in infections in the region, the Financial Times reported on Tuesday.
- 09/26/2023
|
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
- Healthcare stocks generally offer a lot of upside. The cost of healthcare is incredibly expensive in the United States and the companies that deliver it tend to do very well overall.
- 09/24/2023
|
The Score: Moderna, Splunk, Fox and More Stocks That Defined the Week
- Here are some of the major companies whose stocks moved on the week's news.
- 09/22/2023
|
Moderna Is Expecting Massive Growth Over the Next Decade. Is the Stock a No-Brainer Buy?
- Moderna is investing in such areas as oncology, rare diseases, and infectious diseases. The biotech projects it could bring in $30 billion in annual sales 10 years from now.
- 09/22/2023
|
Moderna: Covid Curse
- Moderna, Inc. revenues have now slumped due to lower Covid vaccine demand, but the company ramped up aggressive spending on R&D. The company faces up to $8 per share of losses in 2024 to 2025 due to the Covid curse. The stock isn't appealing due to the squeeze of lower revenues and higher expenses.
- 09/21/2023
|
Does This Message From Moderna Mean Bad News for Novavax?
- Moderna and Novavax both are focused on the coronavirus vaccine market of the future. The two companies each are developing vaccine candidates to prevent coronavirus and flu.
- 09/21/2023
|
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
- The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.
- 09/20/2023
|
Fall Covid shot rollout gets off to a bumpy start as some patients see insurance delays
- The reports are fueling confusion among insured patients about whether they can still access Covid shots for free — just as cases tick up across the country.
- 09/20/2023
|
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
- Facing significant patent cliffs, Pfizer is putting faith in new launches. Moderna has nearly doubled its pipeline in three years.
- 09/20/2023
|
Beware! 3 Value Stocks Waving Massive Red Flags Right Now.
- Value stocks are the perfect haven in today's choppy stock market. Instead of looking to high-flying tech stocks, many investors are flocking to companies with low price-to-book ratios and other undervaluation metrics.
- 09/20/2023
|
Beware! 3 Nasdaq Stocks Waving Massive Red Flags Right Now.
- After a blistering run in this year's first half, the stock market has changed. Many high-flying stocks have taken a turn for the worse since the dog days of summer and are now flashing warning signs to investors.
- 09/20/2023
|
Uninsured Americans can still get free Covid boosters — here's how to find them
- The new Covid vaccines from Pfizer and Moderna began to roll out last week after the CDC recommended them to all Americans ages six months and up.
- 09/19/2023
|
Moderna to cut mRNA drug substance production at Lonza facility
- Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand.
- 09/19/2023
|
2 Stocks That Sank Hard on Monday
- Short-term investors in Moderna are worried about lower expected vaccine adoption. Unity Software's new fee structure has caused some backlash.
- 09/18/2023
|
Here Are 15 New Reasons to Be Bullish About Moderna Stock
- Moderna's coronavirus vaccine revenue is tanking, and it could continue to fall. However, the company has plenty of activity ongoing in the pipeline, with new medicines on the way.
- 09/18/2023
|
Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine
- Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.
- 09/15/2023
|
UK regulator approves Moderna's updated COVID vaccine
- The UK drug regulator said on Friday it has approved an updated COVID-19 vaccine by Moderna , making it the second shot to be used in the country's vaccination campaign this autumn.
- 09/15/2023
|
This 1 Number May Completely Change Your Opinion About Moderna
- Moderna's coronavirus vaccine sales are on the decline -- but other blockbuster products may be on the way. These products should more than compensate for any lost vaccine sales.
- 09/15/2023
|
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
- It's been a rough year to invest in pharma stocks. The industry is adjusting to a sector that is less reliant on Covid-19 vaccines and is adapting to the effects of inflation as well as pressure from regulators to cap the price of many drugs.
- 09/14/2023
|
Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data
- Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.
- 09/14/2023
|
Why COVID Vaccine Demand Might Not Be That Strong
- BA.2.86 is a new COVID variant health officials have been eyeing lately. But recent reports suggest that it may not be all that concerning.
- 09/14/2023
|
The 7 Best Meme Stocks to Buy Now: September 2023
- Given the horrendous performance of meme kings like AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) lately, searching for the best meme stocks may be the last thing on your mind right now. In fact, considering GME's continued declines, and AMC's capitulation in recent weeks, you may think that the meme stock phenomenon has completely gone the way of the dodo.
- 09/14/2023
|
Moderna, Inc. (MRNA) R&D Day and Business Updates (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) R&D Day and Business Updates September 13, 2023 1:00 PM ET Company Participants Stephane Bancel - CEO Stephen Hoge - President Jackie Miller - SVP, Therapeutic Area Head, Infectious Diseases Darin Edwards - Executive Director, COVID Vaccines Program Leader Raffael Nachbagauer - Program Leader for Influenza Vaccines Arpa Garay - Chief Commercial Officer Kyle Holen - Head of Development, Oncology and Therapeutics Michelle Nguyen - Director of Marketing James Mock - CFO Conference Call Participants Geoff Meacham - BofA Michael Yee - Jefferies Evan Wang - Guggenheim Salveen Richter - Goldman Sachs Gina Wang - Barclays Tyler Van Buren - TD Cowen Hartaj Singh - Oppenheimer Steve Chesney - Redburn Atlantic Stephane Bancel Thank you for those joining us here and thank you for those joining us online today. Before I start, let me just remind you that we'll be making forward-looking statements, and of course, Investing in Moderna entails risk.
- 09/14/2023
|
'This Is Not a Covid Vaccine Company,' Moderna CEO Says
- Stephane Bancel told Barron's the company won't be defined by its Covic-19 vaccine even as it uses the same technology to develop other vaccines.
- 09/14/2023
|
Moderna Reports Successful Trial of Flu Vaccine, Plans More Treatments Ahead
- Moderna (MRNA) was one of the best-performing stock in the S&P 500 as the vaccine maker reported its experimental flu shot met its primary endpoint in a Phase 3 trial.
- 09/13/2023
|
Moderna CEO on New Flu Vaccine, Curing Cancer
- Stephane Bancel, Moderna CEO, talks about seeking regulatory approval for a new version of its influenza vaccine, and new ways to treat and detect cancer. He speaks on "Bloomberg Markets.
- 09/13/2023
|
Moderna stock rises on positive results in flu vaccine trial
- Moderna (MRNA) shares are ticking up this morning after the pharmaceutical company published positive data from its latest flu vaccine trial. Yahoo Finance Health Care Reporter Anjalee Khemlani outlines Moderna's new post-COVID strategy to expand personalized care, quoting CFO James Mock's plans to prepare new COVID, RSV, and flu vaccines this season.
- 09/13/2023
|
Options Bulls Blast Moderna Stock on Vaccine Tailwinds
- Moderna Inc (NASDAQ:MRNA) stock is up 6.5% to trade at $112.09 at last check, after a late-stage trial of its flu vaccine induced a stronger immune response against all four A and B strains of the virus in comparison to other flu shots.
- 09/13/2023
|
Moderna CEO eyes $8 billion in sales for 2023: ‘Covid is not going away'
- The CEO of Moderna Inc. (NASDAQ: MRNA) showed optimism for the company in a recent interview for Squawk Box on CNBC, foreseeing between $6 billion to $8 billion in sales in 2023, as their COVID-19 booster got approved by the FDA on September 11.
- 09/13/2023
|
Moderna CEO: Covid is not going away
- Moderna CEO Stéphane Bancel joins 'Squawk Box' to discuss the company's new Covid-19 booster vaccine, their new products for cancer treatment, and more.
- 09/13/2023
|
New Covid vaccines could reach Americans as soon as Thursday – here's what you need to know
- Updated Covid vaccines from Pfizer and Moderna will soon be administered at pharmacies, and many other locations across the U.S.
- 09/13/2023
|
Moderna says flu vaccine showed promising results in phase three trial, paving path to approval
- Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix.
- 09/13/2023
|
Moderna Stock Rises on Positive Results From Flu Vaccine
- Moderna expects to launch up to 15 new products over the next five years 'addressing high unmet needs.'
- 09/13/2023
|
Moderna to scale down manufacturing of COVID vaccine
- Moderna on Wednesday announced it was scaling down manufacturing of its COVID-19 vaccine, an updated version of which was approved this week by U.S. regulators, to align with lower post-pandemic demand and help the company sooner hit its target of 75% to 80% gross margin growth.
- 09/13/2023
|
Moderna aims to prove it's ‘more than a COVID company'
- As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. MRNA, -0.53% on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases.
- 09/13/2023
|
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
- It's been a difficult time for biotechnology stocks. After a boom during the Covid-19 pandemic, the entire sector appears to have been abandoned by investors.
- 09/12/2023
|
CDC advisors recommend updated Covid vaccines for all Americans ages 6 months and up
- CDC Director Mandy Cohen still has to sign off on the panel's recommendation before the new Pfizer and Moderna Covid vaccines become available nationwide.
- 09/12/2023
|
CDC advisers recommend updated COVID shots for people 6 months of age and older
- Advisers to the Centers for Disease Control and Prevention voted Tuesday to recommend updated COVID-19 vaccines for people 6 months of age and older. The 13-to-1 vote comes just one day after the U.S. Food and Drug Administration approved the updated shots from Moderna Inc. MRNA, -0.53% and Pfizer Inc. PFE, +0.65%.
- 09/12/2023
|
Moderna, Inc. (MRNA) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) Morgan Stanley 21st Annual Global Healthcare Conference September 12, 2023 12:15 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, good afternoon, everybody.
- 09/12/2023
|
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
- The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.
- 09/12/2023
|
Health Canada approves Moderna COVID-19 vaccine for Omicron, urges boosters
- Canadian health officials on Tuesday authorized Moderna's COVID-19 vaccine targeting the Omicron subvariant, urging all Canadians over the age of six months to get fresh inoculations as the nation sees an uptick in infections.
- 09/12/2023
|
FDA Approves Pfizer & Moderna's New COVID Booster Vaccines
- Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
- 09/12/2023
|
Novavax recovers from 13% slump after Pfizer and Moderna get a lead on Covid booster
- Novavax, Inc. (NASDAQ:NVAX) shares recovered some lost ground in Tuesday premarket trading after slumping almost 13% on Monday after it missed out on US Food and Drug Administration (FDA) approval for its new Covid-19 booster vaccine. The FDA signed off on updated jabs from Pfizer and its German partner BioNTech, and Moderna on Monday, with Novavax telling Reuters that its vaccine is still under review.
- 09/12/2023
|
Moderna Teams With Germany's Immatics to Develop Cancer Vaccines and Therapies
- Moderna (MRNA) and German biotech firm Immatics announced an agreement to work on development of vaccines and treatments for cancer using the science behind Moderna's COVID-19 shots.
- 09/11/2023
|
FDA Approves New Covid Vaccines To Target Latest Strains
- The updated booster shots arrive as new coronavirus variants circulate.
- 09/11/2023
|
Pfizer and Moderna updated COVID vaccines approved by FDA
- The U.S. Food and Drug Administration on Monday approved updated mRNA COVID vaccines from Moderna Inc. MRNA, -1.36% and Pfizer Inc. PFE, -1.04%. People five years of age and older are eligible for a single dose of an updated mRNA vaccine if at least two months have passed since their last COVID shot, while previously vaccinated children six months through four years of age are eligible for one or two doses of an updated shot, depending on the previous vaccine they received, according to the FDA.
- 09/11/2023
|
US FDA authorizes updated COVID vaccines
- The U.S. health regulator on Monday authorized updated COVID-19 vaccines that closely match the Omicron variants that are circulating, starting the process to deploy the shots this month.
- 09/11/2023
|
Pfizer and Moderna Covid Vaccines Approved by FDA
- This year's rollout marks a definitive transition to a commercial market for the shots., which had previously been purchased by the U.S. government.
- 09/11/2023
|
FDA approves updated Covid vaccines from Pfizer and Moderna as hospitalizations rise
- The Biden administration said it expects the new Pfizer and Moderna vaccines targeting the omicron variant XBB.1.5 to be available in mid-September.
- 09/11/2023
|
Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development
- Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative therapies for cancer patients with high unmet medical need. Under the agreement, the German drug developer will receive an upfront payment of $120 million.
- 09/11/2023
|
Moderna, Immatics to work jointly on cancer vaccines
- Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone payments.
- 09/11/2023
|
Apple, Moderna, Inflation, and More to Watch This Week
- The Consumer Price Index is expected to be up 3.6%. Results from Oracle, Adobe, and Lennar.
- 09/10/2023
|
3 Meme Stocks That Could Actually Rebound in Q4
- It's the question everybody wants to know: Are meme stocks dead? Well, according to an August report from the Associated Press, apparently not.
- 09/09/2023
|
COVID Vaccine Sales Are Declining. But Here's How They're Still Driving Growth at Moderna.
- Investors have shied away from Moderna in recent times as demand for its one and only product -- the coronavirus vaccine -- declines. But that particular product could be the driving force behind a whole new phase of revenue to come.
- 09/08/2023
|
2 Nasdaq 100 Stocks That Are Surefire Buys in September and 1 to Avoid Like the Plague
- Despite bouncing 42% (year-to-date) through the end of August, the Nasdaq 100 still sits 7% below its all-time high. Two Nasdaq 100 components have well-defined moats within their specific industries that should cultivate a sustained double-digit growth rate.
- 09/08/2023
|
Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant
- Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.
- 09/07/2023
|
3 Stocks to Buy For the COVID Resurgence
- The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.
- 09/07/2023
|
7 Biotech Stocks to Sell in September Before They Crash & Burn
- Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.
- 09/06/2023
|
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
- CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat at Morgan Stanley's 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.
- 09/06/2023
|
Moderna: Updated Covid vaccine is effective against newer variant
- CNBC's Angelica Peebles reports on the latest news from Moderna.
- 09/06/2023
|
Moderna vaccine effective against latest Covid strain
- Moderna Therapeutics Inc (NASDAQ:MRNA) has told investors that its revised Covid vaccine appears effective against the BA.2.86 subvariant, a highly mutated form of the coronavirus. Clinical trials revealed an 8.7-fold surge in neutralizing antibodies against this subvariant, which is closely monitored by global health agencies like the WHO and the CDC.
- 09/06/2023
|
Moderna Stock Gains. Its Vaccine Is Effective Against New Covid Strain.
- The news comes amid concerns about rising cases in the U.S.
- 09/06/2023
|
Moderna says updated COVID vaccine effective against BA.2.86 Pirola variant
- Moderna Inc. MRNA on Wednesday released clinical trial data indicating that its updated COVID-19 vaccination is effective against the BA.2.86 Pirola variant, which is being closely monitored by researchers due to concerns that it could more easily break through existing immunity. The new shot showed an 8.7 to 11-fold increase in neutralizing antibodies against BA.2.86 and other circulating variants, including the EG.5 Eris variant and FL.1.5.1, Moderna said in a release.
- 09/06/2023
|
Moderna's Updated Covid Vaccine Is Effective Against Pirola Variant—As Concern Over New Strain Grows
- Experts are worried the highly mutated variant, a relative of omicron formally called BA.2.86, could trigger a new wave of cases.
- 09/06/2023
|
Moderna says updated COVID vaccine is effective against newer variant
- Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections.
- 09/06/2023
|
Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial
- Moderna, Pfizer and Novavax are slated to roll out new vaccines targeting XBB.1.5 within weeks, pending approvals from the FDA.
- 09/06/2023
|
Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?
- The U.S. is reporting increases in positive coronavirus tests and in coronavirus hospitalizations. Pfizer, Moderna, and Novavax are readying their updated vaccines for the fall vaccination season.
- 09/05/2023
|
3 Beaten-Down Biotech Stocks Bound for a Bounce Back
- Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market when the pandemic was over.
- 09/02/2023
|
Surprise! This Potential AI Winner Isn't a Tech Stock.
- We often think of tech stocks when we think of artificial intelligence investing. But other areas could benefit from this exciting technology.
- 09/02/2023
|
Judge withdraws from Medicare drug price case after stock ownership is revealed
- Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.
- 09/01/2023
|
COVID is evolving quickly in white-tailed deer, study finds
- The COVID-19 virus is evolving in white-tailed deer at triple the rate it evolves in humans–and future changes could have serious consequences for people as well as livestock, according to a study published Monday in the journal Nature Communications.
- 08/28/2023
|
Alnylam to appeal ruling on patents related to Moderna's COVID vaccines
- Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spikevax.
- 08/25/2023
|
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
- Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
- 08/25/2023
|
CDC expects new Covid vaccines from Pfizer, Moderna and Novavax to be available in mid-September
- The updated Covid vaccines from Pfizer, Moderna and Novavax still need green lights from the FDA and the CDC before they roll out to the public.
- 08/25/2023
|
Covid Hospitalizations Jump. So Could Vaccine Demand.
- Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.
- 08/22/2023
|
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
- Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.
- 08/22/2023
|
Covid is going to be a problem for the stocks of vaccine makers, says Jefferies' Michael Yee
- Michael Yee, Jefferies senior biotech analyst, joins 'Squawk Box' to discuss the market performance of Covid vaccine stocks, as companies prepare to roll out new modified boosters to combat new variants, and more.
- 08/22/2023
|
Why Moderna, BioNTech SE, and Novavax Surged Today
- Last week, Moderna and BioNTech partner Pfizer said their new COVID vaccines work against the current dominant strain of omicron growing across the U.S. Today, the Biden administration announced a campaign for citizens to get the new boosters this fall.
- 08/21/2023
|
Moderna and Pfizer stocks rise amid new Covid variants
- Yahoo Finance Health Care reporter Anjalee Khemlani breaks down Covid vaccine maker stocks including Moderna (MRNA), Pfizer (PFE), and BioNTech (BNTX), rising as concerns grow about new Covid variants.
- 08/21/2023
|
Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout
- Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.
- 08/21/2023
|
Moderna: Buy Before The Fall Covid-19 Wave
- Moderna's COVID-19 vaccine was found to be over 95% effective at preventing illness, hospitalizations, and deaths. Experts predict another COVID-19 wave starting in September 2023, leading to increased revenue for Moderna. MRNA upgraded its sales guidance for the second half of 2023 to $6-8 billion, anticipating a spike in COVID-19 cases.
- 08/21/2023
|
Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant
- Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.
- 08/18/2023
|
New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant
- The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide.
- 08/18/2023
|
2 Biotech Stocks That Could Make You Richer
- Sanofi has a number of exciting growth drivers, some of which have earned approval relatively recently. Moderna shows it isn't just a pandemic stock as several non-COVID candidates inch toward approval.
- 08/18/2023
|
After hours stock movers August 17, 2023: Ross Stores, Applied Materials, Moderna
- Yahoo Finance anchor Seana Smith breaks down the after hours stock movers for August 17, 2023 which include Ross Stores, Applied Materials, and Moderna.
- 08/17/2023
|
Moderna's updated COVID vaccine effective against 'Eris' variant in humans
- Moderna said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the "Eris" and "Fornax" subvariants in humans.
- 08/17/2023
|
Moderna says new Covid vaccine was effective against Eris variant in early trial
- Moderna's vaccine and new shots from Pfizer and Novavax are slated to roll out within weeks, pending potential approvals from the Food and Drug Administration.
- 08/17/2023
|
Moderna says updated COVID vaccine effective against widely circulating Eris variant
- Moderna Inc. said Thursday that preliminary clinical trial data show that its updated COVID-19 vaccine is effective against newer variants that are starting to circulate widely. The shot significantly boosted neutralizing antibodies against the Eris, or EG.5, variant, as well as the Fornax FL 1.5.1 variant that is starting to surge in parts of the U.S., the company said in a release.
- 08/17/2023
|
MRNA Stock Alert: Why Is Moderna Up 7% Today?
- Who knew getting sick could make you richer? Today, investors in Moderna (NASDAQ: MRNA ) certainly feel that way, as MRNA stock shoots roughly 7% higher.
- 08/17/2023
|
Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?
- With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.
- 08/15/2023
|
Stock screen spotlights 20 companies whose 2024 earnings estimates have risen most sharply
- With another earnings season almost complete, it might be useful for investors to look further ahead. Each earnings season, we can see 70% to 80% of the S&P 500 “beating” consensus quarterly profit estimates.
- 08/14/2023
|
Pfizer, Moderna and Novavax developing jab to combat new Covid strain
- Three US pharmaceutical companies, Pfizer Inc (NYSE:PFE), Moderna Therapeutics Inc (NASDAQ:MRNA), and Novavax Inc, are gearing up to release updated Covid-19 vaccines this autumn. The new jabs are designed to combat recent strains, although not specifically the newly identified Eris variant.
- 08/14/2023
|
3 Pharma Stocks to Sell in August Before They Crash and Burn
- With pharmaceutical companies, it's all about the pipeline of new medications. Drugmakers, and their pharma stocks, are judged based on sales of current medications and potential sales of future prescriptions.
- 08/11/2023
|
3 Healthcare Stocks to Sell in August Before They Crash and Burn
- Healthcare continues to lag in the broader market. Year to date, the Standards and Practices (S&P) 500 Health Care index is down 2% versus a 17% gain in the benchmark S&P 500 index.
- 08/09/2023
|
Deutsche Bank Downgrades Moderna (MRNA)
- Fintel reports that on August 3, 2023, Deutsche Bank downgraded their outlook for Moderna (NASDAQ:MRNA) from Buy to Hold.
- 08/05/2023
|
Moderna (MRNA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Moderna (MRNA) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/04/2023
|
Moderna, Inc. (MRNA) Q2 2023 Earnings Call Transcript
- Moderna, Inc. (NASDAQ:MRNA ) Q2 2023 Results Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Gena Wang - Barclays Capital Dina Elmonshed - Jefferies Luca Issi - RBC Capital Markets Edward Tenthoff - Piper Sandler Emmanuel Papadakis - Deutsche Bank Alexandria Hammond - Bank of America Securities Evan Wang - Guggenheim Partners Simon Baker - Redburn Partners Operator Good day and thank you for standing by. Welcome to Moderna Second Quarter 2023 Conference Call.
- 08/03/2023
|
Moderna expects up to $4B in COVID-19 vaccine sales to private market in 2023
- Moderna said it expects up to $4 billion in sales of its COVID-19 shots to the private market during 2023, depending on U.S. vaccination rates.
- 08/03/2023
|
Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View
- Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.
- 08/03/2023
|
Moderna shares up after hiking forecast on Covid-19 vaccine
- Moderna stock is on the rise after the company hikes its full-year forecast on its Covid-19 vaccine. Yahoo Finance Live's Julie Hyman breaks down the story.
- 08/03/2023
|
Moderna Stock Reverses Losses After 2-Year Bottom
- Moderna Inc (NASDAQ:MRNA) stock is currently enjoying a modest post-earnings pop, reversing its losses after earlier dropping to a two-year low of $108.26.
- 08/03/2023
|
Moderna's stock jumps 5% premarket after narrower-than-expected loss and revenue beat
- Moderna Inc.'s stock MRNA, -3.26% rallied 5.5% in premarket trade Thursday, after the COVID vaccine market posted a narrower-than-expected second-quarter loss and revenue that was far below last year's but still topped consensus estimates. The company had a net loss of $1.38 billion, or $3.62 a share, for the quarter, after income of $2.197 billion, or $5.24 a share, in the year-earlier period.
- 08/03/2023
|
Moderna stock seen higher on better-than-feared earnings
- Moderna Therapeutics Inc (NASDAQ:MRNA) stock points higher in premarket as it reported better than feared second quarter earnings The mNRA vaccine maker reported a net loss of US$1.4 billion on US$300 million of revenue in its second quarter, representing a US$3.62 loss per share – versus market expectations of US$3.84 per share. Chief executive Stéphane Bancel pointed to the ‘seasonal nature' of Covid-19 as Moderna's outlook forecast full year 2023 Covid-19 vaccine sales between US$6 billion and US$8 billion, depending on Covid vaccination rates in the US.
- 08/03/2023
|
Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales
- Moderna and its rivals Pfizer and Novavax have all seen a steep drop in sales of Covid vaccines and treatments as the world moves on from the pandemic.
- 08/03/2023
|
Moderna's stock jumps 5% premarket after narrower-than-expected loss and revenue beat
- Moderna Inc.'s stock MRNA, -3.26% rallied 5.5% in premarket trade Thursday, after the COVID vaccine market posted a narrower-than-expected second-quarter loss and revenue that was far below last year's but still topped consensus estimates.
- 08/03/2023
|
Moderna sees up to $8 bln in 2023 COVID vaccine sales on private market hopes
- Moderna Inc on Thursday raised its annual forecast for COVID-19 vaccine sales to up to $8 billion on hopes of a boost in the fall season as sales move to a private market in the United States from government contracts.
- 08/03/2023
|
3 ‘Strong Buy' Biotech Stocks You Should Be Loading Up On Now
- Medical stocks, in general, aren't enjoying the market-wide reversal we're seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical device and healthcare facility companies, has returned less than 1% since January.
- 08/02/2023
|
Should You Buy Moderna (MRNA) Ahead of Earnings?
- Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/02/2023
|
3 Cheap Healthcare Stocks That Smart Investors Will Snap Up Now
- Healthcare has been a laggard this year. A slowpoke, a dawdler, an idler.
- 08/01/2023
|
Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?
- Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
- 07/31/2023
|
New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here's why
- Pfizer, Moderna and Novavax are slated to deliver new single-strain Covid shots targeting the omicron subvariant XBB.1.5 in September.
- 07/29/2023
|
Cathie Wood Is Buying Up Shares of This Beaten-Down Biotech. Should You?
- Superstar investor Cathie Wood bought shares of Moderna over a period of two days this week. The biotech company may become a respiratory vaccine giant -- with coronavirus, RSV, and flu vaccines -- in just a few years.
- 07/27/2023
|
Merck and Moderna launch late-stage trial of V940 with Keytruda as treatment for high-risk melanoma
- Merck & Co. MRK, -1.16% and Moderna Inc. MRNA, -0.93% said Wednesday they have launched a Phase 3 trial of Moderna's V940 in combination with Merck's Keytruda as a treatment for patients with high-risk, or Stage IIB-IV melanoma. The trial is the first Phase 3 study of a planned comprehensive clinical development program being initiated following positive data from a Phase 2 trial that was reported at two cancer conferences, AACR and ASCO, earlier this year.
- 07/26/2023
|
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
- Growth investors are frequently looking for biotech stocks to buy. So what exactly is a biotech stock?
- 07/24/2023
|
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
- We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.
- 07/21/2023
|
Obey the Sell Signals: 3 Blue-Chip Stocks to Let Go
- FOMO is carrying the day, week and month on Wall Street. And the rally is starting to spread beyond the tech sector.
- 07/20/2023
|
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
- Vertex dominates the cystic fibrosis market and is dipping its toes in new areas. Moderna's mRNA vaccine platform could lead to major approvals in the coming years.
- 07/19/2023
|
Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030
- The market is ignoring Moderna due to its reliance on one product today. But that could be a mistake.
- 07/19/2023
|
Moderna Co-Founder Bought Up This Embattled Biotech Stock
- Flagship Pioneering, an investment vehicle helmed by Noubar Afeyan, a co-founder of Moderna and its chairman, bought $12.5 million of shares of biotech Evelo.
- 07/18/2023
|
Biden administration asks Pfizer, Moderna and Novavax for 'reasonable' prices on updated Covid vaccines
- Pfizer, Moderna and Novavax have not disclosed the exact pricing of their new vaccines, which will target the circulating omicron subvariant XBB.1.5.
- 07/13/2023
|
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
- CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update.
- 07/13/2023
|
We've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen Richter
- Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space.
- 07/11/2023
|
Prime Day for Stocks? Disney, Moderna and 13 More That Look Like Bargains.
- Amazon Prime shopping days are here, and everyone loves good deals, Barron's looked for some in the stock market, and found 15 stocks primed to go higher.
- 07/11/2023
|
The Perfect 10 Portfolio Is Ready to Roll
- The phrase “Perfect 10” doesn't just apply to bathing beauties. It's the name of one of my favorite hypothetical stock portfolios.
- 07/10/2023
|
Are We Heading for a Recession? Here's What Investors Should Do.
- The Fed has forecast a recession -- but some economists aren't so sure it will happen. It's important to take a long-term view when investing and consider your own investing style.
- 07/09/2023
|
Moderna: Potential To Get Second Product To Market
- Moderna, Inc. has submitted multiple regulatory submission of mRNA-1345 as an RSV vaccine in older adults ages 60 and older; additional regulatory submissions expected in coming months. The global respiratory syncytial virus market is expected to reach $4.20 billion by 2027. GlaxoSmithKline obtained regulatory approval of its RSV vaccine in adults ages 60 and older known as Arexvy; analysts estimate that it could generate peak sales of $2.5billion.
- 07/06/2023
|
Wait Before Buying Moderna Stock, Says Bear Signal
- Shares of pharmaceutical concern Moderna Inc (NASDAQ:MRNA) are 4.3% lower today at $118.25, one day after the company inked a deal to research, develop, and manufacture mRNA medicines in China.
- 07/06/2023
|
Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine
- Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.
- 07/06/2023
|
A Big Test Is Looming for Pfizer, Moderna, and Novavax
- All three companies are working on updated vaccines for COVID. A new variant, XBB.1.5, led to a spike in COVID cases in China earlier this year.
- 07/06/2023
|
$1 Billion Deal For Moderna To Expand Product Pipeline in China
- The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and where investors think we are in the business cycle.
- 07/06/2023
|
Moderna inks deal to make mRNA medicines in China
- US drugmaker Moderna has signed a deal to make mRNA medicines in China as part of its first major investment in the country, despite escalating trade and political tension between Washington and Beijing.
- 07/06/2023
|
3 Value Stocks to Consider Selling Before They Do Your Portfolio In
- Selling value stocks is vital for investors who prioritize safeguarding their portfolios. Within portfolio management, it becomes imperative to identify the opportune moment to divest from value stocks that fail to deliver anticipated returns.
- 07/05/2023
|
Moderna Shares Advance After Striking mRNA Drug Development Deal With China
- Moderna shares rose 1.5% on Wednesday after signing an agreement with China to research, develop, and make mRNA treatments there.
- 07/05/2023
|
Three-Stock Lunch: UPS, Moderna and Coinbase
- Michael Landsberg, Landsberg Bennett Private Wealth Management CIO, joins 'Power Lunch' to discuss Landsberg's thoughts on three stocks: UPS, Moderna, and Coinbase.
- 07/05/2023
|
Markets Fall at Midday Ahead of the Release of the Fed's Latest Meeting Minutes
- U.S. equities declined at midday on Wednesday, July 5, 2023, ahead of the release of meeting minutes from the Fed's June policy meeting.
- 07/05/2023
|
Moderna reaches agreement reportedly valued at up to $1B to develop mRNA drugs in China
- Moderna has reached a memorandum of understanding and a land collaboration agreement to research, develop, and manufacture mRNA medicines in China, the company has confirmed to multiple media outlets. As first reported by Chinese publication Yicai on Tuesday, the Massachusetts-based vaccine maker is set to announce investment in China of as much as $1 billion.
- 07/05/2023
|
Moderna stock pops after company makes regulatory submissions in U.S., Europe, Switzerland and Australia for its RSV vaccine
- Moderna Inc.'s stock MRNA, +2.43% rose 3% Wednesday, after the company said it has made regulatory submissions in Europe, Switzerland and Australia for its mRNA-1345 vaccine which targets RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency, Swissmedic in Switzerland, and the Therapeutic Goods Administration in Australia.
- 07/05/2023
|
Moderna Stock Is Surging on Deal to Make Vaccines in China
- Drugmaker Moderna reached an agreement to produce mRNA vaccines in China. One report noted the company could invest up to $1 billion in the country.
- 07/05/2023
|
Moderna strikes deal to develop mRNA drugs in China
- The deal is the biotech company's first agreement with China after the Asian nation repeatedly refused to accept mRNA vaccines from U.S.-based manufacturers.
- 07/05/2023
|
Moderna says it has signed deal in China with view to research and make mRNA medicines
- Vaccine maker Moderna Inc said on Wednesday it had signed a memorandum of understanding and a land collaboration agreement to work towards opportunities for it to research, develop and manufacture mRNA medicines in China.
- 07/05/2023
|
Is Moderna Heading for a Critical Moment?
- Moderna recently asked regulators for authorization of its updated coronavirus vaccine. The company says it's ramped up production and is ready to deliver doses for the fall vaccination season.
- 07/05/2023
|
Worst Stocks Of 2023's First Half: Battered Banks And Vaccine Makers
- The well's run dry for the sector thus far this year as energy prices stabilized.
- 07/03/2023
|
Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab
- Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.
- 07/03/2023
|
Moderna files for European authorization of updated COVID vaccine
- U.S. biotech firm Moderna said on Monday it had submitted a regulatory application to the European Medicines Agency (EMA) seeking authorization for its updated COVID-19 vaccine to target the XBB.1.5 sub-variant.
- 07/03/2023
|
Moderna: Declining Performance And Relative Weakness
- Moderna NASDAQ: MRNA was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion as COVID-19 cases surged around the globe.
- 06/30/2023
|
Is Moderna Stock A Buy As It Doubles Down On Its Cancer Vaccine Efforts?
- Is Moderna stock a buy after unveiling new results for its Merck-partnered cancer vaccine? Is MRNA stock a buy today?
- 06/29/2023
|
Moderna and 7 More Stocks That Can Beat Apple in Second Half
- Big Tech is having its best start to the year ever. But a different group of stocks may thrive in the second half.
- 06/29/2023
|
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
- Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 06/28/2023
|
3 Pharma Stocks That Have Big Investors Running for the Exit
- Pharmaceutical stocks are trailing the market this year. So far in 2023, the Dow Jones U.S. Select Pharmaceuticals Index is down 5.4% while all three major indices are positive on the year.
- 06/28/2023
|
Moderna stock price forecast: UBS sees a 60% upside
- Moderna Inc (NASDAQ: MRNA) has been in a sharp downtrend since the start of this year but a UBS analyst says a full recovery is on the cards. Moderna shares could return to $191 Eliana Merle now recommends buying Moderna shares as they can climb to $191 – a 60% upside from their previous close.
- 06/26/2023
|
Moderna stock up after upgrade to Buy from Neutral
- Yahoo Finance anchor Rachelle Akuffo reports on Moderna stock up after the stock receives an upgrade to Buy from UBS. Yahoo Finance Live breaks down the company's stock movement.
- 06/26/2023
|
Markets Little Changed Midday to Start the Last Trading Week of 2023's First Half
- U.S. equities were little changed at midday on Monday, June 26, 2023 heading into the last trading week of the month, quarter, and first half.
- 06/26/2023
|
Moderna Stock Is a Buy. The Pipeline Is Underappreciated, Says Analyst.
- UBS analyst Eliana Merle upgraded Moderna stock to Buy from Neutral, but trimmed the price target. The Covid and RSV businesses alone are worth $123 a share, she says.
- 06/26/2023
|
Moderna Stock Upgrade Has Call Traders Moving In
- UBS upgraded Moderna Inc (NASDAQ:MRNA) to "buy" from "neutral" this morning, but also lowered its price targe to $191 from $221.
- 06/26/2023
|
UBS upgrades Moderna to buy while cutting price target
- UBS upgraded its rating on vaccine maker Moderna MRNA, -1.64% to buy from neutral on valuation grounds, but cut its price target to $191 from $221. “We acknowledge the uncertainty around the commercial/endemic COVID market and uncertainty around '23 revenues, which has been a key investor focus and headwind,” said analysts led by Eliana Merle.
- 06/26/2023
|
Wall Street Says This Beaten-Down Stock May Climb Nearly 78%. Is That Too Optimistic?
- Moderna shares delivered enormous gains during the first year and a half of the pandemic. Since then, though, the stock has suffered as investors worry about declining revenues.
- 06/24/2023
|
Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine
- Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.
- 06/23/2023
|
Moderna files for US FDA authorization of updated COVID vaccine
- Moderna said on Thursday it has completed the submission of a regulatory application to the U.S. Food and Drug Administration for its updated COVID-19 vaccine to target subvariant XBB.1.5.
- 06/22/2023
|
Moderna files for FDA approval of updated Covid vaccine for fall
- Moderna said the submission is based on the FDA's recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.
- 06/22/2023
|
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
- The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
- 06/22/2023
|
Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start
- The FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall.
- 06/20/2023
|
Civitas and Mueller Can Boast High Profit, Low Debt
- Two of the badges of corporate success are high profits and low debt.
- 06/19/2023
|
Why Peter Hotez says he won't debate RFK Jr. after weekend of Rogan, Musk taunts
- That's Dr. Peter Hotez, the dean of the National School of Tropical Medicine at Baylor College of Medicine, on MSNBC, explaining why he's turned down a debate on Joe Rogan's podcast with Robert F. Kennedy Jr., who's seeking the Democratic nomination for president and according to the RealClearPolitics average is polling at about 16% in national polls, behind President Joe Biden at 62%.
- 06/19/2023
|
7 Value Stocks to Dump Before They Decline Even Further
- The key to making profits in the markets has been to buy large-cap growth stocks, and sell value stocks. At least, that's what it seems like, when you take into account that the surge of the S&P 500 index year-to-date is largely attributable to big gains among big tech stocks.
- 06/18/2023
|
FDA recommends that updated Covid shots target omicron subvariant XBB.1.5 this fall
- The FDA's decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5.
- 06/16/2023
|
FDA Panel Endorses Updating COVID Jab to Target XBB Strain
- An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.
- 06/16/2023
|
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
- 06/16/2023
|
FDA advisers endorse updating COVID vaccines to target latest omicron strain
- Today's vaccines still contain the original coronavirus strain, the one that started the pandemic — even though that was long ago supplanted by mutated versions as the virus rapidly evolves.
- 06/15/2023
|
Moderna, Inc. (MRNA) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 7:40 PM ET Company Participants Jamey Mock - CFO Lavina Talukdar - Head of IR Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thanks so much for joining us, I am Salveen Richter, Biotechnology Analyst at Goldman Sachs.
- 06/14/2023
|
7 Stocks to Sell in June Before They Crash and Burn
- As we pass the halfway mark of 2023, it's time to consider which stocks to sell in June. If investors continue to have trouble understanding whether the markets are due for another correction soon it's for good reason.
- 06/13/2023
|
Get Out Now! 3 Value Stocks That Are Poised to Plunge.
- With the stock market rising quickly, many companies have become expensive. Understandably, investors are considering value stocks as an alternative to frothy growth picks.
- 06/12/2023
|
3 Top AI Stocks to Buy Hand Over Fist
- AI stocks don't necessarily have to be technology companies. Some e-commerce and healthcare companies are investing in AI -- this can benefit their businesses and investors over time.
- 06/12/2023
|
Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now?
- Moderna is developing a personalized cancer vaccine in partnership with Merck. Moderna recently reported clinical-trial results that suggest its cancer vaccine does a lot to prevent skin cancer tumors from returning after they've been surgically removed.
- 06/10/2023
|
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
- Etsy, Moderna, and Walgreens have each slid in the double digits this year. It's important to consider whether their long-term outlooks make them buys at today's levels.
- 06/08/2023
|
As AI advances in healthcare, industry players wrestle with its risks
- As artificial-intelligence tools show promise in transforming healthcare, technology companies, healthcare providers, drugmakers and other players are also focused on its potentially damaging side effects.
- 06/07/2023
|
Moderna, Pfizer hit with new patent lawsuits over COVID vaccines
- Biotech firm Promosome LLC sued Moderna , Pfizer and BioNTech , in federal court in San Diego, California, on Tuesday, accusing their COVID-19 vaccines of infringing a patent related to messenger RNA technology.
- 06/06/2023
|
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading
- Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.
- 06/06/2023
|
3 Biotech Stocks to Sell in June Before They Crash and Burn
- The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline.
- 06/06/2023
|
Moderna, Inc. (MRNA) ASCO Investor Event Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) ASCO Investor Event Conference Call June 5, 2023 7:00 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head of Investor Relations Stephen Hoge - President Kyle Holen - Senior Vice President and Head of Development, Therapeutics and Oncology Conference Call Participants Edward Tenthoff - Piper Sandler & Co. Tyler Van Buren - Cowen and Company, LLC Mani Foroohar - SVB Securities LLC Luca Issi - RBC Capital Markets Gena Wang - Barclays Bank plc Michael Yee - Jefferies LLC Evan Wang - Guggenheim Securities Lavina Talukdar Okay. Good evening, everyone, and welcome to Moderna's ASCO 2023 event.
- 06/06/2023
|
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
- Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 06/05/2023
|
Moderna and Merck reveal new data on individualized cancer treatment
- Moderna MRNA, +1.55% and Merck & Co. MRK, +1.43% on Monday released new results from a trial evaluating Moderna's mRNA-based investigational individualized neoantigen therapy in combination with Merck's Keytruda in patients with high-risk melanoma. The combined therapy demonstrated a meaningful improvement in distant metastasis-free survival, a key secondary endpoint of the study, the companies said in a release.
- 06/05/2023
|
Moderna cancer vaccine used with Merck Keytruda reduces risk of deadly skin cancer spreading
- Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society.
- 06/05/2023
|
2 Blue-Chip REITs At Big Discounts
- Real estate is the worst-performing sector of the stock market over the last year as the market has shunned REITs. Over the long term, however, REITs have consistently been strong performers. As REITs are being dumped like garbage, we sift through the rubble to find two blue-chip REITs that are now deeply discounted.
- 06/05/2023
|
Better Healthcare AI Stock: Moderna vs. Doximity
- Moderna hopes AI will make drug discovery faster and more precise. Doximity is using AI to help doctors save time.
- 06/02/2023
|
Moderna to Present at Upcoming Conferences in June 2023
- CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences: 2023 Jefferies Healthcare Conference on Thursday, June 8th at 10:30 a.m. ET 44th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 14th at 4:40 p.m.
- 06/01/2023
|
2 Healthcare AI Stocks to Buy on the Dip
- Moderna is working with IBM technology to potentially discover new mRNA medicines. Medtronic is using AI in various specialties and says it could be the key to personalized medicine.
- 05/31/2023
|
Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines
- Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its patents.
- 05/26/2023
|
Moderna says looking for opportunities in China after registering legal entity
- U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy.
- 05/26/2023
|
Is Moderna Stock A Buy After Unexpectedly Turning A First-Quarter Profit?
- Is Moderna stock a buy after the company reported a 19-cent gain in the first quarter vs. calls for losses?
- 05/25/2023
|
7 Stocks That Even Company Insiders are Selling
- Insider buying, or the legal, reported purchase of shares in a company by its C-suite/board members/large shareholders, is considered a bullish signal. However, does that mean it is best to sell/avoid stocks insiders are selling?
- 05/24/2023
|
Report of new COVID wave in China pushes shares of vaccine makers higher
- Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the impact an outbreak could have on U.S. companies.
- 05/23/2023
|
Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?
- Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 05/23/2023
|
Is Moderna Stock a Buy Now?
- Moderna's vaccine-related sales have started to decline. However, the biotech is getting closer to new approvals.
- 05/23/2023
|
Bank Of America Upped Its Forecast For Stocks — Just Not The Ones You Think
- Bank of America is getting more bullish on S&P 500 stocks. Just not the ones that have been driving the S&P 500 higher all year.
- 05/23/2023
|
3 Stocks You'll Be Glad You Bought at These Prices
- Moderna's respiratory vaccine business could be a major growth driver in a few years. Etsy's capital-light business model helps it generate strong levels of free cash flow.
- 05/23/2023
|
Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy
- Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.
- 05/22/2023
|
Here's what Pfizer and Moderna say is next for their Covid vaccines
- Pfizer and Moderna are ushering in a new era for their Covid shots that aims to simplify what people need to do to coexist with the virus.
- 05/22/2023
|
Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich
- These biotech stocks are swinging for the fences. They may hit homers, they may strike out.
- 05/22/2023
|
TipRanks reveals the top 10 health care sector analysts of the past decade
- TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.
- 05/21/2023
|
Biotech Stocks Are Already Risky -- Now There Are 3 New Headwinds to Face in 2023
- Trends in drug development are shifting quickly these days. Research and development costs for pre-clinical trials are going to rise more.
- 05/19/2023
|
Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%
- Its bottom line didn't turn red last quarter, as many investors might have been expecting. However, that doesn't mean the company is out of the woods.
- 05/18/2023
|
3 Magnificent Growth Stocks to Buy to Help Build a Millionaire Portfolio
- Amazon is a leader in two high-growth industries and should benefit from that over time. Moderna aims to capture as much as half of the respiratory vaccine market later this decade.
- 05/18/2023
|
Growth Stocks Are Back — Analysts Like These 8 The Best
- Growth stocks in the S&P 500 are racing back. And analysts are scrambling to choose their favorites.
- 05/17/2023
|
Could Latecomer Moderna Match Big Pharma Rivals in RSV?
- Moderna may be close to entering a new billion-dollar market. But it's a step behind GSK and Pfizer.
- 05/16/2023
|
Is It Too Late to Buy Moderna Stock?
- Demand for Moderna's billion-dollar product is falling. But the company has laid out plans to expand beyond the coronavirus vaccine -- and bring in billions from more than one product by 2027.
- 05/15/2023
|
Warning! 3 Stocks That Are Waving Big Red Flags
- The current recovery in the stock market has been uneven. Tech is booming, financials are lagging and everything in between is a mixed bag.
- 05/14/2023
|
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
- Investors will love Johnson & Johnson's commitment to dividend payments. Vertex Pharmaceuticals already delivers billion-dollar earnings -- and new programs could further lift growth.
- 05/11/2023
|
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
- The global RSV vaccine market isn't all that big, and healthcare giants are battling for market share. Potential vaccines from Pfizer and Moderna have demonstrated high efficacy in late-stage trials.
- 05/11/2023
|
As COVID public health emergency ends, ‘whack-a-mole' virus won't be easy to track
- As the U.S. COVID-19 public health emergency comes to an end on Thursday, the fight against COVID goes on–-and some new challenges begin for those who hope to keep the virus at bay.
- 05/10/2023
|
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
- Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 05/09/2023
|
Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market
- Moderna's next big moment may come at the start of 2023's fall vaccination season. The vaccine giant's infrastructure and supply chain are ready -- and it says its discussions with commercial buyers have been "positive.
- 05/09/2023
|
Is Moderna a Value Stock to Buy Right Now?
- Moderna doesn't look like a value stock right now. With a big potential for its COVID-19, flu, and RSV vaccines, though, it could look like a bargain in retrospect.
- 05/07/2023
|
Is Moderna Building a Respiratory Vaccine Empire?
- Moderna's coronavirus vaccine revenue is declining -- but it still should remain at blockbuster levels. And the company has big plans beyond the coronavirus vaccine that could bring enormous rewards by 2027.
- 05/06/2023
|
Moderna stock closes higher on earnings beat, unexpected profit
- Yahoo Finance Live anchors Akiko Fujita and Seana Smith discuss a rise in shares of Moderna as the company's Q1 earnings beat exceeded investor expectations.
- 05/04/2023
|
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
- Moderna MRNA reported earnings of 19 cents per share for the first quarter of 2023, beating the Zacks Consensus Estimate and our model estimate of a loss of $1.77 and $2.09, respectively. Earnings declined 98% in the quarter.
- 05/04/2023
|
COVID-19 ‘is not leaving the planet,' Moderna CEO says
- Moderna Therapeutics CEO Stéphane Bancel joins Yahoo Finance Live to discuss first-quarter earnings, COVID-19 vaccine sales, profit growth, and the outlook for the biotechnology company's RSV vaccine.
- 05/04/2023
|
Moderna stock rises on Q1 earnings, positive vaccine guidance
- Yahoo Finance Live's Rachelle Akuffo and Brad Smith discuss the rise in stock for Moderna following first-quarter earnings.
- 05/04/2023
|
Moderna gets shot in the arm from unexpected 1Q profit, COVID vaccine sales outlook
- Moderna shares rose after the biotechnology company unexpectedly reported a profit for the first quarter and reaffirmed its 2023 COVID-19 vaccine sales expectations. The company posted earnings per share of $0.19, down from $8.58 in the same quarter a year earlier, but significantly outperforming Wall Street's expectation of a loss per share of $1.77.
- 05/04/2023
|
Moderna CEO Stéphane Bancel on surprise Q1 profit, post-Covid future
- Moderna CEO Stéphane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, what's next for the biotech company in a post-Covid future, and more.
- 05/04/2023
|
Moderna Jumps After Unexpectedly Reporting Profit In The First Quarter
- Moderna stock advanced Thursday after the company reported unexpected profit in the first quarter and beat sales expectations. The post Moderna Jumps After Unexpectedly Reporting Profit In The First Quarter appeared first on Investor's Business Daily.
- 05/04/2023
|
Moderna stock up premarket after posting surprise profit and revenue that crushed estimates
- Moderna Inc.'s stock MRNA, -0.96% rose 1.8% premarket Thursday, after the biotech blew past estimates for first-quarter earnings, even as profit and revenue fell sharply amid dwindling demand for COVID vaccines. The biotech posted net income of $79 million, or 19 cents a share, for the quarter, down from $3.657 billion, or $8.58 a share, in the year-earlier period.
- 05/04/2023
|
These Have Been 3 of the Best-Performing Healthcare Stocks Since 2020
- Demand for Moderna's COVID-19 vaccine will taper off this year, but investors remain bullish on its prospects. McKesson is a top distributor of pharmaceuticals and a key cog in the healthcare industry.
- 05/04/2023
|
Moderna Reports Earnings. What Comes After Covid Vaccine Will Be the Focus.
- As the biotech reports first-quarter earnings, the focus will be on Moderna's pipeline of future vaccines and cancer treatments and whether they can fill the hole left by dwindling Covid vaccine sales..
- 05/03/2023
|
Should You Buy Moderna (MRNA) Ahead of Earnings?
- Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/03/2023
|
This Cathie Wood Stock Is Tanking In 2023. Here's Why You Should Be Buying It
- Cathie Wood's investments are often in high-flying growth stocks. Moderna's long-term value won't be diminished by its near-term headwinds.
- 04/30/2023
|
Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?
- Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.
- 04/28/2023
|
Better Healthcare AI Buy: Moderna vs. Medronic
- Moderna expects AI to help it become even faster and more efficient in drug development. Medtronic recently signed a deal with Nvidia that could bring it a step closer to dominance in AI healthcare.
- 04/28/2023
|
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
- Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 04/27/2023
|
Better Buy: Pfizer vs. Moderna
- Pfizer and Moderna both face declines in coronavirus vaccine demand, and that should lower vaccine revenue. But both healthcare companies are set to launch new products that should boost growth.
- 04/26/2023
|
Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19
- Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19.
- 04/25/2023
|
6 Best Healthcare Stocks to Buy Right Now
- The United States healthcare system includes two sectors: public endeavors like Medicare and Medicaid and private health insurance companies. Healthcare stocks represent a significant section of the U.S. economy, with many medical companies included in indexes like the S&P 500.
- 04/25/2023
|
Is Moderna Setting Expectations Too High?
- Moderna's management expects revenue of between $8 billion and $15 billion by 2027. That's going to come primarily from COVID, RSV, and flu vaccine sales.
- 04/25/2023
|
The Best Stocks to Invest $20,000 in Right Now
- Investing across a few different companies could bring a lot of positive elements to your portfolio -- from dividends to growth potential. Healthcare is a great place to look for safe stocks and stocks offering high-growth opportunities.
- 04/23/2023
|
Can This AI Deal With IBM Be a Game-Changer for Moderna?
- Moderna plans to use IBM's AI and quantum computing platforms in its mRNA research. The biotech's CEO aims for “breakthrough advances.
- 04/22/2023
|
Moderna: Critically Undervalued With a Promising Pipeline
- It's long been speculated that artificial intelligence (AI) and quantum computing could rapidly speed up advancements in many areas of science and technology, as both are able to parse massive amounts of information to gain pattern-based insights far faster than humans can. In the past, this has rarely come to fruition because it's difficult to direct that much computing power in a way that can yield the desired results.
- 04/20/2023
|
Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
- CAMBRIDGE, MA / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its first quarter 2023 financial results, and provide a corporate update.
- 04/20/2023
|
Where Will Moderna Be in 1 Year?
- Moderna's coronavirus vaccine business will lose steam in the next 12 months. The company is looking at steady progress with its pipeline.
- 04/20/2023
|
Is Moderna About to Face the Same Challenge as Other Biotechs?
- Moderna reported positive data from its personalized cancer vaccine candidate. The biotech company aims to expand beyond its blockbuster coronavirus vaccine program.
- 04/20/2023
|
Moderna Stock: Bear vs. Bull
- Moderna's coronavirus vaccine sales are on the decline -- and that has investors worrying about the future. Still, Moderna may not be a one-product company for very long.
- 04/19/2023
|
FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations
- To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
- 04/19/2023
|
MRNA Stock Drops But Options Are Cheap; Play The Downside With This Debit Spread | IBD
- Using a bear put spread, here's how you can bet on a move to the downside in Covid vaccine maker Moderna while limiting your risk. New to trading?
- 04/18/2023
|
Top Stocks To Buy Now? 3 Healthcare Stocks To Know
- Healthcare stocks for your Mid-April 2023 watchlist.
- 04/18/2023
|
FDA authorizes additional omicron Covid shots for seniors and people with weak immune systems
- Although the burden of the pandemic has eased substantially, the CDC says Covid continues to kill more than 1,300 people per week.
- 04/18/2023
|
Moderna's Flu Vaccine Struggles: Is Novavax Stock Now a Better Buy?
- Moderna's experimental flu vaccine works well against influenza A strains but not against B strains (so far). This further solidifies Novavax's lead in the race to develop a combination COVID-19/flu vaccine.
- 04/18/2023
|
These 2 Stocks Were Monday's Big Disappointments
- Stock markets overcame weakness earlier in the day on Monday to finish modestly higher. Roblox reported business metrics for the month of March that raised concerns among shareholders about future growth.
- 04/17/2023
|
Why Moderna Stock Plunged Today
- Moderna disclosed positive results from a cancer trial over the weekend. However, results weren't better than already high expectations.
- 04/17/2023
|
Moderna Slumps as Vaccine Momentum Wanes
- Moderna ( MRNA , Financial) emerged as one of the biggest beneficiaries of the pandemic after it developed one of the first Covid-19 vaccines. However, the momentum created by the pandemic is fading, and the problem for Moderna is that the vaccine was the company's big breakthrough - its first blockbuster.
- 04/17/2023
|
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence
- Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.
- 04/17/2023
|
Moderna Cancer-Therapy Sees More Upbeat Data
- New data bolster the case for Moderna's experimental cancer treatment, but the path to turning it into a marketable product remains a long one.
- 04/17/2023
|
Moderna shares fall despite promising data from cancer vaccine trial
- Moderna's mRNA vaccine, when combined with Merck's blockbuster drug Keytruda, showed promise in treating melanoma, a kind of skin cancer.
- 04/17/2023
|
Moderna (MRNA) Stock Sinks Despite Positive Cancer Vaccine Update
- Moderna (NASDAQ: MRNA ) stock is sinking this morning despite releasing positive data about its cancer vaccine yesterday. Specifically, when used in combination with Merck's (NYSE: MRK ) drug, Keytruda, Moderna's shot lowered “the risk of [cancer] recurrence or death by 44% compared to Keytruda alone” in certain cancer patients, Moderna reported.
- 04/17/2023
|
This Prediction May Completely Change Your Opinion of Moderna
- Investors have worried about declining coronavirus vaccine revenue at Moderna. The company has many potential products in the pipeline though -- and a path to revenue growth.
- 04/17/2023
|
Wall Street analysts are bullish on Moderna stock price: should you?
- Moderna (NASDAQ: MRNA) stock price will be in the spotlight on Monday after the company announced important outcome of its skin cancer vaccine. The shares, which closed at $157 on Friday, are expected to jump when the markets open.
- 04/17/2023
|
Moderna, Merck combo cancer-vaccine treatment shows ‘significant' promise
- A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday.
- 04/16/2023
|
Moderna Shows Progress Toward Cancer Vaccines
- An mRNA shot helped prevent relapse in high-risk melanoma patients.
- 04/16/2023
|
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
- 04/14/2023
|
Moderna, Legend Biotech advanced to the major league from the minors. But how do you spot a rookie company ready to move to the ‘show'?
- We have seen a host of companies such as Moderna Inc and Legend Biotech Corp grow to join the major league of biotech companies. But how do you spot the rookie in the minors ready to make the step up and what are the red flags?
- 04/14/2023
|
Final Trades: Vertex, ConocoPhillips, Moderna & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 04/12/2023
|
Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback
- Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.
- 04/12/2023
|
Moderna stock drops on mixed data tied to flu vaccine approval
- The Yahoo Finance Live team discusses the three stocks to watch, including Moderna, whose stock fell after a release of contrary data related to their flu vaccine.
- 04/11/2023
|
Moderna withholds declaring ‘early success' for its Influenza vaccine
- Shares of Moderna Inc (NASDAQ: MRNA) are trading down on Tuesday after the biotechnology company said it did not have enough data to declare “early success” for its Influenza vaccine.
- 04/11/2023
|
Moderna says there are not enough cases to declare early success for its mRNA flu vaccine
- CNBC's Meg Tirrell reports on news from Moderna that it will delay results from its flu vaccine trials.
- 04/11/2023
|
Moderna Stock Falls After Vaccines Update
- The biotech company is working on new drugs for Lyme disease and Covid-19 as it prepares to roll out six new products with “sizable markets.”
- 04/11/2023
|
Could Moderna Become a Warren Buffett Stock?
- Warren Buffett doesn't typically invest in biopharma stocks. Moderna has programs that could eventually make it more appealing to him.
- 04/11/2023
|
Moderna stock slides following experimental flu vaccine setback
- Yahoo Finance Live anchors Julie Hyman and Brad Smith discuss the decline in stock for Moderna.
- 04/11/2023
|
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
- Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
- 04/11/2023
|
Moderna Stock Skids Below Key Line On Unexpected Flu Shot Debacle
- Moderna stock skidded Tuesday on a mixed update for its mRNA-based flu vaccine. The update could impact the shot's commercial timing.
- 04/11/2023
|
Vaccines For Lyme Disease And Norovirus? Moderna Working On Shots Targeting Tick-Borne Infection And Vomiting Bug
- Lyme is Moderna's first attempt at creating a vaccine for a bacterial infection.
- 04/11/2023
|
Moderna Stock Slides Despite Positive Vaccines Update. Here's Why.
- The biotech company is working on new drugs for Lyme disease and Covid-19 as it prepares to roll out six new products with “sizable markets.”
- 04/11/2023
|
Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027
- Moderna said it sees a corresponding operating profit from its Covid, RSV, and flu vaccines in the range of $4 billion to $9 billion in 2027.
- 04/11/2023
|
Moderna is developing a vaccine candidate against Lyme disease that would be its first bacterial vaccine
- Moderna Inc. MRNA, +1.19% outlined its clinical goals for its mRNA platform on Tuesday to mark its 4th Vaccine Day, including a new development candidate against Lyme disease that would be its first bacterial vaccine. The company, whose first product to be approved by the U.S. Food and Drug Administration was its COVID vaccine, said it has dosed a first participant in a late-stage trial of its next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283.
- 04/11/2023
|
3 Overvalued Blue-Chip Stocks Not Worth Your Green
- This year, stock markets have experienced growth, although not uniformly. Some stocks are recovering, while others are still declining or stagnating.
- 04/11/2023
|
Moderna expects to have cancer and heart disease vaccines ready by the end of the decade
- Moderna Therapeutics Inc is aiming to develop life-saving vaccines for cancer, heart disease, and other conditions by 2030, according to remarks made by the company's chief medical officer, Dr Paul Burton, to the Guardian. Burton highlighted the potential of messenger RNA (mRNA) technology, which has seen significant advancements since the beginning of the Covid pandemic, and its applications in various disease areas.
- 04/11/2023
|
Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030
- Moderna's chief medical officer said advancements in mRNA technology since the outset of the Covid pandemic have ushered in a golden age for new vaccines.
- 04/10/2023
|
Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag
- The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.
- 04/10/2023
|
Moderna Surges On A Key Win For Its Merck-Partnered Cancer Vaccine In Europe
- Moderna stock inched ahead Monday after European regulators granted its Merck-partnered personalized cancer vaccine a key designation. The post Moderna Surges On A Key Win For Its Merck-Partnered Cancer Vaccine In Europe appeared first on Investor's Business Daily.
- 04/10/2023
|
Inflation Data, Disney Layoffs, Moderna's Prospects, and More Market News
- Plus Brad Stone, head of Bloomberg's global tech coverage, shares insights about Amazon and what to watch in the growing AI industry.
- 04/08/2023
|
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
- Medical stocks are holding up amid economic and market uncertainty. The post 5 S&P 500 Stocks Showing Strength As Recession Fears Rise appeared first on Investor's Business Daily.
- 04/07/2023
|
5 Top Growth Stocks to Buy Before the Next Bull Market
- When the market is in the doldrums, it's time to go bargain hunting. Many top growth stocks have suffered in recent times -- and some have what it takes to soar when the general environment improves.
- 04/06/2023
|
Could This Move by Johnson & Johnson Equal Billions for Moderna?
- J&J is dropping out of the adult RSV vaccine race. This leaves the market to Moderna, Pfizer, and GSK; all three are close to reaching commercialization with their vaccine candidates.
- 04/02/2023
|
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
- 03/31/2023
|
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
- Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out. The post J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out appeared first on Investor's Business Daily.
- 03/31/2023
|
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
- Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out. The post J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out appeared first on Investor's Business Daily.
- 03/29/2023
|
Moderna's CEO Just Gave Investors a Huge Reason to Sell the Stock
- Demand for the company's COVID-19 vaccine could fall by significantly more than what investors were expecting. Revenue this year could top $5 billion, but in 2024 it may be much lower than that.
- 03/29/2023
|
2 Nasdaq 100 Stocks to Buy Hand Over Fist Right Now
- Your portfolio needs to have stocks that'll expose it to long-term growth. Moderna's shares are selling on the cheap right now, and its growth runway is long.
- 03/28/2023
|
Could CRISPR Therapeutics Become the Next Moderna?
- CRISPR has some important elements in common with vaccine giant Moderna. And the company is heading for an important moment in its growth story.
- 03/27/2023
|
3 Things About Moderna That Smart Investors Know
- Moderna's post-pandemic vaccine sales aren't likely to reach the levels we've seen during the height of the pandemic. Now, the company is preparing for its next phase of growth.
- 03/25/2023
|
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
- Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
- 03/24/2023
|
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 03/24/2023
|
7 Blue-Chip Stocks Sitting in the Sweet Spot
- Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won't do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they're tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts.
- 03/23/2023
|
Why Moderna wants to raise the cost of its COVID-19 vaccine
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss key takeaways from Moderna CEO Stéphane Bancel's testimony before the Senate and why the pharmaceutical biotechnology company wants to raise the cost of its COVID-19 vaccine to match market competition.
- 03/23/2023
|
Generation Bio, Moderna announce collaboration
- Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid therapeutics. Moderna will make an upfront payment of $40 million in cash, in addition to a $36 million equity investment “at a premium over recent share prices.
- 03/23/2023
|
Moderna plans 400% increase in price of Covid vaccine
- Public Citizen Access to Medicines Director Peter Maybarduk and Northwestern healthcare economist Craig Garthwaite joins CNBC's Brian Sullivan and ‘Last Call' to discuss the debate over Moderna's decision to raise the price of its Covid vaccine.
- 03/22/2023
|
Moderna CEO defends price increase for COVID vaccine to Congress
- Moderna CEO Stéphane Bancel tried to defend the company's plan to increase the price of its COVID-19 vaccine during a congressional hearing that raised longstanding questions about how drugs should be priced in the U.S.
- 03/22/2023
|
Moderna CEO Stephane Bancel defends fivefold price hike of Covid vaccine during Senate grilling
- Bernie Sanders pressed Stephane Bancel during the Senate hearing to make a commitment that Moderna will not increase the vaccine's list price to $130.
- 03/22/2023
|
Moderna CEO defends $130 COVID vax price after Bernie Sanders jab
- "On top of all this, we're expecting a 90% reduction in demand," Bancel said. "As you can see, we're losing economies of scale.
- 03/22/2023
|
Sen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearing
- CNBC's Meg Tirrell reports on the Senate hearing on drug prices, which featured an exchange between Sen. Bernie Sanders and Moderna CEO Stéphane Bancel.
- 03/22/2023
|
Moderna CEO to Face Senate Committee About Covid Vaccine Pricing
- Sen. Bernie Sanders is expected to focus on the company's plans to charge insurers $130 per dose for its Covid-19 vaccine.
- 03/21/2023
|
2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market
- Loading up on quality stocks while valuations are low is a good idea. Pfizer's pipeline will be getting a bolt-on expansion with its Seagen acquisition.
- 03/20/2023
|
Very Good News For REIT Investors
- We just had two major bank failures, but deposits should be safe. Future interest rate expectations are now lower and this is very good news for REITs.
- 03/20/2023
|
12-Stock Portfolio -- 25 Growth Stocks to Buy Now
- If I were starting a new growth stock portfolio today, here are the stocks I'd buy.
- 03/19/2023
|
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
- The vaccine's revenue would help Pfizer make up for looming patent cliffs. GSK's annual financials were the healthiest of the three companies.
- 03/17/2023
|
This High-Growth Company Is Expanding. Time to Buy the Stock?
- Moderna recently announced an expansion plan, which includes hiring new employees and opening new offices. This is a sign of the company's confidence in its own future.
- 03/16/2023
|
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 03/15/2023
|
3 Vaccine Stocks to Watch for Their Post-Pandemic Moves
- During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved.
- 03/14/2023
|
Is It Time to Buy the Nasdaq's 3 Worst-Performing February Stocks?
- JD.com is based in China, which is why many investors stay away from it. Even in a tough advertising market, SiriusXM managed to grow.
- 03/14/2023
|
Why Moderna Stock Zoomed 7% Higher Today
- An analyst got notably more bullish on the well-known biotech, upgrading his recommendation on its shares. The market responded with a share bump-up.
- 03/13/2023
|
2 Top Biotech Stocks to Buy In March and Hold Forever
- Long-term investments in biotech tend to be hard to come by. Moderna's gargantuan pipeline means that it has a very long growth runway ahead.
- 03/13/2023
|
A Nasdaq Bull Market Is Coming: 2 Revolutionary Stocks to Buy and Hold
- Moderna is helping move the vaccine industry forward with its mRNA approach. Exact Sciences' products help patients and physicians better fight against cancer.
- 03/12/2023
|
Moderna plans to hire 2,000 workers, open new offices in West Coast
- Moderna Inc. MRNA, +2.59% said Friday it is expanding in the U.S., opening new offices in South San Francisco, Calif., and Seattle, and hiring 2,000 workers worldwide by the end of the year.
- 03/10/2023
|
Where Will Moderna Be In 5 Years?
- Moderna's coronavirus vaccine brought in a lot of money, but now it's fading. Other programs will take a couple of years to potentially hit the market.
- 03/10/2023
|
Moderna Stock: Bear vs. Bull
- Moderna's coronavirus vaccine revenue is on the decline -- along with vaccine demand -- as we head toward a post-pandemic situation. Still, vaccine revenue isn't over.
- 03/09/2023
|
Is It Too Late to Buy Moderna Stock?
- Moderna had a good run over the last few years, but now sales are headed downward. There isn't any new revenue source coming to the rescue for at least a few years.
- 03/09/2023
|
February's 7 Worst-Performing S&P 500 Stocks to Buy on the Cheap
- The S&P 500 lost 2.6% in February. However, on the plus side, the index has gained nearly 5% year-to-date through March 7.
- 03/09/2023
|
Roquefort develops a fifth programme using a technology pioneer by Moderna and BioNTech
- Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said has developed a new platform of potential anti-cancer messenger RNA (mRNA) therapeutics, expanding the company's portfolio to five in-house programmes. The initiative consists of four pre-clinical putative treatments focusing on the company's MDK, or Midkine, target - a protein that plays a key role in the development and progression of cancer.
- 03/08/2023
|
The 5 Best and Worst Performing Large-Cap Stocks in February 2023
- Investing in large-cap stocks is considered one of the best ways to invest in the stock market.
- 03/07/2023
|
Moderna, Inc. (MRNA) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 9:10 AM ET Company Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Okay. Great. Well, let's go ahead and keep going.
- 03/06/2023
|
10 S&P 500 Stocks Are Practically Immune To More Fed Rate Hikes
- Is the Fed done jacking up interest rates or not? Angst over that question is torturing the stock market — but a handful of S&P 500 stocks aren't worried.
- 03/06/2023
|
2 Reasons to Buy Moderna Stock, and 1 Reason to Sell
- Moderna's multi-year run of earning billions from its COVID-19 vaccine is winding down. It still has a massive pipeline of other pharmaceutical offerings that are full of promising projects.
- 03/06/2023
|
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks of 2023?
- Lumen's slowing growth, high debt, and dividend cut spooked the bulls. Moderna and Pfizer both face tough post-pandemic slowdowns.
- 03/05/2023
|
Better Growth Stock: Moderna vs. CRISPR Therapeutics
- Moderna's pipeline programs may drive another huge phase of growth. The potential approval of CRISPR's first product could be a major catalyst for the stock.
- 03/05/2023
|
Is Moderna Stock a Buy Now?
- The company is looking to transition beyond its COVID-19 vaccine, and that could mean a bumpy ride for investors.
- 03/03/2023
|
Moderna May Be Just Getting Started in This Big Market
- We still may be able to count on Moderna for blockbuster revenue -- and over the long term.
- 03/02/2023
|
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 03/02/2023
|
New Investor? Buy These 2 Growth Stocks
- These long-term stocks look cheap right now.
- 03/01/2023
|
February's Stock Winners And Losers: Tesla And Nvidia Lead Charge, Moderna Lags Behind
- Bulls piled into the nation's largest chipmaker and most valuable car company this month, with shares of each company surging about 20%.
- 02/28/2023
|
8 Sinking Stocks Wipe The Smirks Off Millennials' Faces
- Millennial investors might think investing is easy and "stocks only go up." But a few of their popular holdings are sinking fast.
- 02/27/2023
|
3 Crucial Things to Know About Moderna Right Now
- This vaccine leader is preparing for a post-pandemic world.
- 02/27/2023
|
Moderna to make milestone payments to NIH for COVID vaccine
- Moderna Inc will make certain contingent development, commercial and regulatory milestone payments to the U.S. National Institutes of Health (NIH) related to the development of COVID-19 vaccines, the company said in a filing on Friday.
- 02/24/2023
|
Why Moderna Stock Dropped Today
- An investment firm sees more losses ahead for the biotech's investors.
- 02/24/2023
|
Does This Number Mean It's Time to Sell Moderna Stock?
- 2023 may be a year of transition for the biotech.
- 02/24/2023
|
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
- Startling cancer vaccine results from Moderna could drive the company's second act and usher in the next big thing in biotech. Here's what you need to know.
- 02/24/2023
|
Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y
- Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.
- 02/23/2023
|
Moderna, Inc. (MRNA) Q4 2022 Earnings Call Transcript
- Moderna, Inc. (NASDAQ:MRNA ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stephane Bancel - Chief Executive Officer Stephen Hoge - President Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Gena Wang - Barclays Matthew Harrison - Morgan Stanley Edward Tenthoff - Piper Sandler Michael Yee - Jefferies Tyler Van Buren - Cowen Jessica Fye - JPMorgan Ellie Merle - UBS Joseph Stringer - Needham Operator Good morning. My name is Kevin and welcome to Moderna's Fourth Quarter 2022 Earnings Call.
- 02/23/2023
|
Moderna Peers Over a Scary Profit Cliff
|
Moderna stock falls as orders for COVID shots slump
- Moderna Therapeutics Inc (NASDAQ:MRNA) stock started Thursday sharply lower as the COVID vaccine maker reported earnings that fell short of market expectations. As demand for COVID shots has dropped the cost of production is on the up, as the drug manufacturer is left with spare capacity.
- 02/23/2023
|
Moderna (MRNA) Lags Q4 Earnings and Revenue Estimates
- Moderna (MRNA) delivered earnings and revenue surprises of -22.53% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2023
|
Moderna Skids After 2023 Guidance Misses By More Than $2 Billion
- Moderna stock fell early Thursday after guidance for 2023 sales missed forecasts following a mixed fourth-quarter report. The post Moderna Skids After 2023 Guidance Misses By More Than $2 Billion appeared first on Investor's Business Daily.
- 02/23/2023
|
Moderna misses on earnings as costs rise from surplus production capacity, lower demand for Covid shots
- Moderna reported quarterly earnings of $3.61 per share, a 68% decrease from the same period in 2021 when it booked $11.29 per share.
- 02/23/2023
|
Moderna's Earnings, Revenue Fall on Fewer Vaccine Sales
- Demand for its Covid-19 vaccine sank from year-earlier highs when the spread of the Omicron variant boosted sales.
- 02/23/2023
|
Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine
- CNBC's Meg Tirrell reports on news from Moderna and Merck.
- 02/23/2023
|
Moderna Earnings Hit by Falling Covid Vaccine Sales. Stock Slides.
- Shares of the biotech company fell early Thursday, wiping out gains from positive news around its cancer vaccine candidate, as fourth-quarter earnings missed expectations.
- 02/23/2023
|
Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half
- Moderna Inc. MRNA, -1.20% said Thursday it had net income of $1.465 billion, or $3.61 a share, in the fourth quarter, down from $4.868 billion, or $11.29 a share, in the year-earlier period. Revenue fell to $5.084 billion from $7.211 billion a year ago.
- 02/23/2023
|
Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation
- Moderna stock jumped late Wednesday after the FDA granted its Merck-partnered cancer vaccine a breakthrough designation. The post Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation appeared first on Investor's Business Daily.
- 02/22/2023
|
Moderna, Merck receives FDA breakthrough status for personalized cancer vaccine
- CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Merck and Moderna receiving FDA breakthrough status for a personalized cancer vaccine.
- 02/22/2023
|
Moderna stock pops after receiving cancer-vaccine candidate gets FDA breakthrough designation
- Moderna Inc. MRNA, -1.20% and Merck Inc. MRK, +0.08% shares increased in after-hours trading Wednesday after the pharmaceutical companies announced that a cancer-vaccine candidate received the “breakthrough therapy” designation from the Food and Drug Administration. Moderna shares rose 4% and Merck shares increased about 1% in late trading.
- 02/22/2023
|
Moderna co-founder talks COVID-19 vaccines, mRNA growth, agriculture portfolio
- Moderna Co-Founder and Flagship Pioneering CEO Noubar Afeyan joins Yahoo Finance Live's Anjalee Khemlani and Rachelle Akuffo to discuss building on mRNA technology, the future of vaccines, keeping COVID-19 vaccines free, and the outlook for Moderna's Senate testimony.
- 02/22/2023
|
9 Stocks Jumped 200% In 3 Years Since Covid Rocked The World
- It's been three years since the Covid crash tanked the S&P 500. But there's been still plenty of ways to make money since.
- 02/22/2023
|
Moderna to collaborate with Life Edit on gene editing therapies
- Moderna Inc. MRNA, -3.91% announced Wednesday a collaboration agreement with privately held Life Edit Therapeutics Inc. to discover and develop in vivo gene editing therapies. Moderna's stock edged up 0.4% in premarket trading.
- 02/22/2023
|
Where Will Moderna Be in 5 Years?
- Moderna shares have what it takes to gain over time.
- 02/21/2023
|
2 Resilient Growth Stocks to Buy and Hold Forever
- These two "pandemic stocks" are still great investments.
- 02/18/2023
|
Three-Stock Lunch: DE, AN and MRNA
- Diamond Hill Capital Management's Heather Brilliant joins CNBC's reporter panel on 'Power Lunch' to discuss Deere, AutoNation, and Moderna, three stocks making moves after earnings results.
- 02/17/2023
|
Moderna stock declines on mixed flu vaccine trial results
- Yahoo Finance's Julie Hyman, Brian Sozzi, and Brad Smith discuss why Moderna stock is down on Friday.
- 02/17/2023
|
Moderna's stock hit as flu-vaccine trial fails on one target. Meanwhile, China declares victory over COVID.
- Moderna Inc.'s stock slid 5% Friday after the COVID vaccine maker said a trial of a flu-vaccine candidate that uses the same technology as its COVID shot had mixed results and failed to meet one of its goals.
- 02/17/2023
|
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
- Moderna stock toppled Friday on mixed results for its flu shot — a rival to experimental vaccines from BioNTech, CureVac and Sanofi. The post Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees appeared first on Investor's Business Daily.
- 02/17/2023
|
Why Is Moderna (MRNA) Stock Down 5% Today?
- Moderna (NASDAQ: MRNA ) stock fell 5% overnight after receiving mixed results on a large-scale study of its seasonal flu vaccine. The vaccine uses the same messenger RNA technology as Moderna's Covid-19 vaccine but targets four strains of influenza simultaneously.
- 02/17/2023
|
Moderna shares fall on mixed flu vaccine study results
- Moderna Therapeutics Inc (NASDAQ:MRNA) shares have fallen more than 5% in pre-market trading after the biotechnology company reported mixed results from a study of its experimental influenza (flu) vaccine mRNA-1010. The Phase 3 randomized trial was designed to evaluate and safety and immunogenicity of mRNA-1010 in adults aged 18 and older in the Southern Hemisphere.
- 02/17/2023
|
Moderna's mRNA flu vaccine met study goals for influenza A, but not B
- CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Moderna's flu vaccine trial results.
- 02/16/2023
|
Moderna stock falls 5% after flu vaccine study results
- Moderna Inc. shares dove more than 5% in after-hours trading Thursday, after the company announced that a study into a flu vaccine candidate failed to reach one of its goals.
- 02/16/2023
|
A Bull Market Is Coming. To Prepare, Take Warren Buffett's Advice.
- Quality and price are two key elements to keep in mind.
- 02/16/2023
|
Moderna's COVID vaccine will remain free for all Americans in coup for Bernie Sanders
- Moderna Inc. will keep its COVID-19 vaccines available and free of charge for all people in the U.S. after the public-health emergency ends, the company said late Wednesday.
- 02/16/2023
|
Moderna and Cirrus Logic Are Balance Sheet Powerhouses
- On a hilltop in your town live two people. Joseph has an income of $400,000 a year but little savings.
- 02/16/2023
|
The 10 Biggest Companies Reporting Earnings in the Fourth Week of February 2023
- Companies with a strong earnings growth rate are usually on traders' radars. Thus, it is important to keep track of stocks that are due to announce their earnings report card.
- 02/15/2023
|
Moderna promises to keep COVID vaccine free
- Moderna Inc. MRNA, +0.95% said Tuesday it will keep its COVID-19 vaccines available and free for all people in the U.S. after the public-health emergency ends. For uninsured or underinsured people, Moderna said it will provide the vaccine at no cost through its patient assistance program.
- 02/15/2023
|
Moderna CEO Stephane Bancel will testify before Senate next month on Covid vaccine price hike
|
Is Moderna Stock A Buy As It Faces Off With Pfizer, GSK In The Massive RSV Market?
- Is Moderna stock a buy after unveiling promising results for its Pfizer- and GSK-rivaling RSV vaccine? Is MRNA stock a buy now?
- 02/15/2023
|
Candy? Flowers? These Top Stocks Offer You Something Even Sweeter
- These stocks may reward you over time.
- 02/14/2023
|
Signal Says Buy the Dip on This Vaccine Stock
- Moderna Inc (NASDAQ:MRNA) stock was last seen trading at $169.88.
- 02/13/2023
|
Here are five companies to pick if Goldman Sachs is right about the stock market being flat in 2023
- Hearts, flowers and CPI data. Get ready for Tuesday.
- 02/13/2023
|
Betting On Biotech
- Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow. Passive investors seeking a defensive position might just purchase the VanEck Pharmaceutical ETF and call it a year.
- 02/10/2023
|
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 02/09/2023
|
Pandemic Profits In Healthcare
- Pfizer and Moderna profited by developing vaccines at a breakneck pace, but should investors add them to their portfolios in 2023? As the race to develop COVID-19 vaccines became paramount, Moderna's years of mRNA research would finally pay off.
- 02/09/2023
|
Is Biotech Immunocore About To Make A 25% Price Move?
- The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.
- 02/07/2023
|
3 No-Brainer Growth Stocks to Buy in 2023
- These stocks all fell by double digits last year.
- 02/03/2023
|
Is Moderna Stock a Buy Now?
- The company is starting the year on a strong note.
- 02/03/2023
|
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
- You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
- 02/02/2023
|
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
- CAMBRIDGE, MA / ACCESSWIRE / February 2, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 to report its fourth quarter and full year 2022 financial results, and provide a corporate update.
- 02/02/2023
|
Moderna's stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023
- Moderna Inc.'s MRNA shares were down 2.8% in trading on Tuesday. Pfizer Inc. PFE, which makes a competing COVID-19 vaccine to Moderna's Spikevax, on Tuesday put out guidance for 2023, saying it expects a total of $13.5 billion in sales of its COVID shot for the year.
- 01/31/2023
|
Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag
- Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
- 01/31/2023
|
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
- The Food and Drug Administration granted Moderna's experimental RSV vaccine an expedited review, but Moderna stock dipped Monday.
- 01/30/2023
|
Moderna's RSV vaccine gets Breakthrough Therapy status
- Moderna Inc. MRNA, -2.01% said Monday that the Food and Drug Administration granted the company's experimental respiratory syncytial virus vaccine a Breakthrough Therapy Designation. Moderna said it plans to apply for approval in the first half of this year.
- 01/30/2023
|
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
- Two of these stocks have what it takes to rebound and deliver lasting gains.
- 01/29/2023
|
Mergers and Acquisitions in 2023 Off To A Strong Start
- Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).
- 01/27/2023
|
Could This RSV News Make Moderna a Hot Buy Again?
- The company could soon have a new vaccine bringing in revenue.
- 01/25/2023
|
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
- Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.
- 01/21/2023
|
Moderna and Pfizer Race to Release RSV Vaccines
- Two of the largest vaccine producers have engaged in the rapid development of RSV vaccines, here's how the companies are tracking so far.
- 01/20/2023
|
GSK faces new RSV vaccine competitor after Moderna data, says Barclays
- GSK is facing a new competitor for its respiratory syncytial virus RSV vaccine after Moderna published data for its alternative, according to analysts at Barclays. “Moderna's efficacy data looks in line with GSK's, and, while there are still a lot of questions to answer (timing of market entry, detailed data, duration of effect), we think GSK's underperformance today reflects consideration of a three-player vs.
- 01/20/2023
|
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
- Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks. The post Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market appeared first on Investor's Business Daily.
- 01/19/2023
|
Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?
- Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 01/19/2023
|
Stocks moving after the closing bell: Kraft Heinz, Microsoft, Party City, Celsius
- Yahoo Finance Live anchor Jared Blikre breaks down the performance of several trending stocks following Wednesday's closing bell.
- 01/18/2023
|
Moderna's mRNA RSV vaccine propels stock gains
- Michael Yee, managing director at Jefferies, joins 'The Exchange' to discuss what's driving Moderna's stock activity, the unique mRNA technology behind the company's RSV vaccine and portfolio opportunities in the biotech business.
- 01/18/2023
|
Moderna CEO on Vaccines, Mutation Risk
- Moderna CEO Stephane Bancel says the current risk of virus mutations out of China are not high. He speaks to Bloomberg from the World Economic Forum in Davos.
- 01/18/2023
|
Moderna is the latest company to produce a promising RSV vaccine
- Moderna's disclosure this week that its respiratory syncytial virus vaccine prevented most infections in older adults in a clinical trial further sets the stage for a competitive new market ahead of next winter's cold season.
- 01/18/2023
|
Moderna Finds Life After Covid-19
- Even as Covid-19 turned Moderna into a biotech giant, the debate on Wall Street over its prospects has continued to rage.
- 01/18/2023
|
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
- Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.
- 01/18/2023
|
Moderna shares soar on positive RSV vaccine trial results
- Moderna Inc stock had added almost 6% on Wednesday morning after the biotechnology company reported positive results from a Phase 3 clinical study involving its vaccine targeting respiratory syncytial virus (RSV). The company said its vaccine mRNA-1345 was 83.7% effective against at least two symptoms of RSV-associated lower respiratory tract disease in adults aged 60 years and older.
- 01/18/2023
|
What's happening to Moderna shares on Wednesday?
- Shares of Moderna Inc (NASDAQ: MRNA) gained as much as 8.0% on Wednesday after the biotech giant reported promising results for its respiratory syncytial virus vaccine in older adults.
- 01/18/2023
|
RSV Vaccine Trial Data Sends Moderna Stock Surging
- Moderna Inc (NASDAQ:MRNA) stock is enjoying vaccine tailwinds today, though outside the realm of Covid this time.
- 01/18/2023
|
Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results
- Moderna (NASDAQ: MRNA ) stock is on the move Wednesday alongside positive results from its latest mRNA-1345 vaccine trial. That trial covers the use of mRNA-1345 as a vaccine for the respiratory syncytial virus (RSV).
- 01/18/2023
|
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
- The Nasdaq looked poised for modest gains once again on Wednesday.
- 01/18/2023
|
Moderna, Tesla, Charles Schwab, and More Market Movers
- Stocks paused Wednesday as investors reacted to a monetary policy decision from the Bank of Japan and looked ahead to a wave of economic data.
- 01/18/2023
|
Davos 2023: Moderna CEO says he wants to have mRNA factory on every continent
- Moderna chief executive Stephane Bancel said he would like to have factories making vaccines based on its messenger RNA technology on every continent as the U.S. company prepares to build four facilities.
- 01/18/2023
|
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
- Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults. The post Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up appeared first on Investor's Business Daily.
- 01/17/2023
|
Moderna's phase three RSV trial found to be 83.7% effective in older adults
- CNBC's Meg Tirrell joins 'Closing Bell' to discuss Moderna's phase three trial results for its RSV vaccine, the decision to submit the vaccine for regulatory review and the competitive landscape for RSV vaccines.
- 01/17/2023
|
Moderna stock rallies 5% after respiratory virus vaccine trial meets endpoints
- Moderna Inc. MRNA, -0.68% shares rallied in the extended session Tuesday after the biotech drug company said results from a late-stage clinical trial for its respiratory virus vaccine met endpoints, and that it will submit for Food and Drug Administration approval by mid-2023. Moderna shares surged as much as 5% after hours, following a 0.7% decline to close the regular session at $190.69.
- 01/17/2023
|
Moderna says RSV vaccine is 84% effective at preventing disease in older adults
- RSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
- 01/17/2023
|
Moderna: Wait For The Turn
- Moderna, Inc. packed more punches against its critics as it delivered surprisingly positive results on its personalized cancer vaccine study with Merck's Keytruda. However, BioNTech's more ambitious approach to its cancer vaccine could pack a serious threat and outdo Moderna's strategy.
- 01/16/2023
|
3 Biopharma Stocks That Could Help Make You a Fortune
- All three are protected by sales of in-demand products, with more on the way.
- 01/16/2023
|
Moderna's Platform Is Game Changing
- Moderna has a strong platform of assets that have the potential to revolutionize the treatment of numerous fields. The COVID-19 business will likely continue to generate billions in annualized revenue, but not enough to justify its valuation.
- 01/15/2023
|
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
- Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 01/13/2023
|
5 Potentially Explosive Stocks to Buy in 2023
- These stocks all dropped in the double digits last year. But their future prospects are brilliant.
- 01/13/2023
|
Moderna under fire for 400% price hike of COVID vaccine: ‘Outrageous'
- The pharmaceutical giant could raise the price of the vaccine from its current $26 per dose to between $110 and $130 per dose.
- 01/12/2023
|
Is Moderna Stock A Buy Or A Sell On Lagging Covid Vaccine Sales?
- Is Moderna stock a buy or a sell after issuing a light preliminary sales outlook for 2022? Is MRNA stock a buy or sell right now?
- 01/11/2023
|
Moderna considers raising COVID vaccine prices
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss reports that Moderna is considering raising the price of its COVID-19 vaccines, Moderna Chairman Noubar Afeyan's response to Senator Bernie Sanders on drug pricing, and the top takeaways from the JPMorgan healthcare conference.
- 01/11/2023
|
Ranking The 10 Largest Biotechs By Pipeline
- The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.
- 01/11/2023
|
Moderna (MRNA) Reports 2023 Business View & Pipeline Updates
- Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.
- 01/10/2023
|
Moderna mulls Covid vaccine price hike as infections rise
- Moderna Therapeuitics Inc is mulling a hike in the US price of its Covid-19 vaccine to between US$110 to $130 a shot as government contracts come to an end, chief executive Stephane Bancel said in an interview yesterday. That would be well above previous guidance, which had indicated a range of US$64-US$100 per jab.
- 01/10/2023
|
Moderna, Inc. (MRNA) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) 41st Annual J.P. Morgan Healthcare Conference January 9, 2023 5:15 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Jessica Fye - J.P Morgan Jessica Fye Hey, good afternoon, everyone.
- 01/09/2023
|
WSJ: Moderna may charge up to $130 per dose of its COVID shot
- Shares of Moderna Inc. MRNA, +2.39% were up 2.5% in trading on Monday afternoon after the Wall Street Journal reported that the company is considering pricing its COVID-19 vaccine at $110 to $130 per dose. That's the same price range that Pfizer Inc. PFE, -4.57% and BioNTech BNTX, -0.11% suggested for their COVID vaccine once the COVID vaccines move into a commercial market.
- 01/09/2023
|
Moderna Considers Price of $110-$130 for Covid-19 Vaccine
- The commercial price for the shot is similar to Pfizer's plans for after government contracting ends.
- 01/09/2023
|
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response
- A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.
- 01/09/2023
|
Moderna's COVID shot to generate $5.0 billion in sales in 2023
- Shares of Moderna Inc. MRNA, +3.94% were up about 1.0% in premarket trading on Monday after the company reiterated that it expects to have $5.0 billion in sales of its COVID-19 vaccine in 2023. Moderna also said its vaccine generated $18.4 billion in sales in 2022, and the company plans to boost spending on research and development to $4.5 billion this year, up from $3.3 billion in 2022.
- 01/09/2023
|
Looking for Growth in 2023? Where to Invest $5,000
- Over time, some of last year's losers could win big.
- 01/07/2023
|
CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
- CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.
- 01/06/2023
|
CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal
- On a resoundingly positive Friday for the market, CytomX Therapeutics (NASDAQ: CTMX ) is providing a large portion of the fireworks. Specifically, CTMX stock skyrocketed more than 50% before settling at a 40% increase as of this writing.
- 01/06/2023
|
Many Investors Wouldn't Touch This Stock With a 10-Foot Pole Last Year. Here's Why It's a Buy in 2023.
- Moderna's vaccine earnings are helping it prepare for the future.
- 01/06/2023
|
CytomX shares surge more than 50% on Moderna partnership
- CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares were last up 57% after hours, following a 7.2% rise to close the regular session at $1.79. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop “messenger RNA-based conditionally activated therapeutics” with Moderna.
- 01/05/2023
|
Moderna Buying Genomics K.K. For $85 Million (MRNA)
- Moderna (MRNA) announced it is buying OriCiro Genomics K.K. These are the details.
- 01/05/2023
|
Moderna to buy Japan-based OriCiro Genomics for US$85M
- Moderna Inc, the biotech pioneering messenger RNA (mRNA) therapeutics and vaccines, said it has struck a deal to buy Japan-based OriCiro Genomics for US$85 million to boost its manufacturing capabilities. "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stéphane Bancel, the CEO of Moderna, in a statement.
- 01/04/2023
|
Moderna Bolsters Its Vaccine Pipeline With $85 Million Deal for Biotech Firm OriCiro
- The small Tokyo-based company's tools will help the pharma giant's messenger RNA manufacturing process.
- 01/04/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Tesla is not alone: 18 (and a half) other big stocks are headed for their worst year on record
- In the worst year for stocks since the Great Recession, several big names are headed for their worst year on record with just one trading day left in 2022.
- 12/29/2022
|
These Are The 5 Best Dow Jones Stocks For 2022
- Biotechs, insurers and heavy equipment were among the best Dow Jones stocks for 2022. An oil stock led, even though oil prices declined.
- 12/29/2022
|
Biotech: 3 Profitable Bios Worth Owning
- The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval.
- 12/28/2022
|
Jefferies analyst reveals his top two biotech stocks for 2023
- Moderna Inc (NASDAQ: MRNA) has tanked nearly 15% in recent days but a Jefferies analyst dubs it one of his best ideas for 2023. Moderna stock could climb another 50% Earlier in December, the biotech company said its candidate vaccine for skin cancer showed encouraging results in a Phase II study (read more).
- 12/27/2022
|
Stock Market Gets More Jittery As Bond Yields Jump Again; Sellers Hit Tesla, Moderna, Nvidia Hard
- The stock market held up relatively well Tuesday, except for technology stocks, which fell hard as the 10-year Treasury yield spiked again. The post Stock Market Gets More Jittery As Bond Yields Jump Again; Sellers Hit Tesla, Moderna, Nvidia Hard appeared first on Investor's Business Daily.
- 12/27/2022
|
This Stock Just Soared by 20%: Should You Buy Now?
- It's been an otherwise poor year for this biotech on the stock market.
- 12/26/2022
|
Biotech is Set for a Blockbuster 2023: Here's Why
- The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?
- 12/23/2022
|
Here's Where to Invest $1,000 Right Now
- The investing year isn't over yet
- 12/23/2022
|
Moderna agrees 10-year vaccine manufacturing deal with UK
- Moderna has agreed to invest in a Covid vaccine research and development and build a new vaccine manufacturing facility in the UK. “The deal is also a major boost for UK health research and will see the UK Health Security Agency (UKHSA) working with Moderna to ensure early vaccine development” said the government.
- 12/22/2022
|
Better Buy: Moderna vs Axsome
- Revenue prospects look promising for both of these biotech companies.
- 12/22/2022
|
Could This Opportunity Make Moderna a Hot Buy Again?
- Merck and Moderna recently announced positive results from a trial involving their personalized cancer vaccine.
- 12/21/2022
|
Jefferies upgrades Moderna stock, raises price target
- Yahoo Finance Live anchors Seana Smith and Pras Subramanian break down the action surrounding Moderna after Jefferies analysts upgraded its stock and price target.
- 12/19/2022
|
Moderna shifts focus to developing cancer vaccinations
- Michael Yee of Jefferies joins 'Closing Bell' to discuss Moderna's shift away from Covid-focused pharmaceuticals toward PCV cancer vaccination, the market size for personalized cancer vaccines and the Moderna-Merck partnership.
- 12/19/2022
|
Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids
- The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.
- 12/19/2022
|
Moderna Stock Is Upgraded on Growth Opportunities Not Related to Covid
- Jefferies analyst Michael Yee upgrades shares of Moderna to Buy from Hold, and boosts the price target to $275.
- 12/19/2022
|
Are These Multibillion-Dollar Vaccine Stocks Still a Buy?
- Moderna and Merck are up on the news regarding their melanoma cancer vaccine.
- 12/18/2022
|
5 No-Brainer Stocks to Buy Before 2023
- These stocks are dirt cheap today. But low valuations may not last for long.
- 12/18/2022
|
3 Beaten-Down Stocks That Could Explode Higher in 2023
- These stocks could have significant upside opportunities ahead.
- 12/17/2022
|
3 Top Stocks to Buy Before 2023
- Here are some great bargains for long-term investors as we approach the end of the year.
- 12/17/2022
|
Moderna's Next $20B Franchise - Learning From Merck's Keytruda
- Keytruda has proved to be MRK's leading sales driver, projected to contribute a significant 35.38% of FY2022 revenues at $20.9B. Given the early clinical success of MRNA and Keytruda combo, we reckon the former has a similarly bright prospect through the next decade, aided by the flu and RSV vaccines.
- 12/16/2022
|
Moderna Comes Alive On Good Performance From Pipeline, Please Try Again
- Moderna, Inc. lauded results from a clinical study readout. The large magnitude of the positive trend in a deadly cancer is an encouraging sign.
- 12/16/2022
|
Is Moderna a Good Stock to Buy Right Now?
- Recent results suggest the company's cancer vaccine candidate can succeed where others have failed.
- 12/15/2022
|
Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?
- Moderna stock rallied by close to 20% in Tuesday's trading, after it announced positive results from mid-stage trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck.
- 12/15/2022
|
Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study
- Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.
- 12/14/2022
|
Why Moderna Shares Are Rising Again Today - Moderna (NASDAQ:MRNA)
- Moderna Inc MRNA shares are trading higher by 8.5% to $214.34 on continued upward momentum after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.
- 12/14/2022
|
Is Moderna Stock a Buy After Its Impressive Cancer Vaccine Results?
- Moderna could have a winner with its personalized cancer vaccine. But the company also faces big questions.
- 12/14/2022
|
Moderna rockets higher as vaccine offers glimpse of 'new paradigm ' in cancer treatment
- Moderna shares rose by almost 20% overnight in the US an experimental cancer vaccine based on its messenger RNA (MRNA) technology boosted survival rates by over 40% in a trial. Shares in pharma companies working on other mRNA-based therapies also jumped on the news with Moderna boss Paul Burton saying the results had “the capacity to be a new paradigm in the treatment of cancer.
- 12/14/2022
|
Moderna, Merck stocks boosted amid joint cancer vaccine trials
- Yahoo Finance health correspondent Anjalee Khemlani joins the Live show to review Moderna and Merck shares following positive results seen in their joint cancer vaccine trial.
- 12/13/2022
|
Melanoma vaccine data should make investors more positive on Moderna, says Jefferies' Michael Yee
- Michael Yee, Jefferies, joins 'Closing Bell' to discuss Moderna popping on strong Melanoma vaccine data.
- 12/13/2022
|
Moderna Soars On Cancer Vaccine News: Here's What To Watch Going Forward - Moderna (NASDAQ:MRNA)
- Moderna, Inc MRNA gapped up 13% to start the trading day on Tuesday and was skyrocketing an additional 12% intraday after announcing that its Merck & Co, Inc MRK partnered cancer vaccine met the primary efficacy endpoint.
- 12/13/2022
|
Encouraging Trial Data Sends Moderna Stock Soaring
- Moderna Inc (NASDAQ:MRNA) is up 23.6% at $204.04 at last check, after a mid-stage trial showed the combination of its experimental melanoma vaccine and Merck's (MRK) immunotherapy Keytruda lowered the risk of skin cancer's recurrence or death by 44%.
- 12/13/2022
|
Why Moderna Stock Is Popping Over 20% Today
- Moderna Stock is ripping higher today after a cancer treatment breakthrough. Is Moderna stock a buy now?
- 12/13/2022
|
Moderna just used a personalized vaccine to treat cancer, and it could signal a major breakthrough in how we treat the disease
- "Now, we are an oncology company," Moderna CEO Stéphane Bancel told Insider.
- 12/13/2022
|
Moderna shares get a boost from Merck vaccine combo
- Moderna Therapeutics Inc (NASDAQ:MRNA) shares rallied after the biotechnology firm told investors that a trial that combined its investigational cancer vaccine with drug giant Merck & Co Inc (NYSE:MRK)'s immunotherapy Keytruda for patients with stage III/IV melanoma reduced the risk of recurrence or death by 44%. Moderna said the Phase 2b trial of its mRNA cancer vaccine in combination with Keytruda demonstrated a "statistically significant and clinically meaningful improvement" in the primary endpoint of recurrence-free survival versus Keytruda alone.
- 12/13/2022
|
Trending Today: 5 Stocks in the News
- So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.
- 12/13/2022
|
Moderna stock jumped 25% on a ‘big day for patients'
- Shares of Moderna Inc (NASDAQ: MRNA) are up nearly 25% on Tuesday after the biotech firm said its experimental vaccine for melanoma showed promising results in a small study.
- 12/13/2022
|
Moderna will apply ‘same intensity' for cancer vaccine as it did for COVID, CEO says
- Moderna CEO Stéphane Bancel speaks with Yahoo Finance's Anjalee Khemlani about the company's MRNA skin cancer vaccine trial with Merck and the pipeline for producing cancer vaccines.
- 12/13/2022
|
Moderna soars 24% after the drug maker posts upbeat results from cancer vaccine trial
- The pharma giant said combining its cancer vaccine with Merck's Keytruda therapy reduced patients' risk by roughly 44%, versus just Keytruda.
- 12/13/2022
|
Moderna and Merck team-up to fight melanoma
- Vaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer
- 12/13/2022
|
Why Moderna Stock Is Skyrocketing Today
- Moderna's personalized cancer vaccine program just received a big boost.
- 12/13/2022
|
Is Moderna Stock A Buy On A Bullish Update For Its Cancer Vaccine?
- Is Moderna stock a buy after the company offered a promising update for its cancer vaccine? Is MRNA stock a buy right now?
- 12/13/2022
|
2 Nasdaq Stocks Taking Big Strides Forward
- As markets soar following a healthy inflation report, investors are watching these two companies closely.
- 12/13/2022
|
Moderna (MRNA) Stock Soars on Cancer Vaccine News
- Moderna (NASDAQ: MRNA ) stock is rising higher on Tuesday following the release of data from a Phase 2B cancer vaccine clinical trial. Moderna is currently testing its cancer vaccine alongside Merck & Co's (NYSE: MRK ) Keytruda immunotherapy.
- 12/13/2022
|
Moderna CEO Stéphane Bancel on promising new data for mRNA cancer vaccine
- Moderna CEO Stéphane Bancel joins CNBC's 'Squawk Box' to discuss promising new data surrounding its experimental cancer vaccine in development with Merck.
- 12/13/2022
|
Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patients
- Merck & Co. Inc. MRK, +0.17% and Moderna Inc. MRNA, -6.89% said Tuesday that their experimental mRNA-based cancer vaccine reduced the risk of recurrence or death when used with Merck's Keytruda in patients with late-stage melanoma. Merck's stock was up 1.9% in premarket trading, while Moderna shares rallied 5.6%.
- 12/13/2022
|
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
- Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results could spark downtrodden Moderna stock.
- 12/13/2022
|
3 Medical Stocks With Solid Growth Drivers to Keep Track Of
- Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.
- 12/12/2022
|
PFIZER VS MODERNA; Which Pharmaceutical Is A Better Stock To Buy Now?
- Pfizer VS Moderna Third Quarter Earnings And Revenue
- 12/10/2022
|
3 Surefire Stocks to End 2022 on a Good Note
- These stocks should help your portfolio shine now and well into the future.
- 12/10/2022
|
FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids
- Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.
- 12/09/2022
|
These Top Stocks Are Rebounding: Should You Buy Before 2023?
- This may be the start of something good.
- 12/08/2022
|
Moderna Stock Is Yo-Yoing On New Omicron Booster Data — Is It A Buy?
- Is Moderna stock a buy after unveiling new test results for its omicron-blocking booster shot? Is MRNA stock a buy right now?
- 12/07/2022
|
Moderna Heads Into 2023 With Several Irons in the Fire
- Known for its Covid-19 vaccine, Moderna Inc. ( MRNA , Financial) holds a strong position in both clinical development and commercial manufacturing scale for mRNA vaccines. Currently, the company has 44 potential treatments and vaccines in different stages, including 24 undergoing clinical trials.
- 12/07/2022
|
Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history
- Pfizer asked a federal court in Boston on Monday to dismiss Moderna's lawsuit seeking monetary damages for alleged patent violations related to the Covid vaccine.
- 12/06/2022
|
Pfizer legal woes continue with battle against Moderna
- Pfizer Inc (NYSE:PFE) and BioNTech have moved to countersue rival Moderna Therapeutics Inc in a legal battle over the development of each company's respective Covid-19 vaccines. Moderna sued the duo in August, accusing them of copying technology which it had begun developing in 2010, long before the pandemic, and ultimately sought damages for the breaking of three of its patents.
- 12/06/2022
|
Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?
- Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.
- 12/05/2022
|
Moderna Stock: Buy, Sell, or Hold in 2023?
- Moderna has reached an important turning point.
- 12/01/2022
|
Moderna Stock Futures: Is COVID Vaccine Maker Moderna Poised To Pop Or Drop?
- Based on that assumption, this would indicate that the annual demand for COVID vaccines would be around 600 million doses.
- 11/29/2022
|
Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference
- CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1st at 9:00 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.
- 11/29/2022
|
These Are the Five Best and Worst Performing Healthcare Stocks in October 2022
- The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.
- 11/28/2022
|
11% Of S&P 500 Stocks Suffer Their Worst Year Ever
- Tesla isn't the only stock that's struggling in 2022. Nearly 60 S&P 500 stocks — or about 11% — are having their worst year ever.
- 11/28/2022
|
The Worst Mistake Moderna Investors Can Make in 2023
- Moderna faces a major transition in 2023.
- 11/26/2022
|
7 Stocks on the Perfect 10 List
- A stock that scores a perfect 10 should be on every investor's list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I'd considering a perfect 10.
- 11/23/2022
|
Buy this Medical Sector Pioneer Stock
- Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.
- 11/22/2022
|
Moderna, Applied Materials Are Candidates for a January Rebound
- Stocks that are killed in a given year often come back to life the following year, especially in January.
- 11/21/2022
|
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
- Innovative products and services could keep these companies growing.
- 11/20/2022
|
Moderna is developing vaccine booster shot to fight South Africa Covid strain
- Moderna's researchers say the current vaccine may be less effective against the South African Covid strain. They are planning to test a booster shot vaccine and develop a new vaccine to target Covid variants.
- 11/19/2022
|
Final Trades: Boeing, Moderna, Melco & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 11/19/2022
|
Moderna, Inc. (MRNA) 13th Annual Jefferies London Healthcare Conference 2022 - (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) 13th Annual Jefferies London Healthcare Conference 2022 Call November 15, 2022 10:50 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Yee - Jefferies Michael Yee [Starts Abruptly] for joining us on our next session. Michael Yee, Senior Biotechnology Analyst at Jefferies.
- 11/16/2022
|
Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal
- Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.
- 11/15/2022
|
Why Moderna Stock Popped Today
- Safe and effective booster shots could be a boon for the biotech.
- 11/14/2022
|
Moderna reports its new COVID-19 booster offers enhanced protection from Omicron
- Yahoo Finance Live anchors Seana Smith and Dave Briggs discuss data from Moderna indicating the heightened efficacy of its latest booster vaccine against the Omicron variant.
- 11/14/2022
|
Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride
- Moderna stock popped Monday after the company said its bivalent Covid booster led to a 15-fold jump in omicron-blocking antibodies. The post Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride appeared first on Investor's Business Daily.
- 11/14/2022
|
Final Trades: Nucor, Moderna, Palto Alto & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 11/14/2022
|
Moderna Stock Is Surging Today: What's Going On? - Moderna (NASDAQ:MRNA)
- Moderna Inc (NASDAQ: MRNA) shares are trading higher Monday after the company announced its bivalent Omicron-targeting booster candidates showed a superior antibody response compared to a booster dose of its
- 11/14/2022
|
Moderna says Covid booster better against omicron BA.5, triggers immune response against BQ.1.1
- Moderna found that the new booster triggered five times more antibodies against omicron BA.5 than the old vaccines in people with prior Covid infections.
- 11/14/2022
|
Moderna says its new COVID-19 boosters work against BA.5, BQ.1.1
- Moderna Inc. MRNA, +1.57% said in a news release on Monday that both of its new COVID-19 boosters produced a better antibody response against the BA.4 and BA.5 variants in a Phase 2/3 clinical than the company's original booster. Moderna has two bivalent boosters, one of which is authorized for use in the U.S. That shot, mRNA-1273.222, produced a "superior neutralizing antibody response" against BA.4 and BA.5 in about 500 clinical-trial participants who had already been vaccinated and boosted.
- 11/14/2022
|
Ready to Sell Moderna? Check Out This Chart First
- Moderna shares are heading for a 35% decline this year.
- 11/10/2022
|
Why Moderna Stock Could Still Be More Than 50% Overvalued
- One valuation model could hint at a further decline for the vaccine stock.
- 11/09/2022
|
Why Moderna Stock Jumped on Monday
- The market was pleased with the biotech's latest regulatory win.
- 11/07/2022
|
The Big Pharma Giants Are Down
- It's evident that big pharma giant Moderna (NASDAQ: MRNA) is going through troubled times. Worse, it's dragging other big Pharma giants with it.
- 11/06/2022
|
Is Moderna a Bad-News Buy?
- Moderna is heading for a big transition.
- 11/06/2022
|
3 Things You Need to Know About Moderna's Post-Pandemic Revenue
- Is the next phase of revenue growth just ahead?
- 11/05/2022
|
7 Cash-Rich Stocks to Buy for Peace of Mind
- Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way.
- 11/04/2022
|
This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters
- Covid vaccine stocks surged Friday after a new study suggested an added benefit of the updated omicron-targeting boosters. The post This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters appeared first on Investor's Business Daily.
- 11/04/2022
|
Is Moderna Stock A Buy Or A Sell As It Yo-Yos On An Influx Of Covid News?
- Is Moderna stock a buy or a sell after cutting its 2022 outlook for Covid vaccines just as Pfizer, BioNTech unveil promising booster news? The post Is Moderna Stock A Buy Or A Sell As It Yo-Yos On An Influx Of Covid News?
- 11/04/2022
|
Moderna's Earnings Collapsed. Time to Sell?
- This drugmaker's bottom line fell down a deep hole in the third quarter and investors want to know if it's time to run for the hills.
- 11/04/2022
|
Moderna stock tumbles after quarterly earnings show revenue declines
- COVID-19 vaccine maker Moderna's shares fell on Thursday following the release of the company's third-quarter earnings, which showed a decline in revenue.
- 11/03/2022
|
Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook
- Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.
- 11/03/2022
|
Moderna, Inc. (MRNA) Q3 2022 Earnings Call Transcript
- Moderna, Inc. (NASDAQ:MRNA ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Lavina Talukdar – Head-Investor Relations Stéphane Bancel – Chief Executive Officer Stephen Hoge – President Arpa Garay – Chief Commercial Officer Jamey Mock – Chief Financial Officer Conference Call Participants Salveen Richter – Goldman Sachs Matthew Harrison – Morgan Stanley Edward Tenthoff – Piper Sandler Michael Yee – Jefferies Gena Wang – Barclays Tara Bancroft – Cowen Jessica Fye – J.P. Morgan Geoff Meacham – Bank of America Eliana Merle – UBS Joseph Stringer – Needham Operator Good morning.
- 11/03/2022
|
Moderna misses on earnings as supply constraints hinder COVID vaccine deliveries
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss third-quarter earnings for Moderna.
- 11/03/2022
|
Global tally of COVID cases and deaths continues to fall; Moderna cuts vaccine-sales outlook by up to $3 billion
- The global tally of COVID-19 cases fell 17% in the week through Oct. 30 from the previous week, while the death toll fell 5%, the World Health Organization said in its weekly update on the virus.
- 11/03/2022
|
Moderna (MRNA) Lags Q3 Earnings Estimates
- Moderna (MRNA) delivered earnings and revenue surprises of -16.78% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Why Is Moderna (MRNA) Stock Down 5% Today?
- Moderna (NASDAQ: MRNA ) stock is falling on Thursday following the release of the vaccine company's earnings report for the third quarter of 2022. The bad news for investors in MRNA stock starts with its diluted earnings per share of $2.53.
- 11/03/2022
|
Moderna tanks 14% after COVID-19 vaccine maker cuts yearly sales outlook and misses 3rd-quarter expectations
- Short-term supply constraints led Moderna to cut its 2022 revenue outlook to a range of $18 billion to $19 billion.
- 11/03/2022
|
Moderna stock slides 11.5% premarket after earnings miss by a wide margin and company cuts sales outlook by up to $3 billion
- Moderna Inc. shares plunged 11% in premarket trade Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and lowered full-year sales guidance by up to $3 billion.
- 11/03/2022
|
Moderna Stock Tumbles on Earnings Miss, Guidance Cut
- The Covid-19 vaccine maker reported earnings early Thursday that missed Wall Street estimates, while cutting its estimate of total vaccine sales this year by between $2 and $3 billion.
- 11/03/2022
|
Moderna shares plummet after Covid vaccine maker lowers 2022 sales outlook
- Moderna also missed revenue and earnings expectations for the quarter.
- 11/03/2022
|
Why Moderna Stock Rose Today
- A rival drugmaker sees higher COVID-related sales ahead.
- 11/01/2022
|
Why Moderna Stock Soared Last Week
- The biotech's promising drug pipeline could drive further gains for shareholders.
- 10/30/2022
|
Three buys and a bail: AbbVie, Eli Lilly, Humana and Moderna
- Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three stocks Sanchez is interested in buying and one the strategist is bailing on.
- 10/28/2022
|
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
- Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 10/27/2022
|
Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?
- There's still considerable near-term uncertainty for both of these vaccine makers.
- 10/26/2022
|
Could This News from Pfizer Equal Billions for Moderna?
- Moderna's shares have suffered amid concern about future vaccine revenue.
- 10/25/2022
|
Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows
- Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking.
- 10/23/2022
|
Why Moderna Stock Rallied Today
- The biotech could offset declining COVID-19 vaccine sales by raising prices.
- 10/21/2022
|
Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?
- Stocks were set to open lower today, but the market seems to have found its groove. Everything from tech stocks to vaccine stocks are moving higher.
- 10/21/2022
|
Pfizer's Covid Vaccine to Cost a Lot More. Why That's Good News for Moderna.
- Pfizer and other pharma companies are under pressure to raise prices to meet revenue targets after government supplies of Covid vaccines runs out.
- 10/21/2022
|
Does This 1 Number Mean Trouble for Moderna?
- Moderna is preparing its business for a post-pandemic world.
- 10/21/2022
|
Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?
- Both companies are developing new drugs but that's where the similarities stop.
- 10/21/2022
|
Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab
- The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.
- 10/20/2022
|
CSCO Stock Short Straddle Could Generate $252 In Option Premium
- When option traders form an opinion that a stock is going to trade sideways, they might look to sell a short straddle. The post CSCO Stock Short Straddle Could Generate $252 In Option Premium appeared first on Investor's Business Daily.
- 10/20/2022
|
3 Potentially Explosive Stocks You'll Want in Your Portfolio Before the Next Bull Market (and They're Dirt Cheap Now)
- Today's economic environment doesn't change these companies' long-term prospects.
- 10/20/2022
|
Why Moderna Stock Dropped Today
- Competition is intensifying.
- 10/19/2022
|
The 7 Most Undervalued Long-Term Stocks to Buy Now
- My task today is to find seven of the most undervalued long-term stocks to buy now. We need to determine two things before stock selection takes place.
- 10/19/2022
|
EMA recommends Moderna's new Omicron-tailored vaccine
- The European Medical Agency on Wednesday recommended authorization of Moderna Inc's COVID-19 vaccine tailored towards targeting the Omicron sub-variants BA.4 and BA.5 for 12 and above ages.
- 10/19/2022
|
Swiss to destroy 9 million expired Moderna COVID-19 jabs
- Switzerland will destroy 9 million doses of Moderna COVID-19 vaccine that have reached their expiry date, with another 5.1 million vaccine jabs set to meet the same fate by February, the government said on Wednesday.
- 10/19/2022
|
Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option Play
- Traders who think Moderna stock will not reclaim the 50-day line could look at a bear call spread at 145-150. The post Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option Play appeared first on Investor's Business Daily.
- 10/19/2022
|
Moderna CEO on COVID vaccines: Not everyone will need an annual COVID-19 booster
- Moderna CEO Stephane Bancel speaks with Anjalee Khemlani at Yahoo Finance's All Markets Summit about the COVID vaccine and why boosters will be necessary each year.
- 10/18/2022
|
Why Moderna Stock Tripped and Fell on Tuesday
- The latest news about the coronavirus is encouraging, so the company's one commercialized product might not be such a popular item.
- 10/18/2022
|
Will This News Send Moderna's Stock Soaring?
- The company has been working on diversifying its pipeline.
- 10/18/2022
|
Moderna CEO Stephane Bancel on the outlook for the extending timeline of mRNA technology efficacy
- Moderna CEO Stephane Bancel spoke with Yahoo Finance on MRNA platform efficacy.
- 10/18/2022
|
What the Smartest Investors Know About Moderna Stock
- It's important to understand Moderna's near-term challenges and its long-term opportunities.
- 10/18/2022
|
3 Growth Stocks That Could Soar 62.6% to 66.3%, According to Wall Street
- Find out why analysts have such high hopes for these top growth stocks.
- 10/18/2022
|
Moderna CEO Stephane Bancel talks business, vaccine demand, and medical advances
- Moderna CEO Stephane Bancel spoke with Yahoo Finance's Anjalee Khemlani at the 2022 Yahoo Finance All Markets Summit.
- 10/17/2022
|
Moderna CEO: Merck deal ‘could be a game changer' for cancer treatment
- Moderna CEO Stéphane Bancel spoke with Anjalee Khemlani at Yahoo Finance's All Markets Summit about the company's deal with Merck to develop a cancer vaccine.
- 10/17/2022
|
Moderna CEO: COVID-19 accelerated manufacturing network by 5 years
- Moderna CEO Stephane Bancel spoke with Anjalee Khemlani at Yahoo Finance's All Markets Summit about Moderna's manufacturing network and how it plays into what the company can now do.
- 10/17/2022
|
Moderna CEO: Our global public health commitment 'is unconditional'
- Moderna CEO Stephane Bancel speaks at the All Markets Summit about the company's commitment to providing COVID-19 vaccines for low- and middle-income countries.
- 10/17/2022
|
Moderna, Gavi cancel COVID-19 vaccine orders for rest of 2022 due to 'sufficient supply'
- Moderna Inc. MRNA, -0.53% said it and GAVI, the Vaccine Alliance supplying vaccines to low- and middle-income countries, have agreed to cancel remaining orders under their 2022 COVID-19 vaccine agreement given "sufficient supply." The biotechnology company has supplied Gavi with nearly 70 million doses of COVID-19 vaccines, in addition to facilitating the donation of more than 100 million doses.
- 10/17/2022
|
3 Beaten-Down Stocks to Buy and Hold
- These stocks could be ready for big bounces.
- 10/15/2022
|
The Importance Of Government Contracting For Pfizer And Moderna
- COVID-19 vaccine Comirnaty and Paxlovid pill should contribute circa 55% to Pfizer's 2022 revenues. Pfizer's revenues from the U.S. government represented 26% of total revenues for Q2 2022, up from 13% reported in 2021.
- 10/14/2022
|
FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids
- Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.
- 10/14/2022
|
Merck And Moderna Move Forward With Melanoma Vaccine - There's A Case For Backing Both
- Back in September 2021,Moderna's and Merck's market cap valuation were only a few billions apart at ~$175bn and ~$182bn, respectively. As the more diversified, future-proofed pharma, it makes sense that Merck's valuation has increased while Moderna's has tanked.
- 10/13/2022
|
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
- Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
- 10/13/2022
|
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
- CAMBRIDGE, MA / ACCESSWIRE / October 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022 to report its third quarter 2022 financial results, and provide a corporate update.
- 10/13/2022
|
Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?
- Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 10/13/2022
|
Moderna Now Priced Attractively For Long-Term Investors
- Moderna's revenue is declining as public resists boosting. The FDA approved the new booster for children aged 6 and up.
- 10/13/2022
|
Moderna and Merck ink US$250mln deal to develop world's first cancer vaccine
- The group that developed a Covid jab using messenger RNA (mRNA) technology has inked a US$250mln deal with to create a cancer vaccine with one of the world's largest pharma companies. Moderna Theraputics Inc is teaming up with Merck to develop and commercialise the personalised cancer drug mRNA-4157/V940, which is currently in phase II trials.
- 10/13/2022
|
These 2 Stocks Gave Investors a Nice Surprise Wednesday
- Markets moved slightly lower in advance of the latest data on inflation.
- 10/12/2022
|
Moderna and Merck enter joint venture to develop cancer vaccine
- Yahoo Finance anchors Seana Smith and Dave Brigs discuss pharmaceutical manufacturers Moderna and Merck are partnering together to develop a cancer vaccine.
- 10/12/2022
|
Moderna to develop a personalized cancer vaccine with Merck
- Michael Yee, Jefferies managing director, joins 'Closing Bell' to share details on the Moderna and Merck announcement about a personalized cancer treatment for people with melanoma and what it means for Q3 earnings.
- 10/12/2022
|
Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine
- The move is welcomed by investors because if successful, it would help Moderna diversify its revenue and profits away from COVID-19 vaccines.
- 10/12/2022
|
Moderna shares jumped 15% on Wednesday: this is why
- Shares of Moderna Inc (NASDAQ: MRNA) jumped as much as 15% this morning after the biotechnology company built on an agreement it signed with Merck & Co Inc (NYSE: MRK) in 2016.
- 10/12/2022
|
CDC officially recommends new boosters for young children
- The Centers for Disease Control and Prevention officially signed off on allowing children as young as 5 years old to get an updated COVID-19 booster shot. CDC Director Rochelle Walensky signed the decision memo on Wednesday afternoon, the same day that the Food and Drug Administration expanded the authorizations for Moderna Inc. MRNA, +7.75% and BioNTech SE BNTX, +4.97% /Pfizer Inc.'s PFE, +0.66% updated COVID-19 boosters.
- 10/12/2022
|
FDA Authorizes New COVID Boosters for Kids
- Like Moderna's and Pfizer's updated vaccines for adults, the child doses target newer strains of COVID-19.
- 10/12/2022
|
Moderna, Merck to jointly develop cancer vaccine
- Yahoo Finance Live's Julie Hyman discusses the rise in shares for Merck and Moderna after Moderna announced the joint development and potential sale of an mRNA-based cancer vaccine.
- 10/12/2022
|
Why Moderna Stock Is Bolting Higher Today
- A cancer vaccine deal with pharma heavyweight Merck is lighting a fire underneath the biotech's shares today.
- 10/12/2022
|
Why Is Moderna (MRNA) Stock Up 10% Today?
- Could this be a collaboration that saves lives? That's the billion-dollar question today as Moderna (NASDAQ: MRNA ) is reportedly working with Merck (NYSE: MRK ) to develop an mRNA-based cancer vaccine.
- 10/12/2022
|
FDA said children between 6 and 17 can get Moderna's new COVID-19 booster
- Shares of Moderna Inc. MRNA, +8.93% soared 9.4% in trading on Wednesday after the Food and Drug Administration said children between the ages of 6 and 17 years old can now get the bivalent COVID-19 booster developed by the company. The regulator also said that children between the ages of 5 and 11 years old can get the updated BioNTech SE BNTX, +5.71% /Pfizer Inc. PFE, +1.77% shot.
- 10/12/2022
|
Merck partners with Moderna to develop a cancer vaccine
- CNBC's Jim Cramer and the 'Squawk on the Street' team discuss Merck's decision to develop a cancer vaccine with mRNA developer Moderna.
- 10/12/2022
|
Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients
- Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer.
- 10/12/2022
|
Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment
- Merck opted Wednesday to help Moderna develop a personalized cancer vaccine based on messenger RNA technology, and MRNA stock rocketed. The post Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment appeared first on Investor's Business Daily.
- 10/12/2022
|
10 Fallen Growth Stocks Will Make You Up To 113% Richer, Analysts Say
- Seeing S&P 500 growth stocks implode is tough to watch, unless you're ready to spot a buy point. The post 10 Fallen Growth Stocks Will Make You Up To 113% Richer, Analysts Say appeared first on Investor's Business Daily.
- 10/12/2022
|
Merck, Moderna to develop personalized cancer vaccine
- Merck & Co. Inc. MRK, +0.63% and Moderna Inc. MRNA, -2.19% said Wednesday that they plan to jointly develop and commercialize a personalized cancer vaccine. The investigational vaccine is currently being tested in a Phase 2 clinical trial as a treatment for patients with high-risk melanoma in combination with Merck's Keytrduda, an anti-PD-1 therapy that has been approved to treat several types of cancer.
- 10/12/2022
|
Smart Investors Will Be Buying All the Dips for These 7 Stocks
- Although the red ink splashed on the equities sector has many bulls in the dumps, it's also important to remember that the doldrums open opportunities for these 7 stocks to buy on the dip. To be fair, you don't want to just react to volatility in a simplistic Pavlovian manner.
- 10/10/2022
|
Better Buy: Moderna vs. Axsome Therapeutics
- Both of these biotechs offer exciting future prospects.
- 10/10/2022
|
Get Ready for the Next Bull Market: 3 Stocks to Buy Right Now
- These leaders look cheap, considering their growth prospects.
- 10/07/2022
|
Why Moderna Stock Couldn't Shake the Thursday Blues
- The CDC's latest report on COVID-19 vaccinations didn't provide enough fuel for shareholder optimism.
- 10/06/2022
|
Moderna: A Great Diversification Into Large Cap
- As a $48B market cap company, Moderna delivers a highly efficacious/safe vaccine for COVID. The company is also advancing a pipeline of both vaccines and therapeutics that are highly promising.
- 10/03/2022
|
2 Growth Stocks That Could Jump 64.1% to 86.1% Higher, According to Wall Street
- Investment bank analysts think both of these stocks have what they need to deliver big gains in the foreseeable future.
- 10/03/2022
|
Moderna turns down China request for vaccine technology: report
- Moderna has so far refused to make a deal for its COVID-19 vaccine with China, due to Beijing wanting the intellectual property behind it.
- 10/02/2022
|
Moderna refused China request to reveal vaccine technology, Financial Times reports
- Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.
- 10/01/2022
|
Here's Why the Post-Pandemic World May Be Even Better for This Vaccine Maker
- Moderna's billion-dollar revenue may be just getting started.
- 10/01/2022
|
Why Moderna Was a Sickly Stock Today
- A shuffle at the top of the executive ranks, combined with the continued decline of the coronavirus, rattles some investors.
- 09/29/2022
|
EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster
- The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.
- 09/29/2022
|
These 2 Growth Stocks Have Fallen Out of Grace. Are They Buys?
- These vaccine makers have lost much of the momentum they built earlier in the pandemic.
- 09/29/2022
|
Why Moderna Stock Lagged the Market Today
- The company's latest regulatory advance is overshadowed by developments with another biotech.
- 09/28/2022
|
7 Growth Stocks to Buy Before the Bull Market Returns
- In this market slowdown there appear to be fewer growth stocks to buy, but patience will be rewarded. It's been a forgettable year, to say the least, for equity investors.
- 09/28/2022
|
Why Moderna Stock Crushed the Market Today
- Investors cheered some positive news on the vaccine supply front.
- 09/27/2022
|
Covid-Related Sales Boost BioNTech, Moderna and Gilead
- Covid-related product sales helped make BioNTech SE ( BNTX , Financial), Moderna Inc. ( MRNA , Financial), Gilead Sciences Inc. ( GILD , Financial) and Regeneron Pharmaceuticals Inc. ( REGN , Financial) the most productive biopharma companies in 2021, according to a Fierce Pharma ranking.
- 09/27/2022
|
Down 85%, Is There Any Hope for This Struggling Vaccine Stock?
- The problem? Novavax arrived late to the market.
- 09/26/2022
|
Better Growth Stock: Moderna vs. Teladoc
- Both of these stocks are looking pretty cheap.
- 09/24/2022
|
General Mills, Meta Platforms, Moderna: Stocks That Defined the Week
- Here are seven major companies whose stocks moved on the week's news.
- 09/23/2022
|
Moderna asks FDA to authorize omicron Covid boosters for children as young as 6 years old
- Moderna has asked the FDA to authorize omicron boosters for adolescents ages 12 to 17-years-old and for kids ages 6 to 11-years-old.
- 09/23/2022
|
Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On? - Moderna (NASDAQ:MRNA)
- Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.
- 09/23/2022
|
Moderna expects the shortage of its updated COVID-19 booster to soon be resolved
- Moderna Inc. MRNA, -0.22% said Wednesday that it expects to resolve supply issues for its new COVID-19 booster “in the coming days.”
- 09/21/2022
|
3 Beaten-Down Stocks That Could Soar 51% to 70% From Their 52-Week Lows, According to Wall Street
- Analysts remain very bullish about these former big winners.
- 09/21/2022
|
Moderna stock remains a great pick for long-term investors: Analyst
- Moderna Inc (NASDAQ: MRNA) has taken a big hit over the past seven weeks, which, as per an Oppenheimer analyst, is a fantastic opportunity for the long-term investors. Reasons to own the Moderna stock At a price-to-earnings multiple of just over four, the biotech firm is quite attractive in terms of valuation.
- 09/20/2022
|
You should probably keep owning Moderna or buy some, says Oppenheimer analyst
- Hartaj Singh, Oppenheimer analyst, joins 'Squawk on the Street' to discuss how to play the biotech sector and more.
- 09/20/2022
|
Is Moderna a Post-Pandemic Buy?
- Moderna is ready for a post-pandemic world.
- 09/20/2022
|
Vaccine Stocks: Down but Not Out?
- Whether the pandemic is over or not, plenty of people are still looking for protection against COVID-19.
- 09/19/2022
|
Why Moderna Stock Dropped Today
- President Biden's comments weighed on the biotech's shares.
- 09/19/2022
|
The biggest wave of Covid injections are behind us, says Jefferies' Michael Yee
- Jefferies analyst Michael Yee joins 'Closing Bell' to discuss biotech and pharmaceutical stocks and how President Biden's comments yesterday that the pandemic is over are impacting those stocks.
- 09/19/2022
|
Moderna stock drops amid President Biden's signaling an end to COVID pandemic
- Yahoo Finance anchors Dave Briggs, Seana Smith and Rachelle Akuffo report on Moderna and other COVID vaccine stocks dropping after President Biden hints at a potential end to the pandemic.
- 09/19/2022
|
Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?
- It's a mixed day for the stock market, but it's not a good day for vaccine stocks. Across the board, these names are getting sold.
- 09/19/2022
|
Moderna, BioNTech, and Novavax plunge after President Biden says the COVID-19 pandemic 'is over'
- "The pandemic is over. We still have a problem with COVID. We're still doing a low of work on it. But the pandemic is over," Biden said.
- 09/19/2022
|
Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is over
- Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with "60 Minutes" that aired on Sunday. Moderna Inc. MRNA, -9.41% fell 9.2%, Pfizer Inc. PFE, -1.76% was down 1.7% and its German partner BioNTech SE BNTX, -9.15% was down 8.4%.
- 09/19/2022
|
Why BioNTech, Moderna And Novavax Shares Are Diving - Moderna (NASDAQ:MRNA), BioNTech (NASDAQ:BNTX)
- BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo
- 09/19/2022
|
Moderna And Covid-19 Stocks: Market-Maker Stock Price Range Forecasts
- The World Health Organization list of Vaccine makers, rapid antigen test manufacturers, and therapeutics were bundled together as a participants group for coming price-range-forecast comparison. The forecasts are near-term (3-5 months only) derived from necessary hedging actions to protect Market-Makers' (short) shares borrowed to supply-balance buyers' demand volumes in block trade market orders from “institutions”.
- 09/15/2022
|
Here's Why Wall Street Is Super Bullish on Moderna Stock
- Wall Street thinks the bear market has pushed this top biotech stock down too far.
- 09/15/2022
|
If You've Got $5,000, Buying These 5 Top Stocks Right Now Would Be a Genius Move
- These stocks have what it takes to deliver lasting gains down the road.
- 09/15/2022
|
Why Moderna Stock Is on Fire Today
- A possible vaccine supply deal with China has investors piling into the biotech's shares.
- 09/14/2022
|
What's Moderna's Next Billion-Dollar Market? The Answer May Surprise You.
- Moderna wants to conquer a virus we all know pretty well.
- 09/14/2022
|
Moderna, Inc. (MRNA) Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Matthew Harrison - Biotech Analyst at Morgan Stanley Matthew Harrison Good morning everybody. Thanks for joining us for the next session.
- 09/13/2022
|
Moderna says Japan regulator has approved partial change to NDA for its omicron-targeting COVID booster
- Moderna Inc. MRNA, +0.71% said Monday the Japanese regulator has approved a partial change to its new drug application for its omicron-targeting COVID booster, MRNA-1273.214. The approval from the Ministry of Health, Labour and Welfare is based on data from a Phase 2/3 trial in which the booster met all primary endpoints, including superior neutralizing antibody response against omicron compared to the currently approved dose of Spikevax in previously uninfected trial participants.
- 09/12/2022
|
This 1 Number Could Completely Change Your Opinion of Moderna
- Moderna's recent prediction should lift one of investors' biggest fears.
- 09/12/2022
|
Is It Too Late to Buy Moderna Stock?
- The answer may depend on your investment horizon.
- 09/10/2022
|
Why Moderna Stock Triumphed on Thursday
- A prognosticator is particularly hopeful for the company's planned triple vaccine.
- 09/08/2022
|
U.S. COVID-19 vaccine market could be up to $13 billion-Moderna exec
- Vaccine maker Moderna Inc's chief commercial officer (CCO) said on Thursday that the size of the future COVID-19 vaccine market in the United States could be in the range of $5.2 billion to $12.9 billion, depending on the price of shots and who is eligible to receive them.
- 09/08/2022
|
Put Option Strategy To Generate 11.2% Yield On Cash Or Own Moderna At $82
- Put options are a way to generate yield with downside protection. MRNA's high volatility makes selling options more attractive.
- 09/08/2022
|
Moderna Stock Moves Higher on Upgrade to "Buy"
- Moderna Inc (NASDAQ:MRNA) received an upgrade from Deutsche Bank to "buy" from "hold" this morning, as well as a price-target hike to $165 from $155.
- 09/08/2022
|
Why Moderna Stock Slumped Today
- New vaccine guidelines by U.S. health authorities may dampen sales of the biotech's top coronavirus vaccine.
- 09/06/2022
|
Shifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, Pfizer
- It looks like there will be plenty of Covid vaccines available for a fall and winter surge, but once the money in the current program runs out, the U.S. government won't be paying for them.
- 09/06/2022
|
Moderna: Patient Investors Are Given Another Fantastic Buy Point On The Pullback
- MRNA has fallen nearly 30% from its August highs, as it got rejected by the $200 resistance level again. As a result, we urged investors to be cautious in July. Investors need to be wary about Moderna's ability to sustain its revenue visibility post-FY22, as its growth cadence from its COVID vaccines is expected to decline.
- 09/05/2022
|
7 Growth Stocks That Could 10X by 2027
- MarketWatch published an article early in 2022 which highlighted last year's best-performing S&P 500, mid-cap, small-cap, Nasdaq-100, and Dow 30 stocks. Some of the names on the five lists were cited by analysts as the top growth stocks to buy in 2022.
- 09/05/2022
|
PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion
- Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.
- 09/02/2022
|
Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters
- The CDC green-lighted updated Covid boosters from Pfizer and Moderna, helping vaccine stocks edge higher Friday. The post Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters appeared first on Investor's Business Daily.
- 09/02/2022
|
FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters
- Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.
- 09/01/2022
|
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
- Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
- 09/01/2022
|
Why Moderna Stock Slumped on Wednesday
- Good news for the world lowers bullishness on the company's future.
- 08/31/2022
|
Pfizer, Moderna booster shots are set to receive FDA authorization
- Pfizer and Moderna's COVID booster shots for the Omicron BA.5 variant are set to receive FDA approval as the United States agrees to purchase more of the updated vaccines.
- 08/31/2022
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 08/31/2022
|
PFE, MRNA Stocks: What to Know as the FDA Approves New Booster Shots
- Source: shutterstock.com/PhotobyTawat Pfizer (NYSE: PFE ) and Moderna (NASDAQ: MRNA ) stocks are in the news Wednesday as the FDA approves new booster shots for Covid-19. The new booster shots approved by the FDA are specifically for the Omicron variant of Covid-19.
- 08/31/2022
|
Pfizer, Moderna Nab FDA Authorization For Updated Covid Boosters
- Vaccine stocks mostly creeped higher Wednesday after the FDA authorized updated Covid booster shots from Pfizer and Moderna. The post Pfizer, Moderna Nab FDA Authorization For Updated Covid Boosters appeared first on Investor's Business Daily.
- 08/31/2022
|
U.S. clears updated COVID boosters targeting newest variants
- The U.S. on Wednesday authorized its first update to COVID-19 vaccines, booster doses that target today's most common omicron strain. Shots could begin within days.
- 08/31/2022
|
FDA Authorizes Moderna and Pfizer Omicron Booster Shots
- The move comes just as the country braces for a potential fall surge in Covid-19 infections.
- 08/31/2022
|
Could Pfizer Beat Moderna in This New Billion-Dollar Market?
- Pfizer and Moderna are both tackling a common respiratory virus.
- 08/31/2022
|
Should Pfizer Investors Be Worried About Moderna's Lawsuits?
- Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.
- 08/31/2022
|
Moderna's (MRNA) Omicron Based Jab gets Approval in Australia
- Moderna (MRNA) receives provisional approval in Australia for its Omicron-containing bivalent booster vaccine mRNA-1273.214 in adults, making it the first bivalent COVID-19 vaccine approved for use in Australia.
- 08/30/2022
|
After Double-Digit Percentage Declines, Are Vaccine Stocks Buys?
- They still might offer solid long-term opportunities for investors.
- 08/30/2022
|
Is Moderna Stock A Buy As FDA Mulls Its Updated Covid Booster Shot?
- Is Moderna stock a buy after asking the FDA to sign off on its BA.4- and BA.5-tailored Covid booster? Is MRNA stock a buy now?
- 08/29/2022
|
Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab
- Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.
- 08/29/2022
|
Moderna Suing Pfizer Isn't a ‘Big Deal' Yet | TheStreet
- Moderna is planning to sue Pfizer for patent infringement, but it's not a big deal just yet. SUBSCRIBE | http://t.st/TheStreetTV MORE VIDEOS: https://www.thestreet.com/video ACTION ALERTS PLUS | https://www.thestreet.com/signup/action-alerts-plus-video REAL MONEY PRO | https://www.thestreet.com/signup/real-money-video LINKEDIN | http://linkedin.com/company/theStreet FACEBOOK | https://www.facebook.com/TheStreet/ TWITTER | http://twitter.com/thestreet INSTAGRAM | https://www.instagram.com/thestreet/?hl=en #Investing #Stocks #Vaccine #WallStreet #Pfizer #Moderna #covid
- 08/29/2022
|
The 8 Most Profitable U.S. Companies Practically Print Money
- Imagine companies three times as profitable as the S&P 500 — putting them in a good position to handle whatever comes next. The post The 8 Most Profitable U.S. Companies Practically Print Money appeared first on Investor's Business Daily.
- 08/29/2022
|
Swiss regulator grants temporary authorization for Moderna bivalent COVID booster for adults age 18 and older
- Moderna Inc. MRNA, -3.77% said Monday the Swiss regulator has granted temporary authorization to its bivalent omicron-targeting COVID booster for use in adults aged 18 and older. "Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 ug of mRNA-1273 (Spikevax) and 25 ug of a vaccine candidate targeting the Omicron variant of concern (BA.1)," the company said in a statement.
- 08/29/2022
|
Better COVID Booster Stock: Moderna vs. Pfizer
- These vaccine leaders are set to target the latest coronavirus variant.
- 08/29/2022
|
Could This Move by Moderna Cost Pfizer Billions?
- Moderna's complaint is focused on two critical innovations.
- 08/28/2022
|
Moderna sues Pfizer and BioNTech
- CNBC's Shep Smith reports on a lawsuit filed by Moderna against Pfizer and BioNTech for patent infringement.
- 08/26/2022
|
Moderna Sues Pfizer Over mRNA Technology Used in COVID Vaccines
- Moderna is suing Pfizer and BioNTech over patents it said it filed years ago on the life-saving technology.
- 08/26/2022
|
Moderna sues Pfizer, BioNTech over alleged mRNA patent infringement
- Moderna filed a lawsuit against Pfizer and BioNTech claiming the biopharmaceutical companies infringed on Moderna's patents related to mRNA technology in develop of their COVID-19 vaccine. The lawsuit, to be filed in the U.S.
- 08/26/2022
|
Moderna sets up clash with Pfizer and BioNTech with patent lawsuits in the U.S. and Germany
- Moderna Inc. on Friday filed lawsuits against Pfizer Inc. and German partner BioNTech SE, alleging the pair infringed patents relating to its mRNA platform, a key technology behind all of their COVID vaccines.
- 08/26/2022
|
Pfizer prepared to ‘vigorously defend' itself against Moderna's allegations
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Pfizer's response to its Moderna lawsuit allegations.
- 08/26/2022
|
Factbox-Moderna sues Pfizer as patent owners fight over mRNA vaccine technology
- Pfizer /BioNTech and Moderna have been hit with patent lawsuits by other companies related to their COVID-19 vaccines.
- 08/26/2022
|
Moderna sues Pfizer, BioNTech over COVID vaccine patent
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moderna's decision to sue rival vaccine maker Pfizer over the delivery technology used in COVID-19 vaccines.
- 08/26/2022
|
Report finds Americans losing up to $1 billion in wages from long COVID, and Moderna sues Pfizer and BioNTech over mRNA patents
- Some 16 million Americans of working age have long-term COVID and about 2 to 4 million are not working as they struggle with their symptoms, according to a new report from the Brookings Institution.
- 08/26/2022
|
Moderna sues Pfizer and BioNTech for patent infringement over COVID vaccine
- Moderna alleges Pfizer and its German partner BioNTech copied their mRNA technology while developing their COVID-19 vaccine.
- 08/26/2022
|
Moderna Sues Pfizer And BioNTech Over Covid-19 Vaccine
- The company says Pfizer and BioNTech copied Moderna's mRNA technology without its permission.
- 08/26/2022
|
Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot
- Moderna is suing Pfizer and BioNTech for patent infringement, claiming the duo copied its mRNA technology. All three vaccine stocks fell.
- 08/26/2022
|
Moderna sues Pfizer after saying it wouldn't enforce its patents for COVID-19 vaccine technology
- Moderna is suing competing vaccine maker Pfizer and its German partner BioNTech, alleging the pharmaceutical companies copied its technology.
- 08/26/2022
|
Moderna sues Pfizer and BioNTech for patent infringement relating to the mRNA platform used to develop COVID vaccines
- Moderna Inc. MRNA, +0.44% said Friday it is suing Pfizer Inc. PFE, +0.99% and German partner BioNTech SE BNTX, +1.59% for infringing patents relating to its mRNA platform, the source of the COVID vaccines developed by the three parties. The suit is to be filed Friday in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
- 08/26/2022
|
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
- Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.
- 08/26/2022
|
Pfizer And Moderna Are In A Race With Omicron; Will The Vaccine Stocks Be Too Late?
- Companies are working to develop updated Covid boosters. Will they be too late to make a difference for the vaccine stocks — and society?
- 08/26/2022
|
1 Bear Market Blunder Investors Are Still Making
- Focusing on the short term could lead to long-term losses.
- 08/25/2022
|
Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab
- Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.
- 08/24/2022
|
The S&P 500 Has Pulled Back From Its August Peak. Moderna, Carnival, and Match Are Part of the Blame.
- Investors have pulled back from the stock market in the wake of downbeat economic data, as they wait for commentary from the Federal Reserve on Friday.
- 08/24/2022
|
Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
- Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.
- 08/24/2022
|
These Are The Top 10 Holdings Of Patrick Degorce
- Patrick Degorce is the founder and chief executive officer (CEO) of Theleme Partners.
- 08/23/2022
|
Moderna completes FDA submission for new COVID-19 booster
- Moderna Inc. MRNA, +0.92% said late Tuesday it has completed its submission to the U.S. Food and Drug Administration for the emergency-use authorization for its experimental bivalent COVID-19 booster for those who are 18 years old or older. The new shot targets the original strain of the virus as well as the BA.4 and BA.5 strains, thought to be the prevalent ones in the U.S. and other countries.
- 08/23/2022
|
Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot
- Moderna stock inched higher late Tuesday just before announcing it asked the FDA to sign off on its updated Covid booster shot. The post Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot appeared first on Investor's Business Daily.
- 08/23/2022
|
Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada
- Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.
- 08/23/2022
|
Moderna to supply Canadian government with 12 million doses of its bivalent COVID vaccine
- Moderna Inc. MRNA, -2.60% said Monday it will supply the Canadian government with 12 million doses of its bivalent COVID vaccine that targets the original virus and the omicron variant. The government has exercised an option to purchase 4.5 million doses and moved ahead with the scheduled delivery of 1.5 million doses from 2023 to 2022.
- 08/22/2022
|
3 Growth Stocks That Could Soar 51% to 385%, According to Wall Street
- Expectations for these stocks are still sky high.
- 08/22/2022
|
Could SIGA Technologies Become the Next Moderna?
- Shares of the company have jumped more than 60% in just the past month.
- 08/20/2022
|
Ups & Downs: Top Pharmaceutical Stocks Post-COVID
- Here is a rundown of the top pharmaceutical stocks to know about, ranked by market capitalization: Johnson & Johnson, Pfizer, Eli Lilly, AbbVie
- 08/20/2022
|
3 Growth Stocks That Could Soar 35% to 84%, According to Wall Street
- Analysts still have great expectations for these beaten-down stocks.
- 08/20/2022
|
Why Moderna Was Sinking This Week
- Investors are worried that big change in public policy might have an outsize impact on the company.
- 08/19/2022
|
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
- The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks. The post Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions appeared first on Investor's Business Daily.
- 08/19/2022
|
These Are The Biggest Companies with Over 30% Sales Growth
- Sales growth is a very important financial metric that investors consider before making a buy decision.
- 08/18/2022
|
Why Moderna Stock Was Wilting on Wednesday
- Investors traded down the company's shares following news of a top-level managerial change.
- 08/17/2022
|
Has Moderna Made a Bear Market Blunder?
- The company has stood pat while other businesses have been busy with M&A.
- 08/17/2022
|
Moderna names PerkinElmer exec as new CFO
- Moderna Inc on Wednesday named former PerkinElmer executive James Mock as the company's chief financial officer, effective Sept. 6.
- 08/17/2022
|
Moderna CFO David Meline to retire, to be succeed by PerkinElmer's James Mock
- Moderna Inc. MRNA, -4.99% said Wednesday that Chief Financial Officer David Meline will retire, effective Sept. 6. Moderna shares fell 0.6% in premarket trading.
- 08/17/2022
|
Buy the dips, says Virtus' Joe Terranova
- Joe Terranova, Virtus Investment Partners, joins 'Closing Bell: Overtime' to discuss the markets.
- 08/16/2022
|
Why Moderna Stock Is Sliding Today
- There wasn't any negative news from the vaccine maker.
- 08/16/2022
|
Why Moderna Stock Climbed Today
- The biotech's COVID-19 vaccine sales could be about to receive a boost.
- 08/15/2022
|
Three Stock Lunch: Disney, Moderna and Exxon Mobil
- Delano Saporu, New Street Advisors CEO, joins 'Power Lunch' to discuss Saporu's investing take on three stocks: Disney, Moderna and Exxon Mobil. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis.
- 08/15/2022
|
Is Moderna Stock a Buy Now After the U.K.'s Omicron Vaccine Approval?
- The pioneering COVID-19 fighter claims another victory, and shareholders are celebrating.
- 08/15/2022
|
Is Moderna Preparing To Soar 20% And Tackle This Big Level? What To Watch On The Weekly Chart
- Moderna, Inc (NASDAQ: MRNA) spiked up almost 5% off Friday's closing price at one point on Monday, before hitting a resistance level at the $179 level and running into a group of sellers.
- 08/15/2022
|
MRNA Stock Alert: What to Know as U.K. Approves Updated Moderna Booster
- The U.K.'s regulatory authority just approved Moderna's (NASDAQ: MRNA ) bivalent Covid-19 booster vaccine called mRNA-1273.214. Bivalent means it addresses two strains of Covid-19, and this particular booster shot targets the omicron variant as well as the original virus.
- 08/15/2022
|
Stocks gaining in early trading: Nvidia, AMD, Tesla, Moderna, Gilead
- Yahoo Finance Live's Brad Smith breaks down how stocks are moving in early trading.
- 08/15/2022
|
U.K. regulator is first to authorize Moderna's bivalent COVID booster for adults aged 18 and older
- The U.K. regulator has become the first to authorize Moderna's bivalent COVID vaccine booster for use in adults aged 18 and older.
- 08/15/2022
|
Moderna's Omicron Booster Approved In The U.K. In World First
- The booster shot targets two coronavirus variants and contains half omicron-specific vaccine and half original vaccine.
- 08/15/2022
|
UK regulator authorizes Moderna bivalent COVID vaccine booster for adults aged 18 and older
- Moderna Inc. MRNA, -0.37% said Monday the U.K. regulator has authorized its bivalent COVID vaccine booster for use in adults aged 18 and older. The Medicines and Healthcare products Regulatory Agency gave the nod to the booster dubbed mRNA-1273.214 which targets the original virus strain, as well as the omicron variant.
- 08/15/2022
|
With Growth Slowing, Is Moderna Stock Still Worth A Look?
- While Moderna's revenue grew by about 9% year-over-year to $4.
- 08/10/2022
|
MRNA vs. TECH: Which Stock Should Value Investors Buy Now?
- MRNA vs. TECH: Which Stock Is the Better Value Option?
- 08/08/2022
|
Two Appealing Biotech Stocks for Two Distinct investors
- Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
- 08/08/2022
|
COVID vaccine manufacturer Moderna's CEO discusses the company's Q3 earnings
- Moderna CEO Stéphane Bancel discusses the reasons behind the company's Q3 success, and his anticipations for Q4. Segment originally aired on August 3, 2022.
- 08/07/2022
|
Prediction: This Bear Market Will Test Your Resolve In (At Least) 3 Ways
- Your portfolio is counting on you to pass the tests.
- 08/07/2022
|
Where Will Moderna Be in 1 Year?
- The biotech's fortunes could reverse.
- 08/06/2022
|
How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak
- The medicine Siga Technologies developed to combat biowarfare is now being used in the ongoing viral outbreak, and Siga stock has exploded.
- 08/04/2022
|
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
- Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its latest quarterly report, along with a share buyback plan. On Wednesday, the Invesco Nasdaq Biotechnology ETF (IBBQ) increased 4.2%, the ETFMG Treatments Testing and Advancements ETF (GERM) advanced 5.
- 08/03/2022
|
4 Stocks With High Return on Equity
- When a company's return on equity ratio is superior to most of its competitors, it generally indicates the company has been very efficient in generating profits. Thus, investors may want to consider the following stocks, since they are performing better than most of their peer group companies in terms of a higher ROE ratio.
- 08/03/2022
|
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
- Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program.
- 08/03/2022
|
Moderna CEO: ‘We are seeing very strong' vaccine demand
- Moderna CEO Stéphane Bancel speaks with Yahoo Finance's Anjalee Khemlani about earnings, COVID-19 vaccine demand, the biotech company's pipeline, and monkeypox vaccine development.nce
- 08/03/2022
|
Moderna, Inc.'s (MRNA) CEO Stephane Bancel on Q2 2022 Results - Earnings Call Transcript
- Moderna, Inc. (NASDAQ:MRNA ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stephane Bancel - Chief Executive Officer David Meline - Chief Financial Officer Stephen Hoge - President Paul Burton - Chief Medical Officer Arpa Garay - Chief Commercial Officer Conference Call Participants Matthew Harrison - Morgan Stanley Elizabeth Webster - Goldman Sachs Michael Yee - Jefferies Sheldon Fan - Barclays Geoff Meacham - Bank of America Ellie Merle - UBS Operator Good morning. My name is Kevin, and I will be your operator.
- 08/03/2022
|
Moderna Just Gave Investors 499 Million Reasons to Worry
- Investors are cheering the company's Q2 results. But there was a troubling detail in Moderna's update.
- 08/03/2022
|
Moderna stock gets boost from earnings beat, COVID-19 vaccine sales
- Yahoo Finance's Anjalee Khemlani discusses second-quarter earnings for Moderna, the Biden administration's fall booster campaign, COVID-19 vaccine sales, and longer-term vaccine growth.
- 08/03/2022
|
Moderna (MRNA) Stock Pops on Strong Sales, Earnings Beat
- MRNA) research Coronavirus (Covid 19) vaccine. Row of vaccine bottles with blurred Moderna company logo on background.
- 08/03/2022
|
Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates
- Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2022
|
Moderna's 2Q earnings beat expectations, but it writes off $500 million in expiring Covid shots
- Moderna took a nearly $500 million hit on write-downs for vaccine inventory that has expired or is expected to expire before is can be used.
- 08/03/2022
|
Moderna's stock rises 3% after beating earnings expectations in the second quarter
- Shares of Moderna Inc. MRNA, -0.43% gained 3.8% in premarket trading on Wednesday after the company beat earnings and revenue expectations in the second quarter of the year. Moderna had net income of $2.2 billion, or $5.24 per share, in the second quarter of the year, down from $2.8 billion, or $6.46 per share, in the same quarter a year ago.
- 08/03/2022
|
Moderna retains COVID vaccine sales view on weak demand from low-income nations
- Moderna Inc on Wednesday maintained its full-year sales outlook for its COVID-19 vaccine, following a similar prediction by bigger rival Pfizer Inc a week ago, amid tepid demand from low-to-middle income countries.
- 08/03/2022
|
3 Health Care Stocks in Great Financial Health
- Health care's potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy.
- 08/02/2022
|
Products Are in, Platforms Are Out for Biotech Investors
- Platforms are out.
- 08/01/2022
|
Could This News Change Everything for Moderna?
- Moderna's blockbuster product is set for a new wave of demand.
- 08/01/2022
|
Why Moderna Was a Stock Market Star on Friday
- The biotech keeps up a steady supply of coronavirus vaccine boosters to a very reliable customer.
- 07/29/2022
|
Moderna And BioNTech: I Back The Former To Drive Share Price Upside In 2022
- Moderna and BioNTech are the two mRNA giants behind the dominant COVID vaccines SpikeVax and Comirnaty. The two companies have a great deal in common, and the share prices typically track very close to one another.
- 07/29/2022
|
LA County dodges face mask mandate as community transmission rates stabilize, and government orders 66 million doses of Moderna's pending booster
- Los Angeles County has dropped a plan for a universal indoor face-mask mandate as COVID cases and hospitalizations have stabilized, with community transmission expected to fall to “medium” from “high” in the coming weeks.
- 07/29/2022
|
U.S. to pay Moderna $1.7 billion for 66 million doses of a new COVID-19 vaccine booster
- Shares of Moderna Inc. MRNA, +0.03% gained 3.8% in premarket trading on Friday after the company said the U.S. will buy 66 million doses of a bivalent COVID-19 booster candidate that can better protect against the BA.5 strain. That vaccine is not yet in clinical trials but studies are expected to begin "in the near future," a Moderna spokesperson told MarketWatch earlier this week.
- 07/29/2022
|
Is Moderna's Cheaper Valuation A Buying Signal?
- Moderna is one of the least expensive companies in the S&P 500 in terms of valuation. In this article, we'll examine other aspects of the company.
- 07/29/2022
|
Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
- Monkeypox cases are significantly growing during the past few months, especially catalyzed by an increase in international travel. On July 23, WHO declared the Monkeypox spread as a global health emergency, indicating the agency's high degree of concern around the severity of the disease and its spread.
- 07/26/2022
|
Is Moderna Stock A Sell On Projections For Its First Quarterly Decline Since 2020?
- Is Moderna stock a sell on analyst expectations for its first quarterly decline since 2020? Is MRNA stock a sell right now?
- 07/26/2022
|
7 Best Cash Cow Stocks to Buy for Stable Returns
- Investors seeking shelter from the market selloff through 2022 can take a look at some of the best cash cow stocks to buy. The post 7 Best Cash Cow Stocks to Buy for Stable Returns appeared first on InvestorPlace.
- 07/24/2022
|
Is This Vaccine Stock a Buy After Big News?
- Two years after the onset of COVID-19 in the U.S., a new vaccine is coming to market -- who will it help?
- 07/22/2022
|
2 Nasdaq 100 Stocks to Buy Hand Over Fist and 1 to Avoid Like the Plague
- The high-growth Nasdaq 100 is home to two amazing deals and one deceptive value trap.
- 07/21/2022
|
Moderna: Undervalued Despite The Robust Demand Outlook
- With the help of its new subsidiaries and distribution partnerships, the company has been able to sell its products to new customers in 2022. From 2 May 2022 to 18 July 2022, the number of Moderna's COVID-19 vaccine administered in Argentina increased from 7 million doses to 11 million doses.
- 07/20/2022
|
Is It Too Late to Buy Moderna Stock?
- More products may be on the horizon.
- 07/20/2022
|
Why Moderna Stock Bumped Higher Today
- The company wins yet another approval for its coronavirus vaccine.
- 07/19/2022
|
3 Healthcare Stocks That Could Help Set You Up for Life
- These players are trading at bargain prices today.
- 07/19/2022
|
Moderna After The COVID Vaccine Bolus
- Moderna was a clinical-trial stage company before the COVID pandemic. The bolus of COVID vaccine revenue greatly inflated the stock price.
- 07/19/2022
|
Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada
- Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.
- 07/18/2022
|
Here's How To Trade This Pattern On BlackBerry, Moderna And Palantir Stocks
- BlackBerry Ltd (NYSE: BB), Moderna Inc (NASDAQ: MRNA) and Palantir Technologies Inc (NYSE: PLTR) have been showing strength in comparison to the general market recently and are all trading in uptrends. An uptrend occurs when a stock consistently makes a series of higher highs and higher.
- 07/15/2022
|
Moderna's COVID-19 Vaccine Scores Canadian Approval For Kids Below 5 Years
- Health Canada has approved the use of Moderna Inc's (NASDAQ: MRNA) mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 µg per dose in children six months to 5 years. Positive interim results from the Phase 2/3 KidCOVE study, announced in March, showed a.
- 07/14/2022
|
Moderna's COVID-19 vaccine OK'd in Canada for children aged 6 months and older
- Moderna Inc. said Thursday its COVID-19 vaccine Spikevax was approved by Health Canada for use in children aged six months to five years. The biotechnology company said the two-dose regimen for children in that age group is completed in one month, the same as for adults, adolescents and children over five years old.
- 07/14/2022
|
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
- Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
- 07/13/2022
|
Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022
- CAMBRIDGE, MA / ACCESSWIRE / July 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 3, 2022 to report its second quarter 2022 financial results, and provide a corporate update.
- 07/13/2022
|
What's Happening With Moderna Stock?
- Covid-19 vaccine producer Moderna stock has rallied by almost 50% over the past month and currently trades at about $175 per share.
- 07/13/2022
|
Moderna (MRNA) Announces First Participant In Phase 1 Trial Of Nipah Virus Vaccine mRNA-1215
- Moderna, Inc. (NASDAQ: MRNA) announced the first participant has been dosed in a Phase 1 trial of its Nipah virus (NiV) vaccine candidate mRNA-1215. These are the details.
- 07/12/2022
|
Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5
- Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.
- 07/12/2022
|
Options Action: Buyer bets big on Moderna
- Mike Khouw, Optimize Advisors CIO, joins 'Fast Money' to break down Monday's options action.
- 07/11/2022
|
PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents
- Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.
- 07/11/2022
|
Which Coronavirus Stock Could Fetch Higher Returns?
- This article will compare Pfizer, Moderna, and Novavax to see which of these coronavirus stocks will yield the highest returns. The post Which Coronavirus Stock Could Fetch Higher Returns?
- 07/11/2022
|
New omicron variant worries experts as it spreads in India, and Moderna says new booster offers better protection against BA.4 and BA.5
- A new, highly infectious subvariant of omicron is raising concerns among scientists and health experts as it spreads in India and other countries, including the U.S.
- 07/11/2022
|
Moderna says one of its COVID-19 booster candidates better protects against BA.4 and BA.5
- Moderna Inc. MRNA, +2.22% said Monday that a bivalent COVID-19 booster that equally protects against BA.1 and the original strain of the virus produced a better antibody response against the BA.4 and BA.5 subvariants in people who were fully vaccinated and boosted than its currently authorized COVID-19 booster. The new data tested neutralizing antibody levels one month after the second booster was administered, and the findings were consistent across age groups, the company said.
- 07/11/2022
|
Moderna: Attacked The Pessimism With Aplomb (Technical Analysis)
- Our Speculative Buy rating on Moderna stock has played out accordingly and reached our near-term price target. Therefore, investors are urged to pay attention to price action for helpful clues. Notwithstanding, we believe the risk/reward profile is no longer attractive to add exposure. Investors should consider layering out.
- 07/07/2022
|
What's Going On With Moderna Stock?
- Moderna Inc (NASDAQ: MRNA) shares are trading higher Thursday amid rising monkeypox concerns. According to a Reuters report citing the country's Public Health Authority, Slovakia confirmed its first case of monkeypox today.
- 07/07/2022
|
Final Trades: Moderna, Crocs, Lamar & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 07/07/2022
|
Why Moderna Stock Is Surging Today
- The biotech is benefiting from the broader market's gains.
- 07/07/2022
|
Is Moderna Stock a No-Brainer Buy With Omicron Boosters on the Way?
- There's still significant risk associated with investing in this vaccine stock.
- 07/07/2022
|
3 Growth Stocks Trading at Value P/E's
- The depressed P/E ratios of these three S&P 500 growth stocks make them value stocks in a growth wrapper—and bargain buys for investors.
- 07/07/2022
|
Oppenheimer's Ari Wald charts out key level for high-growth stocks
- Ari Wald, Oppenheimer, joins 'Fast Money' to discuss Wald's thoughts on a potential growth stock comeback, if the FOMC minutes mean it's time to get back into technology stocks and more.
- 07/06/2022
|
Can Moderna (MRNA) Keep the Earnings Surprise Streak Alive?
- Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/05/2022
|
Why Moderna Stock Is Jumping Today
- Investors are optimistic about the prospects for Moderna's omicron booster.
- 07/05/2022
|
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
- In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
- 07/01/2022
|
Could This Send Moderna's Stock Soaring Back to $400?
- The healthcare stock last hit the $400 mark in September.
- 06/30/2022
|
FDA recommends updating COVID booster shots to fight Omicron
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.
- 06/29/2022
|
FDA Panel Recommends Modifying COVID Jabs to Target Omicron
- The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.
- 06/29/2022
|
FDA advisers recommend Covid fall boosters
- CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on FDA advisers recommendation for covid fall boosters.
- 06/28/2022
|
7 Biotech Stocks With Key Catalysts Coming in July
- Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.
- 06/27/2022
|
Could This Be Moderna's Ticket to Long-Term Success?
- Moderna's vaccine is now available for almost everyone.
- 06/27/2022
|
2 Biotech Stocks That Could Make You Richer
- These two companies have moved in opposite directions this year.
- 06/26/2022
|
Why Pfizer and Moderna Would Profit As CDC Recommends Covid Vaccine For Toddlers
- Why Many parents are concerned about the effect of the coronavirus pandemic on their children.
- 06/25/2022
|
1 Green Flag for Moderna's Fall Vaccine Plan, and 1 Red Flag
- Moderna is ready to step back into the limelight.
- 06/25/2022
|
CDC panel backs Moderna vaccine for children aged 6 to 17, and study finds vaccines saved about 20 million lives in their first year
- A panel of advisers to the Centers for Disease Control and Prevention voted unanimously Thursday to recommend Moderna's COVID vaccine for children and adolescents aged 6 to 17.
- 06/24/2022
|
CDC panel recommends Moderna two-dose Covid vaccine for kids ages 6 to 17
- CDC Director Dr. Rochelle Walensky is expected to sign off on the recommendation later Thursday,.
- 06/23/2022
|
Moderna (MRNA) Reveals New Data on Bivalent COVID Booster
- Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.
- 06/23/2022
|
Moderna CEO: COVID variant vaccine to be ready for shipping in August
- Moderna's Chief Executive Stephane Bancel said the company's COVID-19 variant vaccine would be ready to ship in August, saying the bottleneck supply was regulatory.
- 06/22/2022
|
This Warren Buffett Advice Could Save Your Portfolio in a Bear Market
- Buying more shares of a distressed stock could just end up putting more of your money at risk.
- 06/22/2022
|
So What's Going On With Moderna Shares Rising Today?
- Moderna Inc (NASDAQ: MRNA) shares are trading higher after the company released data on its bivalent COVID booster candidate. Data showed potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5.
- 06/22/2022
|
COVID-19 vaccines slowly begin to roll out for young kids
- Yahoo Finance's Anjalee Khemlani discusses the rollout of COVID vaccines for kids 6 months to 5 years, plus a new test that could indicate when a person needs a booster shot.
- 06/22/2022
|
COVID cases surge again in Europe and Moderna says booster candidate protects against BA.4 and BA.5 omicron subvariants
- COVID cases are again surging in Europe, driven by the BA.4 and BA.5 subvariants of omicron that are deemed to be 10% to 15% more infectious than earlier variants and are spreading fast in Portugal, France, Germany, Italy, Spain, Greece, the Netherlands and Denmark.
- 06/22/2022
|
Moderna to open new vaccine factory in the UK
- Moderna Therapeutics Inc (NASDAQ:MRNA) has announced plans to open its first vaccine factory in the UK, praising Britain's "world-class life sciences and research community" efforts during COVID-19. A deal worth £1bn will see the vaccine manufacturer collaborate with the UK government to build a manufacturing facility for messenger RNA vaccines for COVID and flu.
- 06/22/2022
|
Moderna's Covid Booster Shot Produces Strong Antibodies Against Fast-Spreading Omicron Subvariants
- The company is hoping to offer the booster shot, which targets both omicron and the original coronavirus strain, in the fall.
- 06/22/2022
|
Moderna's bivalent booster also protects against BA.4 and BA.5 subvariants
- Moderna Inc. MRNA, +1.53% said it shared new data with regulators about its bivalent COVID-19 booster's antibody response against the BA.4 and BA.5 subvariants as it seeks to update its authorized booster with the new formulation. Moderna's bivalent booster protects against both omicron and the original strain of the virus.
- 06/22/2022
|
Got $3,000? These Stocks Could Double Your Money by 2030
- These companies offer plenty of reasons to be optimistic.
- 06/22/2022
|
Why Pfizer and Moderna Bumped Higher on Tuesday
- The two companies receive yet another green light for their respective coronavirus vaccines.
- 06/21/2022
|
FDA Authorizes PFE & MRNA's COVID Jabs for 6 Months & Older Kids
- FDA authorizes Pfizer (PFE) and BioNTech's Comirnaty for use in children aged six months through four years. Moderna's (MRNA) Spikevax gains EUA for use in individuals aged 6 months through 17 years.
- 06/20/2022
|
5 Stocks That Could Hold Up in a Recession
- Suddenly, investors are looking for companies that can survive a possible recession. Corporations with high profitability and low debt seem a pretty good bet.
- 06/20/2022
|
Best Health Care Stocks To Buy Now? 3 To Watch
- Check out these health care stocks this holiday-shortened week.
- 06/20/2022
|
Should You Really Buy Stocks Now or Wait a While Longer?
- Some stocks are trading at incredibly low prices.
- 06/19/2022
|
Covid-19 Vaccinations For Children Starting At Age 6 Months Approved By CDC
- Despite continued skepticism from parents and some scientific advisers, the Centers for Disease Control and Prevention on Saturday recommended Covid-19 vaccines for children as young as 6 months. The ruling means young children could be injected as soon as Tuesday. Covid-19 has been stubbornly resistant to fading away, and new cases are still rising in...
- 06/18/2022
|
CDC Advisers Recommend COVID Vaccines for Kids as Young as 6 Months Old
- Very young children may be able to start receiving shots early next week.
- 06/18/2022
|
CDC Signs Off On Covid Vaccines For Young Children—Shots To Begin Next Week
- Babies as young as 6 months can now get vaccinated.
- 06/18/2022
|
CDC panel recommends COVID-19 vaccine for children as young as 6 months old
- "We've taken a major step forward today," said Dr. Oliver Brooks, one of the members of the advisory panel.
- 06/18/2022
|
CDC advisers recommend COVID-19 shots for children under 5
- U.S. health advisers on Saturday recommended COVID-19 vaccines for infants, toddlers and preschoolers — the last group without the shots.
- 06/18/2022
|
CDC Panel Recommends Covid Vaccines For Young Children
- Shots are expected to start going in arms next week.
- 06/18/2022
|
CDC advisors recommend Covid vaccines for children as young as 6 months
- The CDC committee voted unanimously to recommend the shots for use in infants through preschoolers after two days of meetings that were open to the public.
- 06/18/2022
|
FDA Authorizes Covid Vaccine for Kids 5 and Under
- Covid-19 vaccines for children ages 5 and under from Pfizer Inc. and Moderna Inc. received authorization from US regulators, meaning almost all the American population can soon get pandemic protection. Former FDA Associate Commissioner Peter Pitts says this is a step in the right direction.
- 06/17/2022
|
Why Moderna Stock Is Rising Today
- The FDA authorized Moderna's COVID-19 vaccine for immunizing children.
- 06/17/2022
|
Moderna, Pfizer stocks edge higher after FDA authorizes COVID vaccines for kids
- Yahoo Finance Live's Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.
- 06/17/2022
|
FDA Approves COVID Vaccines for Kids as Young as 6 Months Old
- Pending the CDC's signoff, both Moderna and Pfizer shots could be available for the youngest children within days.
- 06/17/2022
|
FDA clears Pfizer, Moderna Covid vaccines for young children
- The U.S. FDA has authorized Moderna's and Pfizer's Covid-19 vaccines for kids as young as 6 months. CNBC's Meg Tirrell joins 'Squawk on the Street' with the details.
- 06/17/2022
|
FDA authorizes Pfizer and Moderna COVID-19 vaccines for children as young as 6 months old
- The vaccines will be available for young children once the CDC recommends them, which will likely happen this weekend.
- 06/17/2022
|
FDA authorizes both mRNA vaccines for young children
- The Food and Drug Administration announced Friday that it authorized the COVID-19 vaccines developed by BioNTech SE BNTX, -6.41% /Pfizer Inc. PFE, -2.12% and Moderna Inc. MRNA, -5.80% for children as young as six months old. The regulator said Moderna's two-dose vaccine is now authorized for children between the ages of 6 months old and 17 years old.
- 06/17/2022
|
FDA authorizes Pfizer and Moderna's Covid vaccines for children as young as 6 months
- The White House expects vaccinations to begin as soon as Tuesday.
- 06/17/2022
|
FDA clears COVID-19 vaccines for children under 5
- The U.S. Food and Drug Administration has authorized user of the COVID-19 vaccines from Pfizer and BioNTech, and from Moderna, for kids between 6 months and 5 years of age. The FDA's decision follows a length review process, and the dosage for children under 5 is greatly reduced relative to those for older children and […]
- 06/17/2022
|
Moderna is a buy at $128 as it moves to re-establish support and resistance levels
- Moderna Inc. (NASDAQ:MRNA) is trading at $128. The price is just below the support level of $140.
- 06/16/2022
|
Why Pfizer, BioNTech, and Moderna Stocks Are Sinking Today
- Blame it on the overall stock market sell-off.
- 06/16/2022
|
FDA Panel Recommends Pfizer & Moderna COVID Jabs for Young Kids
- The FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.
- 06/16/2022
|
Does This FDA Panel Vote Make Moderna a Buy?
- It could open a up a whole new market for Moderna's COVID-19 vaccine.
- 06/16/2022
|
Moderna, Pfizer COVID vaccines for children under 5 approved by the FDA
- Yahoo Finance senior health care reporter Anjalee Khemlani details the latest FDA advisory panel votes on Pfizer and Moderna's two-dose COVID vaccine for children.
- 06/15/2022
|
FDA Panel Recommends Moderna's and Pfizer's COVID Vaccine for Children as Young as 6 Months
- If the recommendation is backed by the FDA commissioner and the CDC, toddlers could receive their first dose as early as next week.
- 06/15/2022
|
FDA advisers recommend Moderna's Covid vaccine for children ages 6 months through 5
- CNBC's Meg Tirrell joins 'Closing Bell' to report on the FDA's advisers recommendation for Moderna's Covid vaccine for children ages 6 months to 5.
- 06/15/2022
|
Of Highest-Earning Pharmas, Moderna Shares Have Suffered the Most
- It is generally accepted that health care stocks are a good defensive play in a declining market. It does not matter how many Teslas you have in the garage, they are not going to help if you become sick.
- 06/15/2022
|
Moderna And Pfizer Covid Vaccines For Young Children Endorsed By FDA Panel
- The FDA typically follows the recommendations of the advisory panel.
- 06/15/2022
|
FDA committee recommends Moderna's COVID-19 vaccine for young children
- The Food and Drug Administration is expected to authorize at least one COVID-19 vaccine for the nation's youngest children in a move that may provide a choice in shots to parents who have been eager to immunize children with few protective options until this point.
- 06/15/2022
|
Covid vaccine for kids under 5 move closer to FDA authorization after committee backs shots
- The FDA will likely accept the recommendation and authorize the shots this week.
- 06/15/2022
|
FDA panel recommends authorizing Moderna's COVID-19 vaccine for babies and little kids
- Pfizer and Moderna have COVID-19 vaccines for babies as young as 6 months old up for review. Shots could begin next week.
- 06/15/2022
|
Moderna, Inc. (MRNA) Management Presents at 43rd Annual Goldman Sachs Global Healthcare Conference (Transcript)
- Moderna, Inc. (NASDAQ:MRNA ) 43rd Annual Goldman Sachs Global Healthcare Conference Call June 14, 2022 12:20 PM ET Company Participants Lavina Talukdar - Head, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good morning, everyone. Really pleased to have Moderna here with us.
- 06/15/2022
|
Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics
- An FDA advisory committee voted in favor of the use of Moderna's (MRNA) COVID-19 vaccine in individuals aged 6 years to 17 years. A meeting to discuss the use of the vaccine in the younger population is scheduled for today.
- 06/15/2022
|
Could This News From Moderna Mean Trouble for Novavax?
- Novavax and Moderna both are betting on the booster market.
- 06/15/2022
|
FDA Panel Endorses Moderna's COVID Vaccine for Kids 6 to 17
- If the FDA gives the official OK, there will be a second COVID-19 vaccine option for kids and teens.
- 06/14/2022
|
FDA advisers recommend Moderna's COVID-19 vaccine for ages 6-17
- CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report FDA advisers have recommended Moderna's COVID-19 vaccine for children ages 6-17.
- 06/14/2022
|
U.S. FDA advisers back Moderna COVID vaccine for 6-17 year olds
- (Reuters) -Advisers to the U.S. Food and Drug Administration on Tuesday recommended that the agency authorize Moderna Inc's COVID-19 vaccine for children and teens aged 6 to 17 years of age.
- 06/14/2022
|
FDA Advisors Back Moderna Covid-19 Vaccine for 6- to 17-Year-Olds
- The authorization sets the stage for Wednesday's meeting, when the same advisors will consider vaccines from Pfizer and Moderna for younger children.
- 06/14/2022
|
FDA panel supports Moderna's COVID-19 vaccine for kids aged 6-17
- NEW YORK — An FDA advisory panel on Tuesday endorsed Moderna's MRNA, +3.78% COVID-19 vaccine for teens and school-age children aged 6-17.
- 06/14/2022
|
FDA committee recommends Moderna Covid vaccine for kids age 6 to 17
|
Moderna to invest 500 million euros in Spain, PM Sanchez says
- Moderna plans to invest around 500 million euros ($520.60 million) in a new laboratory in Spain to boost its production of vaccines, Spanish Prime Minister Pedro Sanchez said on Tuesday.
- 06/14/2022
|
Pfizer, Moderna COVID vaccines deemed effective for kids under 5
- The FDA announced that COVID vaccines from both Pfizer and Moderna were effective in children under the age of 5, signaling good news for approval.
- 06/13/2022
|
Pfizer, BioNTech's COVID Jab Safe in Young Kids Per FDA
- Per the FDA reviewers, the available data supports Pfizer (PFE) and BioNTech (BNTX) vaccine's effectiveness in preventing COVID infection in kids six months to under five years of age as a three-dose primary series.
- 06/13/2022
|
FDA says Pfizer 3-shot vaccine safe for children under 5, ahead of panel meeting that will also review Moderna's 2-shot regimen
- Federal health officials said Sunday that Pfizer's COVID-19 vaccine appears safe and effective for children below the age of five, clearing another hurdle on the path toward adding that group to the nation's vaccine program.
- 06/13/2022
|
Is This Downtrodden Stock a Value Trap?
- Probably yes, but it could still be a good purchase for investors with the right mindset.
- 06/13/2022
|
Pfizer, Moderna Vaccines Are Effective In Young Children, FDA Says—Here's How They Differ And What Happens Next
- The FDA's assessment comes just days before an independent panel is set to meet and decide whether to recommend approving the vaccine for young children.
- 06/13/2022
|
Moderna Stock: Bull vs. Bear
- The company has generated billions of dollars in profit and revenue.
- 06/12/2022
|
3 Reasons Why Moderna Stock Is so Cheap Right Now
- It's facing a wicked trio of headwinds.
- 06/10/2022
|
Moderna: The Worst Is Likely Over
- The Street remains unconvinced with Moderna's ex-COVID vaccines pipeline, as it estimates peak revenue and profitability in FY22. We think it explains why the market has de-rated MRNA stock. However, our price action analysis suggests a formidable double-bottom bear trap could have formed. As a result, we believe it's increasingly likely that the worst is truly over.
- 06/09/2022
|
Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal
- Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.
- 06/09/2022
|
Why Moderna Stock Is Moving Lower Today
- Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday as vaccine stocks fall in sympathy with Novavax Inc (NASDAQ: NVAX) following reports the FDA's decision on the company's COVID-19 vaccine could be delayed. According to a CNBC report, citing an agency.
- 06/09/2022
|
Cathie Wood's Ark Invest Buys Moderna Stock After $100 Billion Crash—And Sells Rival Vaccine-Maker Pfizer
- Shares of Moderna have tumbled 40% this year while Ark's Genomic Revolution ETF has fallen nearly 50%.
- 06/09/2022
|
New Moderna Covid-19 vaccine five times more effective
- Moderna Inc has unveiled a new Omicron Covid-19 vaccine that it says is five times more effective at boosting antibodies compared to its previous jab. The vaccine, which would also protect against the first Wuhan strain, might only need to be administered once a year as a result.
- 06/09/2022
|
Here's Why Moderna May Dominate the Vaccine Market This Fall
- Moderna is following through on its promises.
- 06/09/2022
|
Moderna, Inc. (MRNA) CEO Stephane Bancel Presents at 2022 Jefferies Global Healthcare Conference Call Transcript
- Moderna, Inc. (NASDAQ:MRNA ) 2022 Jefferies Global Healthcare Conference Call June 8, 2022 3:00 PM ET Company Participants Stephane Bancel - Chief Executive Officer Conference Call Participants Michael Yee - Jefferies Michael Yee Well, thank you everyone for joining us here at a great afternoon session here. I am up here with CEO of Moderna, Stephane Bancel.
- 06/08/2022
|
Alibaba stock extends gains, Moderna shares pop and Spirit Airlines delays buyout vote,
- Yahoo Finance Live anchors Rachelle Akuffo, Dave Briggs and Seana Smith look at the news surrounding several of today's trending stocks, including Alibaba stock extending gains, Moderna's shares up on data regarding its COVID-19 booster shot and the latest in Spirit Airlines' deal with Frontier.
- 06/08/2022
|
Moderna says new version of COVID shot boosts Omicron protection
- Moderna said a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot.
- 06/08/2022
|
MRNA Stock Forecast: 3 Analysts Predict Where Moderna Will Go From Here
- Moderna (MRNA) stock is in the spotlight today as investors react to news of a new vaccine for Covid-19 that works on Omicron. The post MRNA Stock Forecast: 3 Analysts Predict Where Moderna Will Go From Here appeared first on InvestorPlace.
- 06/08/2022
|
Moderna's next-generation COVID-19 shot provides ‘superior' protection against omicron
- Moderna's MRNA, +3.95% experimental next-generation COVID-19 vaccine provides more protection against omicron than the original shot, and the company is aiming to make it available to Americans this summer.
- 06/08/2022
|
Moderna Stock Pops on Upgraded Covid-19 Booster Data
- Moderna Inc (NASDAQ:MRNA) revealed earlier a study of an upgraded version of its Covid-19 vaccine, which also targets the Omicron strain, produced a better immune as a booster than its original shot, raising virus-neutralizing antibodies eightfold.
- 06/08/2022
|
What's next for Moderna stock as firm announces modified booster against Corona strains
- On Wednesday, June 8, Moderna (NASDAQ: MRNA) announced an enhanced version of their coronavirus vaccination designed to protect against the.
- 06/08/2022
|
Moderna's new Covid booster provides superior protection against omicron
- CNBC's Meg Tirrell joins 'Squawk Box' to break down Moderna's latest data surrounding its combo Covid-19 booster aimed at protecting against omicron and the original strain of the virus.
- 06/08/2022
|
Moderna Booster Targeting Omicron Shows Stronger Immune Response Than Original Vaccine
- Moderna's modified Covid-19 booster shot that targets the Omicron variant shows a stronger immune response than the original vaccine.
- 06/08/2022
|
Moderna says its bivalent COVID-19 shot produced a better response against omicron than its booster
- Shares of Moderna Inc. MRNA, +3.81% were up 2.1% in premarket trading on Wednesday after the company said its experimental bivalent COVID-19 vaccine that targets the original strain of the virus and the omicron variant produced a higher antibody response that its original COVID-19 booster shot one month after administration. The preliminary data from the Phase 2/3 study with 437 participants was shared in a news release.
- 06/08/2022
|
Moderna's Booster Shot Targeting Omicron And Original Strain Could Be Available Late Summer After Promising Trials
- Moderna chief executive Stéphane Bancel said early data suggests the bivalent shot could provide more long-lasting protection against variants of concern than the company's original formula alone.
- 06/08/2022
|
Three Stock Lunch: Ford, Moderna and Exxon Mobil
- Jeff Mills, Bryn Mawr Trust CIO and CNBC contributor, joins 'Power Lunch' to discuss Mills' take on three stocks: Ford, Moderna and Exxon Mobil.
- 06/07/2022
|
Moderna Stock Still Has Further To Fall
- Moderna only has one commercialized product and is unlikely to replace falling COVID-vaccine revenue. Spikevax revenue could fall to $2bn by 2024 amid waning demand for vaccines and preference for other shots.
- 06/06/2022
|
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
- Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
- 06/06/2022
|
Can the Best-Selling Drugs of 2021 Repeat Their Performance?
- These were the industry's bestsellers last year, but how long can they stay on top?
- 06/05/2022
|
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
- Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead of These June Catalysts appeared first on InvestorPlace.
- 06/03/2022
|
Best Health Care Stocks To Invest In Today? 3 In Focus
- Could these health care stocks be worth jumping on now?
- 06/03/2022
|
Why Moderna and Pfizer Lagged the Market Today
- The amendment to a European Union supply agreement is spooking investors.
- 06/02/2022
|
Should Investors Worry About Moderna's European Vaccine Delivery Delay?
- There's really not much to worry about with Moderna's latest news.
- 06/02/2022
|
Does This News From Switzerland Mean Trouble for Moderna?
- It has to do with vaccine demand.
- 06/02/2022
|
Moderna, EU push back COVID vaccine deliveries by several months
- (Reuters) -Moderna Inc will delay its COVID-19 vaccine deliveries to the European Union by several months under an agreement announced on Thursday.
- 06/02/2022
|
Moderna amends agreement with EC on booster dose deliveries
- Shares of Moderna Inc. MRNA, -1.33% fell 1.1% in premarket trading Thursday, after the COVID-19 vaccine maker said it amended its agreement with the European Commission, so member states can delay deliveries of the vaccine booster product Spikevax. The company said deliveries of the booster doses that were scheduled for the second quarter of 2022 can now be delivered later this year or in early 2023.
- 06/02/2022
|
Moderna to Present at Upcoming Conferences in June 2022
- CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences: 2022 Jefferies Healthcare Conference on Wednesday, June 8th at 3:00 p.m. ET 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14th at 12:20 p.m.
- 06/01/2022
|
What Does a Private Vaccine Market Mean for Moderna?
- The shift to a private market may come as soon as this fall.
- 06/01/2022
|
Moderna Stock Looks Strong as the World Needs More Vaccines
- A fresh viral outbreak is a cause for concern, but Moderna's already developing a potential vaccine and MRNA stock could benefit from this. The post Moderna Stock Looks Strong as the World Needs More Vaccines appeared first on InvestorPlace.
- 05/31/2022
|
Better COVID Stock: Pfizer vs. Moderna
- They both dominate the vaccine market today.
- 05/31/2022
|
What Stocks To Invest In Now? 4 Biotech Stocks To Know
- Could these biotech stocks be worth watching in the stock market today?
- 05/30/2022
|
7 Deeply Oversold Stocks to Buy Before They Bounce
- Stocks often over sell after panicking investors get rid of shares, which eventually leads to the stock bouncing back dramatically. The post 7 Deeply Oversold Stocks to Buy Before They Bounce appeared first on InvestorPlace.
- 05/30/2022
|
3 of Nasdaq's Most-Shorted Stocks to Buy Today
- With the market wind at their back, these most-shorted stocks to buy are ready for bullish cycles to emerge in June. The post 3 of Nasdaq's Most-Shorted Stocks to Buy Today appeared first on InvestorPlace.
- 05/27/2022
|
Why Moderna Stock Is Jumping Today
- The vaccine stock is benefiting from an overall market bounce.
- 05/27/2022
|
Better Buy Ahead of FDA Meetings: Moderna vs. Novavax
- June may be a critical month for both companies.
- 05/25/2022
|
4 Nasdaq 100 Stocks Billionaires Piled Into During the First Quarter
- Successful money managers used the Nasdaq bear market as a catalyst to buy into these high-growth stocks.
- 05/25/2022
|
Moderna, Inc. (MRNA) Management on UBS 2022 Global Healthcare Conference Call Transcript
- Moderna, Inc. (NASDAQ:MRNA ) UBS 2022 Global Healthcare Conference Call May 24, 2022 9:15 AM ET Company Participants Eliana Merle - Biotech Analyst, UBS Lavina Talukdar - SVP & Head, Investor Relations Conference Call Participants Eliana Merle Hi, good morning everyone. I'm Ellie Merle, I'm one of the Biotech Analyst here at UBS.
- 05/24/2022
|
This Famed Company Is Working On A Potential Monkeypox Vaccine
- As cases of monkeypox continue to rise, Moderna Inc (NASDAQ: MRNA) is probably working on its platform towards finding a vaccine shot against the disease. The company announced plans to explore potential vaccines for monkeypox at a "preclinical level," according to an .
- 05/24/2022
|
Moderna testing potential monkeypox vaccines
- The World Health Organization said on Tuesday there have been 131 confirmed monkeypox cases and 106 further suspected cases since the first was reported on May 7 outside the countries where it usually spreads.
- 05/24/2022
|
Moderna says it will start developing monkeypox vaccine
- Moderna Inc. MRNA, -4.72% tweeted Monday afternoon that it is "investigating potential monkeypox vaccines at a preclinical level." Several stocks of companies that are developing or have smallpox or monkeypox vaccines and treatments jumped in trading on Monday as more people have become aware of the cluster of cases in Europe.
- 05/24/2022
|
Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5
- Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.
- 05/24/2022
|
Moderna Inc conducting moneypox vaccine trials, report
- Pharmaceutical company Moderna Therapeutics Inc (NASDAQ:MRNA) is testing potential vaccines against monkeypox, as the number of cases continues to rise in the UK and elsewhere. Moderna is said to be conducting pre-clinical trials for a monkeypox vaccine, according to Reuters.
- 05/24/2022
|
Billionaire Moderna CEO Stéphane Bancel Pledges Stock Options Worth $355 Million To Undisclosed Charitable Causes
- Despite a steep Moderna stock crash this year, the longtime biotech executive has amassed a $4.6 billion fortune.
- 05/24/2022
|
